

BETH C. DRAIN, CA CSR NO. 7152

BEFORE THE
INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE AND
APPLICATION REVIEW SUBCOMMITTEE
TO THE
CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE
ORGANIZED PURSUANT TO THE
CALIFORNIA STEM CELL RESEARCH AND CURES ACT
REGULAR MEETING

LOCATION: VIA ZOOM

DATE: OCTOBER 27, 2022
9 A.M.

REPORTER: BETH C. DRAIN, CA CSR
CSR NO. 7152

FILE NO.: 2022-39

**133 HENNA COURT, SANDPOINT, IDAHO 83864
208-920-3543 DRAIBE@HOTMAIL.COM**

BETH C. DRAIN, CA CSR NO. 7152

I N D E X

| ITEM DESCRIPTION | PAGE NO. |
|---|-----------------|
| OPEN SESSION | |
| 1. CALL TO ORDER | 4 |
| 2. ROLL CALL | 4 |
| 3. CHAIRMAN'S REPORT | 9 |
| 4. PRESIDENT'S REPORT: | |
| DR. MILLAN | 14 |
| DR. SAMBRANO | 25 |
| ACTION ITEMS | |
| 5. CONSIDERATION OF SHARED LABS RESOURCES CONCEPT PLAN | 90 |
| 6. CONSIDERATION OF APPLICATIONS SUBMITTED IN RESPONSE TO CLINICAL TRIAL STAGE PROJECTS PROGRAM ANNOUNCEMENT (CLIN 1 OR 2) | 44 |
| 7. CONSIDERATION OF APPLICATIONS SUBMITTED IN RESPONSE TO ALPHA CLINIC NETWORK EXPANSION (INFR4) | 59 |
| 8. CONSIDERATION OF AMENDMENTS TO GRANTS WORKING GROUP BYLAWS | 119 |
| 9. CONSIDERATION OF MINUTES FROM SEPTEMBER 20 APPLICATION REVIEW SUBCOMMITTEE MEETING AND SEPTEMBER 29 ICOC/ARS MEETING | 121 |
| 10. STATEMENT OF INTEREST BY NOMINEE FOR VICE CHAIR | 124 |

BETH C. DRAIN, CA CSR NO. 7152

I N D E X (CONT'D.)

| | |
|---|------------|
| CLOSED SESSION | 129 |
| 11. DISCUSSION OF PERSONNEL (GOVERNMENT CODE SECTION 11126, SUBDIVISION (A); HEALTH & SAFETY CODE SECTION 125290.30(F) (3) (D)) CHAIR/VICE CHAIR UPDATES RECOMMENDATION REGARDING NOMINEE FOR VICE CHAIR, INCLUDING PERCENT EFFORT, COMPENSATION AND START DATE RECOMMENDATION REGARDING PERCENT EFFORT, COMPENSATION AND START DATE FOR CHAIR | |
| ACTION ITEMS | |
| 12. CONSIDERATION OF VICE CHAIR CANDIDATE, INCLUDING PERCENT EFFORT AND COMPENSATION AND START DATE | 130 |
| 13. CONSIDERATION OF CHAIR PERCENT EFFORT, AND COMPENSATION AND START DATE | 134 |
| DISCUSSION ITEMS | |
| 14. GENERAL COMMENTS ON ARS PROCESS | 144 |
| 15. FINANCIAL AUDIT FOR FY 20/21 | 145 |
| 16. PUBLIC COMMENT | 154 |
| 17. ADJOURNMENT | 157 |

BETH C. DRAIN, CA CSR NO. 7152

OCTOBER 27, 2022; 9 A.M.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

CHAIRMAN THOMAS: GOOD MORNING, EVERYBODY.
WELCOME TO THE OCTOBER 2022 MEETING OF THE ICOC AND
APPLICATION REVIEW SUBCOMMITTEE. BEFORE WE GET TO
CALLING THE ROLL, WE NEED TO SWEAR IN OUR NEWEST
MEMBER, JUDY CHOU, WHO WILL BE INTRODUCING HERSELF
IN A FEW MINUTES. BUT BEFORE WE DO THAT, JUDY,
WE'RE GOING TO PUBLICLY, OFFICIALLY SWEAR YOU IN.
SO IF YOU WOULD PLEASE RAISE YOUR RIGHT HAND AND
REPEAT AFTER ME.

(MEMBER CHOU WAS THEN DULY SWORN IN,
NOT REPORTED, NOR HEREIN TRANSCRIBED.)

CHAIRMAN THOMAS: CONGRATULATIONS.
WELCOME TO THE BOARD.

DR. CHOU: THANK YOU.

CHAIRMAN THOMAS: SO WITH THAT, MARIA,
WILL YOU PLEASE CALL THE ROLL.

MS. BONNEVILLE: HAIFAA ABDULHAQ.

DR. ABDULHAQ: YES.

MS. BONNEVILLE: MOHAMMED ABOUSALEM.

DR. ABOUSALEM: PRESENT.

MS. BONNEVILLE: KIM BARRETT.

DR. BARRETT: PRESENT.

MS. BONNEVILLE: DAN BERNAL. GEORGE

BETH C. DRAIN, CA CSR NO. 7152

1 BLUMENTHAL .
2 DR. BLUMENTHAL: PRESENT .
3 MS. BONNEVILLE: MICHAEL BOTCHAN .
4 DR. BOTCHAN: HERE .
5 MS. BONNEVILLE: LINDA BOXER .
6 DR. BOXER: PRESENT .
7 MS. BONNEVILLE: JUDY CHOU .
8 DR. CHOU: PRESENT .
9 MS. BONNEVILLE: LEONDRA CLARK-HARVEY
10 DEBORAH DEAS .
11 DR. DEAS: HERE .
12 MS. BONNEVILLE: ANNE-MARIE DULIEGE .
13 DR. DULIEGE: HERE .
14 MS. BONNEVILLE: YSABEL DURON .
15 MS. DURON: PRESENT .
16 MS. BONNEVILLE: MARK FISCHER-COLBRIE .
17 DR. FISCHER-COLBRIE: HERE .
18 MS. BONNEVILLE: FRED FISHER. ELENA
19 FLOWERS .
20 DR. FLOWERS: PRESENT .
21 MS. BONNEVILLE: JUDY GASSON .
22 DR. GASSON: HERE .
23 MS. BONNEVILLE: LARRY GOLDSTEIN .
24 DR. GOLDSTEIN: HERE .
25 MS. BONNEVILLE: DAVID HIGGINS. STEPHEN

BETH C. DRAIN, CA CSR NO. 7152

1 JUELSGAARD.
2 MR. JUELSGAARD: HERE.
3 MS. BONNEVILLE: RICH LAJARA.
4 MR. LAJARA: HERE.
5 MS. BONNEVILLE: PAT LEVITT.
6 DR. LEVITT: HERE.
7 MS. BONNEVILLE: LINDA MALKAS.
8 DR. MALKAS: HERE.
9 MS. BONNEVILLE: SHLOMO MELMED.
10 DR. MELMED: HERE.
11 MS. BONNEVILLE: CHRISTINE MIASKOWSKI.
12 DR. MIASKOWSKI: MORNING.
13 MS. BONNEVILLE: LAUREN MILLER-ROGEN.
14 MS. MILLER-ROGEN: HERE.
15 MS. BONNEVILLE: ADRIANA PADILLA.
16 DR. PADILLA: HERE.
17 MS. BONNEVILLE: JOE PANETTA. AL ROWLETT.
18 MARVIN SOUTHARD.
19 DR. SOUTHARD: HERE.
20 MS. BONNEVILLE: MICHAEL STAMOS.
21 DR. STAMOS: HERE.
22 MS. BONNEVILLE: JONATHAN THOMAS.
23 CHAIRMAN THOMAS: HERE.
24 MS. BONNEVILLE: ART TORRES.
25 MR. TORRES: PRESENT. HAPPY DIA DE LOS

BETH C. DRAIN, CA CSR NO. 7152

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

MUERTOS .

MS. BONNEVILLE: KAROL WATSON. KEITH

YAMAMOTO .

DR. YAMAMOTO: HERE .

MS. BONNEVILLE: WE HAVE A QUORUM .

BETH C. DRAIN, CA CSR NO. 7152

1 CHAIRMAN THOMAS: THANK YOU, MARIA.

2 SO THE FIRST ORDER OF BUSINESS, CHAIR'S
3 REPORT. LET'S GO STRAIGHT TO JUDY AND HAVE HER GIVE
4 A BIT OF AN INTRODUCTION FOR THE BENEFIT OF MEMBERS
5 OF THE BOARD AND MEMBERS OF THE PUBLIC. JUDY.

6 DR. CHOU: THANK YOU. IT'S A GREAT
7 PLEASURE TO BE HERE. I'M HAPPY TO SERVE ON THE
8 BOARD. CURRENTLY MY DAY JOB, I AM CEO AND PRESIDENT
9 OF BIOTECH COMPANY IN SAN FRANCISCO CALLED ALTRUBIO.
10 AND MY CAREER PATH, I'VE BEEN TO VARIOUS DIFFERENT
11 LARGE AND SMALL, MIDSIZE BIOTECH COMPANY. START MY
12 CAREER ACTUALLY IN ACADEMIA.

13 SOMETHING I'M PARTICULARLY PASSIONATE
14 ABOUT, THE JOURNEY THAT TOOK ME INTO THE BIOMEDICAL
15 RESEARCH WAS X-RAY HIT ME HARD PERSONALLY WHEN I WAS
16 IN MEDICAL SCHOOL OBSERVING THE PATIENT AT THE TIME,
17 IT WAS REALLY LONG TIME AGO, TO INTRODUCE A BONE
18 MARROW TRANSPLANTATION AND FAILED. SO I
19 PARTICULARLY FEEL HAPPY ABOUT CONTRIBUTING TO THE
20 REGENERATIVE MEDICINES AND ADVANCED THERAPIES.

21 SO WITH THAT, I WILL STOP HERE AND WILL
22 HOPE THIS JOURNEY ALSO GET TO KNOW ALL OF YOU AND TO
23 SUPPORT RESEARCH ADVANCE THIS AREA.

24 CHAIRMAN THOMAS: THANK YOU VERY MUCH,
25 JUDY. AND, AGAIN, WELCOME. WE ARE DELIGHTED TO

BETH C. DRAIN, CA CSR NO. 7152

1 HAVE YOU AS A MEMBER OF THE CIRM FAMILY.

2 NEXT IS THE PRESIDENT'S REPORT. I WANTED
3 TO, FOR THOSE WHO ARE NOT AWARE, JUST MAKE SURE
4 EVERYBODY KNOWS THAT DEAN DEBORAH DEAS WAS RECENTLY
5 ELECTED TO THE NATIONAL ACADEMY OF MEDICINE, WHICH,
6 AS WE ALL KNOW, IS A VERY PRESTIGIOUS HONOR. SO,
7 DEBORAH, CONGRATULATIONS. WOULD YOU CARE TO SAY FEW
8 WORDS?

9 DR. DEAS: WELL, THANK YOU SO MUCH. AND
10 I'D LIKE TO THANK ALL THE MEMBERS OF THE BOARD.
11 IT'S TRULY A PLEASURE SERVING WITH ALL OF YOU. AND
12 THE MEMBERSHIP IS JUST SOME -- I WAS ECSTATIC TO
13 LEARN THAT I WAS ELECTED, AND IT ALLOWS ME TO HAVE A
14 GREATER VOICE ON THE NATIONAL PLATFORM IN SCIENCE AS
15 WELL AS IN THE AREA OF DIVERSITY, EQUITY, AND
16 INCLUSION. AND I'M ALSO SO PLEASED OF WHAT WE ARE
17 DOING, AND EVERYTHING THAT WE ARE DOING CERTAINLY
18 ALIGNS WITH MY VALUES. AND THIS IS SUCH A GREAT
19 OPPORTUNITY TO NOT ONLY REPRESENT MYSELF, BUT THE UC
20 SYSTEM AS WELL AS CIRM. SO THANK YOU.

21 CHAIRMAN THOMAS: THANK YOU VERY MUCH.
22 CONGRATULATIONS AGAIN. WE ARE ALL VERY PROUD OF
23 YOU.

24 DR. DEAS: THANK YOU.

25 CHAIRMAN THOMAS: AT THE LAST BOARD

BETH C. DRAIN, CA CSR NO. 7152

1 MEETING, I MADE THE SAD ANNOUNCEMENT THAT SUSAN
2 SOLOMON, WHO AS THE FOUNDER AND CEO OF NYSCF, NEW
3 YORK STEM CELL FOUNDATION, HAD PASSED AWAY IN EARLY
4 SEPTEMBER. I JUST WANTED TO LET THE BOARD KNOW
5 THERE WAS AN ANNUAL GALA IN EARLY OCTOBER AND WAS
6 REALLY A TRIBUTE TO SUSAN. AND I WENT BACK, ON
7 CIRM'S BEHALF, TO REPRESENT US AT THAT EVENT. AND
8 HER HUSBAND, PAUL GOLDBERGER, IS AN OLD FRIEND OF MY
9 MINE AS WELL. AND I PERSONALLY PASSED ALONG
10 CONDOLENCES ON BEHALF OF ALL OF THE CIRM FAMILY TO
11 HIM WHICH HE APPRECIATED.

12 ALSO GOT A CHANCE TO GET A TOUR OF THE
13 NYSCF FACILITIES, WHICH, FOR THOSE OF YOU WHO HAVE
14 NEVER SEEN THEM, ARE VERY IMPRESSIVE. IN ADDITION
15 TO FUNDING PI'S LITERALLY AROUND THE WORLD, THEY
16 HAVE OVER A HUNDRED IN-HOUSE SCIENTISTS WORKING ON
17 PROJECTS IN-HOUSE, INCLUDING HAVING A GMP FACILITY.
18 AND IT WAS VERY IMPRESSIVE. DERRICK ROSSI, FORMER
19 CIRM GRANTEE AND CO-FOUNDER OF MODERNA AND CURRENT
20 INTERIM CEO OF NYSCF, GAVE THE TOUR. AND HE WAS
21 VERY, VERY ENTHUSIASTIC ABOUT WHAT WE ARE THERE. SO
22 IT WAS NICE TO HAVE THE OPPORTUNITY TO SEE THAT
23 CLOSE UP AND APPRECIATE THEIR EFFORT.

24 LAST, BUT NOT LEAST, JUST TO GET IT OUT OF
25 THE WAY BEFORE MR. JUELSGAARD SAYS ANYTHING, YES,

BETH C. DRAIN, CA CSR NO. 7152

1 THE DODGERS WENT DOWN INGLORIOUSLY. AND STILL I'M
2 VERY, VERY BITTER ABOUT THIS. I WAS NOTING KRISTINA
3 WAS SENDING ME TEXTS THROUGHOUT TO COMMENT ON THE
4 PADRES' PERFORMANCE, AND I HAD TO BEGRUDGINGLY
5 CONGRATULATE HER ALTHOUGH SHE JOINED THE CLUB AFTER
6 THE NEXT ROUND. SO, STEVE, YOU DON'T NEED TO SAY
7 ANYTHING. I FEEL THE PAIN WITHOUT ANY FURTHER
8 COMMENT. AND SO --

9 MR. TORRES: I HAVE A COMMENT, J.T.

10 CHAIRMAN THOMAS: YES, MR. SENATOR.

11 MR. TORRES: TEXTED BY UNITED STATES
12 SENATOR ALEX PADILLA THAT A VERY DEAR FRIEND OF
13 OURS, ROSALIND WYMAN, PASSED AWAY THIS MORNING. AND
14 IT'S IMPORTANT TO LET YOU KNOW, AS WELL AS I KNOW
15 YOU ALREADY DO, SHE WAS INSTRUMENTAL IN BRINGING THE
16 DODGERS TO LOS ANGELES AS A YOUNG COUNCILWOMAN IN
17 L.A. AND WAS REALLY THE DOYENNE OF THE DEMOCRAT
18 PARTY NATIONALLY AND STATEWIDE, BUT ALSO A GREAT
19 SUPPORTER OF OURS FINANCIALLY FOR OUR CAMPAIGNS FOR
20 PROP 71 AND PROP 14. SHE WAS ABSOLUTELY EMBRACING
21 OF OUR RESEARCH. BUT IT IS SO SAD TO HEAR OF HER
22 PASSING THIS MORNING.

23 CHAIRMAN THOMAS: THANK YOU, MR. SENATOR.
24 FOR THOSE WHO DON'T KNOW THE STORY, WHICH WILL
25 PROBABLY BE MOST OF YOU, ROS WYMAN, AS A VERY YOUNG

BETH C. DRAIN, CA CSR NO. 7152

1 MEMBER OF THE L.A. CITY COUNCIL, TOOK IT UPON
2 HERSELF IN THE LATE 1950S TO CALL THEN DODGER OWNER
3 WALTER O'MALLEY, OWNER OF THE BROOKLYN DODGERS, AND
4 SUGGEST THAT THEY MOVE THE TEAM TO LOS ANGELES,
5 WHICH WAS THE BEGINNING OF SETTING THE WHEELS IN
6 MOTION TO MAKE THAT HAPPEN. AND BY THE WAY, WAS
7 ALSO THE REASON WHY THE GIANTS FOLLOWED SUIT AND
8 MOVED OUT TO SAN FRANCISCO. SO SHE WAS INDEED A
9 PIONEER AND A KEY MEMBER OF THIS WHOLE THING.

10 I'LL JUST GIVE YOU ONE LAST STORY ABOUT
11 ROS. OUR BOYS ALL PLAYED LITTLE LEAGUE IN LOS
12 ANGELES, AND OUR YOUNGEST MIKE, ONE OF HIS BEST
13 FRIENDS WAS EUGENE WYMAN, WHICH IS ROS'S GRANDSON.
14 WHEN YOU'RE OPENING UP LITTLE LEAGUE SEASONS, THE
15 FIRST THING THEY DO IS ON OPENING DAY THERE'S ALWAYS
16 A FIRST PITCH THROWN OUT. AND WHEN MIKE AND EUGENE
17 WERE 12, THEIR LAST YEAR OF LITTLE LEAGUE, ROS THREW
18 OUT THE FIRST PITCH TO EUGENE, WHICH WAS A GREAT
19 MOMENT AND, OF COURSE, UNFORTUNATELY NOT APPRECIATED
20 BY MOST OF THE PARENTS IN THE CROWD, NOT HAVING ANY
21 IDEA WHO ROS WAS OR HER SIGNIFICANCE TO BASEBALL IN
22 SOUTHERN CALIFORNIA AND INDEED THROUGHOUT THE STATE.
23 SO IT WAS A WONDERFUL MOMENT. AND THANK YOU VERY
24 MUCH, ART, FOR SAYING THAT. I APPRECIATE IT.

25 MR. TORRES: SHE WAS MY SWEETHEART. THANK

BETH C. DRAIN, CA CSR NO. 7152

1 YOU.

2 MS. BONNEVILLE: YSABEL HAS HAD HER HAND
3 RAISED, SO I WOULD LIKE TO...

4 CHAIRMAN THOMAS: HELLO, YSABEL. I'M
5 SORRY. I CAN'T SEE ON THE SCREEN. YSABEL.

6 MS. DURON: THANK YOU VERY MUCH, MR.
7 CHAIR. THIS HAS ABSOLUTELY NOTHING TO DO WITH
8 BASEBALL. SO I WOULD LIKE TO -- AND I'M SORRY ABOUT
9 THE PASSING OF ROS. BUT I WANTED TO, AS DEBORAH
10 ANNOUNCED, I AM VERY -- CONGRATULATIONS TO HER, BUT
11 I AM PLEASED TO ANNOUNCE THAT I WAS JUST APPOINTED
12 TO THE AMERICAN CANCER SOCIETY NATIONAL BREAST
13 CANCER ROUNDTABLE. WE WERE OFFICIALLY LAUNCHED ON
14 MONDAY AT THE WHITE HOUSE WITH DR. JILL BIDEN AND
15 THE CANCER MOONSHOT.

16 AND I REFERENCE BACK TO DEBORAH BECAUSE
17 I'M HOPING THAT, AS WE LOOK AT DEI THROUGH THE LENS
18 OF BREAST CANCER AND ITS IMPACT ON OUR COMMUNITIES
19 OF COLOR THROUGHOUT THE COUNTRY, THAT WE CAN FIND
20 SOME ALLIES AND ALLIANCE WITH HER NEW POSITION
21 BECAUSE THIS WILL BE A HEAVY LIFT IN ORDER FOR US TO
22 MAKE SURE THAT WE'RE GOING TO, IN FACT, ADDRESS THIS
23 ISSUE VERY BROADLY, BUT VERY SMARTLY AND ALONG
24 PRECISION MEDICINE LINES. SO APPRECIATE THIS
25 OPPORTUNITY TO SHARE THIS WITH YOU AND ALSO TO SAY

BETH C. DRAIN, CA CSR NO. 7152

1 TO DEBORAH I HOPE WE FIND SOME ALLIANCE IN OUR WORK
2 ALONG THE WAY. THANK YOU.

3 DR. DEAS: OF COURSE AND CONGRATULATIONS.

4 MR. TORRES: CONGRATULATIONS, YSABEL.

5 CHAIRMAN THOMAS: CONGRATULATIONS, YSABEL.
6 THAT'S WONDERFUL NEWS.

7 OKAY. SO THAT CONCLUDES THE CHAIR'S
8 REPORT. ON TO THE PRESIDENT'S REPORT. DR. MILLAN.

9 DR. MILLAN: THANK YOU SO MUCH, MR.
10 CHAIRMAN. OH, THANK YOU SO MUCH FOR PROJECTING
11 THAT, MARIANNE.

12 I'M PLEASED TO PRESENT TODAY FOR
13 DISCUSSION CIRM'S PROGRAMS IN DIVERSITY, EQUITY, AND
14 INCLUSION, WHICH IS VERY TIMELY GIVEN SOME OF THE
15 AMAZING NEWS THAT WE JUST HEARD EARLIER IN THE
16 MEETING. NEXT SLIDE PLEASE.

17 DEI IS IMPORTANT TO CIRM. IT IS EMBEDDED
18 IN OUR MISSION STATEMENT TO ACCELERATE WORLD-CLASS
19 SCIENCE IN DELIVERING TRANSFORMATIVE REGENERATIVE
20 MEDICINE TREATMENTS IN AN EQUITABLE MANNER TO A
21 DIVERSE CALIFORNIA AND WORLD.

22 YOU MAY RECALL WHERE OUR FORMAL DEI
23 EFFORTS BEGAN. LOOK BACK TO 2020 AT THE START OF
24 THE COVID PANDEMIC AND CIRM WAS WINDING DOWN FROM
25 PROP 71 WITH THE REMAINING DOLLARS, AND WE LAUNCHED

BETH C. DRAIN, CA CSR NO. 7152

1 OUR EMERGENCY PROGRAM ANNOUNCEMENT. A CERTAIN BOARD
2 MEMBER, BOARD MEMBER YSABEL DURON, CHALLENGED ALL OF
3 US TO INCORPORATE DEI INTO THAT PROGRAM
4 ANNOUNCEMENT. IT WAS BOTH TIMELY AND APPROPRIATE
5 BECAUSE, AS THE COVID PANDEMIC RAGED ON, WE BECAME
6 INCREASINGLY AWARE OF DRAMATIC DISPARITIES IN
7 HEALTHCARE ACCESS AND OUTCOMES FOR UNDERSERVED AND
8 UNDERREPRESENTED ETHNIC MINORITIES IN CALIFORNIA AND
9 THROUGHOUT THE WORLD.

10 TODAY WE'LL BE GIVING AN UPDATE ON OUR
11 PROGRESS SINCE THAT DEFINING MOMENT. AND I'LL FIRST
12 START OFF WITH JUST SOME BACKGROUND AND AN UPDATE OF
13 WHERE WE ARE AS A BASELINE, AND I'LL BE TURNING IT
14 OVER TO DR. GIL SAMBRANO, OUR VICE PRESIDENT OF
15 PORTFOLIO AND REVIEW, TO PROVIDE AN UPDATE ON THE
16 DEI PROGRESS IN OUR REVIEW PROCESS, WHICH HE'S
17 WORKED VERY HARD ON ALONG WITH THE BOARD MEMBERS WHO
18 SERVE ON THE GWG.

19 THIS IS IMPORTANT BECAUSE THE REVIEW
20 PROCESS IS THE ENTRY POINT FOR PROGRAMS ENTERING
21 CIRM AND IMPACTING HOW WE DEVELOP PROGRAMS GOING
22 FORWARD. NEXT SLIDE PLEASE.

23 NEARLY 40 PERCENT OF AMERICANS BELONG TO A
24 RACIAL OR ETHNIC MINORITY. NEXT SLIDE.

25 YET ETHNIC AND RACIAL MINORITIES ARE

BETH C. DRAIN, CA CSR NO. 7152

1 UNDERREPRESENTED IN CLINICAL TRIALS. THE AMERICAN
2 CANCER SOCIETY JUST THIS YEAR REPORTED THAT BLACK
3 MEN HAVE A 6 PERCENT HIGHER INCIDENCE OF CANCER AND
4 A 19 PERCENT HIGHER MORTALITY THAN WHITE MEN
5 OVERALL. THESE ARE JUST THE PAST FIVE YEARS. AND
6 THE FDA, LOOKING AT APPROVED PRODUCTS FOR CANCER IN
7 2020, LOOKED AT THE 32,000 PATIENTS THAT WERE
8 ENROLLED IN THESE TRIALS. OF THOSE PATIENTS, 8
9 PERCENT WERE BLACK OR AFRICAN-AMERICAN AND 75
10 PERCENT WHITE.

11 IN ANOTHER PUBLICATION BY LARKIN, ET. AL.
12 ON BLOOD ADVANCES JUST THIS YEAR, THEY LOOKED AT THE
13 NATIONAL CANCER INSTITUTE CLINICAL TRIALS IN BLOOD
14 CANCER AML BETWEEN 1983 AND 2016 AND FOUND HUGE
15 DISCREPANCIES AND DISPARITIES BETWEEN OUTCOMES IN
16 YOUNG BLACK PARTICIPANTS OR 11 PERCENT MORTALITY
17 RATE OF 30 DAYS VS. 2 PERCENT IN WHITE PARTICIPANTS.
18 IN THAT SAME REPORT THEY FOUND THAT THERE WERE
19 DIFFERENCES IN THE CELL PROFILES, THE MOLECULAR
20 FEATURES, AND THE GENETICS BETWEEN THE BLACK AND
21 WHITE PARTICIPANTS. IN ADDITION, THERE'S AN
22 INCREASINGLY GROWING BODY OF LITERATURE SHOWING THAT
23 NOT ONLY THE GENETIC DIFFERENCES, BUT SOCIAL
24 DETERMINANTS OF HEALTH IMPACT OUTCOMES. NEXT SLIDE
25 PLEASE.

1 FURTHER, ETHNIC AND RACIAL MINORITIES ARE
2 ALSO UNDERREPRESENTED IN OUR BASIC SCIENCE AND
3 DISEASE MODELS, THE STARTING POINT FOR DISCOVERIES
4 THAT LEAD TO DOWNSTREAM THERAPY DEVELOPMENT. THIS
5 BLUE SNAPSHOT IS A SCREENSHOT THAT ACTUALLY MARIA
6 BONNEVILLE SENT ME FROM SOCIAL MEDIA. IT IS VERY
7 CLEAR THAT THERE ARE DISPARITIES IN OUR CELL MODELS
8 AND SCIENTIFIC MODELS THAT LEAD TO THOSE
9 DISCOVERIES. 80 PERCENT OF GENETIC STUDIES HAVE
10 BEEN DONE EXCLUSIVELY IN EUROPEAN POPULATIONS. AND
11 ON THE CHART ON THE RIGHT, THIS SHOWS THE VARIETY OF
12 DIFFERENT CANCER CELL LINES IN VARIOUS DISEASE
13 CATEGORIES.

14 THE DIFFERENT COLORS ARE REPRESENTATIVE OF
15 THE ETHNIC BACKGROUNDS OF THESE CELL LINES. YOU SEE
16 A LOT OF BLUE, A SEA OF BLUE. THAT BLUE ARE CELL
17 LINES OF EUROPEAN DESCENT. JUST FOR REFERENCE, IN
18 THE ORANGE ARE HISPANIC AND LATINO DESCENTS. AND IN
19 PURPLE, AFRICAN-AMERICAN; GREEN, ASIAN.

20 WE ALONG WITH THE BROADER SCIENTIFIC
21 COMMUNITY ARE SEEKING TO INCORPORATE DIVERSITY INTO
22 OUR BASIC SCIENCE AND DISEASE MODELS. YOU WILL BE
23 HEARING FROM DR. SAMBRANO HOW WE ARE DOING THAT
24 THROUGH FROM THE VERY BEGINNING IN TERMS OF WHAT WE
25 ARE ASKING OUR RESEARCHERS TO DO AND HOW WE ARE

BETH C. DRAIN, CA CSR NO. 7152

1 PROGRESSING THOSE EFFORTS. NEXT SLIDE PLEASE.

2 IN THE MEANWHILE WE ARE CONTINUING TO PUSH
3 FORWARD AND TO ACCELERATE STEM CELL REGENERATIVE
4 MEDICINE DEVELOPMENT PROGRAMS THROUGH THE CLINICS.
5 AND WE NOW HAVE FUNDED 82 CLINICAL TRIALS ACROSS A
6 BROAD RANGE OF INDICATIONS. IN SO DOING, EVER SINCE
7 THE COVID -- SINCE WE STARTED INCORPORATING DEI, WE
8 HAVE ALSO INCORPORATED DEI INTO OUR CLINICAL TRIAL
9 GRANT APPLICATIONS. YOU WILL HEAR A LITTLE BIT MORE
10 DETAIL ON THAT FROM DR. SAMBRANO. THESE DEI PLANS
11 WERE INCLUDED IN A SCIENTIFIC REVIEW BY OUR GRANTS
12 WORKING GROUP. BOARD MEMBERS WHO SERVE ON THE GWG
13 WERE INSTRUMENTAL IN HELPING OUR TEAM FIGURE OUT THE
14 BEST WAY TO EVALUATE THESE DEI PLANS DURING
15 SCIENTIFIC REVIEW. AND THIS HAS IMPACTED THE
16 SCORING, FUNDING DECISIONS, AND MILESTONE-BASED
17 CONTRACTS. NEXT SLIDE PLEASE.

18 SO NOT ONLY ARE WE ASKING THE APPLICANTS
19 TO PROVIDE A DEI PLAN, WE ARE HOLDING THEM
20 ACCOUNTABLE AND HELPING PARTNER WITH THEM TO BE ABLE
21 TO LEARN FROM THIS AND PUSH THESE PLANS FORWARD.
22 DEI MILESTONES ARE INCORPORATED INTO THE GRANT
23 NOTICE AWARD THAT TRACK THE PROGRESS, AND THEY HOLD
24 THE AWARDEES ACCOUNTABLE FOR THEIR PROPOSED PLANS.

25 WE MONITOR DEI PLAN IMPLEMENTATION THROUGH

BETH C. DRAIN, CA CSR NO. 7152

1 QUARTERLY PROGRESS REPORTS AND CLINICAL ADVISORY
2 PANELS. THE TEAM LED BY DR. ABLA CREASEY MANAGES
3 THESE AWARDS, AND THIS IS INCORPORATED INTO HOW THE
4 AWARDS ARE MANAGED THROUGH THE LIFE OF THE GRANT.

5 WE HAVE ALSO, UNDER THE LEADERSHIP OF
6 JENNIFER LEWIS, ALONG WITH OUR LEADERSHIP TEAM
7 MEMBERS, ARE LOOKING AT WAYS TO IMPROVE THROUGH OUR
8 GRANTS MANAGEMENT PORTAL THE TRACKING OF
9 DEMOGRAPHICS ALONG WITH DISEASE INDICATIONS WITH
10 MORE SPECIFICITY AND EXPANDED CATEGORIES, INCLUDING
11 SOCIAL DETERMINANTS OF HEALTH, IN ACCORDANCE WITH
12 BEST PRACTICES AND INVOLVING DESCRIPTORS SUCH AS
13 THOSE BEING DEVELOPED BY THE NATIONAL ACADEMIES AND
14 OTHER GUIDELINES.

15 THIS IS A SNAPSHOT AT THE TOP OF WHAT WE
16 HAVE SO FAR AS A BASELINE OF THE DEMOGRAPHICS. AS
17 YOU CAN SEE, THERE'S STILL UNDERREPRESENTATION OF
18 THE HISPANIC/LATINO POPULATION OVERALL IN THE 61
19 CLINICAL TRIALS THAT WERE LOOKED AT REALLY THE VERY
20 BEGINNING OF 2021. WE WILL HAVE EVEN MORE ROBUST
21 DATA MOVING FORWARD AND WILL CONTINUE TO REPORT ON
22 THIS.

23 AFTER THIS PRESENTATION, THE TEAM AND I
24 ARE HAPPY TO TAKE ANY QUESTIONS, BUT PLEASE KNOW
25 THAT WE'LL HAVE THAT OPPORTUNITY. NEXT SLIDE

1 PLEASE.

2 IN ADDITION TO THE SCIENCE, WE KNOW THAT
3 DISTRUST FEEDS DISPARITY. MISINFORMATION CERTAINLY
4 FEEDS INTO THIS. HOWEVER, FOR THE DAY-TO-DAY
5 INTERACTIONS AND WHAT THE PATIENTS AND THE COMMUNITY
6 SEES DEFINITELY FEEDS INTO THIS. HISPANIC WORKERS
7 MAKE UP 17 PERCENT OF TOTAL EMPLOYMENT ACROSS ALL
8 OCCUPATIONS, BUT ONLY 8 PERCENT OF ALL SCIENCE,
9 TECHNOLOGY, ENGINEERING, AND MEDICINE PROFESSIONALS.
10 ACCORDING TO THE PEW RESEARCH CENTER, RELATIVELY FEW
11 HISPANIC ADULTS SEE SCIENTISTS AS WELCOMING TO
12 HISPANIC PROFESSIONALS IN THESE JOBS WITH 26 PERCENT
13 REPORTING THAT THEY WERE ACCEPTED, 42 PERCENT THAT
14 FELT THAT THEY WERE SOMEWHAT ACCEPTED, AND 29
15 PERCENT FELT THEY WERE NOT AT ALL ACCEPTED.

16 IN ADDITION, IT'S BEEN RECORDED AND IT'S
17 BEEN MENTIONED AT THIS MEETING THAT PATIENTS ARE
18 MOST LIKELY TO PARTICIPATE IN RESEARCH AND IN
19 CLINICAL TRIALS WHEN THEY ARE ASKED BY A TRUSTED
20 PROVIDER, A PROVIDER THEY CAN RELATE TO, A PROVIDER
21 WHO UNDERSTANDS THEM AND CAN RELATE TO THEM AND
22 COMMUNICATE WELL WITH THEM, AND CERTAINLY A PROVIDER
23 WHO CAN SPEAK THEIR LANGUAGE. ABOUT A THIRD OF
24 HISPANIC ADULTS SAY THEY WOULD PREFER A HEALTHCARE
25 PROVIDER WHO SPEAKS SPANISH, AND THEY WOULD PREFER A

BETH C. DRAIN, CA CSR NO. 7152

1 HISPANIC HEALTHCARE PROVIDER. CIRM'S GOAL IS TO
2 FOSTER A CULTURALLY COMPETENT AND DIVERSE SCIENTIFIC
3 MEDICAL WORKFORCE IN ORDER TO BRIDGE DISTRUST, IN
4 ORDER TO INCREASE CONNECTIVITY AND RELATABILITY.
5 NEXT SLIDE PLEASE.

6 LANGUAGE, ABOUT A THIRD OF HISPANIC ADULTS
7 SAY THEY WOULD PREFER A HEALTHCARE PROVIDER WHO
8 SPEAKS SPANISH OR THEY WOULD PREFER -- I THINK THE
9 RECORDING WAS PROJECTING. OKAY.

10 SO AT THE LAST BOARD MEETING, DR. KELLY
11 SHEPARD PROVIDED AN UPDATE ON OUR EDUCATION
12 PROGRAMS, AND THE BOARD ASKED US HOW WE ARE DOING IN
13 TERMS OF DEMOGRAPHICS AND REPRESENTATION. AND SO
14 TODAY WE ARE PRESENTING KIND OF WHERE WE ARE TODAY.
15 THE SPARK PROGRAM, WHICH IS THE HIGH SCHOOL PROGRAM,
16 YOU MAY RECALL THESE ARE LEGACY EDUCATION PROGRAMS
17 WHERE SENATOR TORRES, VICE CHAIR TORRES, WAS
18 INSTRUMENTAL IN SETTING THESE UP. BUT ALL THE WAY
19 BACK FROM THEN TO PRESENT, WE SEE IN ABOUT 400 DATA
20 POINTS THAT WE HAVE RELATIVELY GOOD REPRESENTATION
21 ACROSS ETHNIC AND MINORITY GROUPS IN COMPARISON TO
22 THE CALIFORNIA CENSUS. SIMILARLY, FOR THE
23 UNDERGRADUATE AND MASTER'S PROGRAM, WHICH PRIMARILY
24 COME FROM THE CSU PROGRAMS, THERE'S GOOD
25 REPRESENTATION ACROSS ETHNIC MINORITY SUBGROUPS IN

BETH C. DRAIN, CA CSR NO. 7152

1 COMPARISON TO THE CSU CENSUS.

2 THIS WAS BY DESIGN BECAUSE, ACTUALLY UNDER
3 PROPOSITION 71, THE EDUCATION PROGRAMS WERE DIRECTED
4 TO PROVIDE BROADENED PARTICIPATION OF INDIVIDUALS
5 REPRESENTING THE DIVERSITY OF CALIFORNIA, INCLUDING
6 THOSE WHO MAY NOT HAVE HAD OPPORTUNITIES AND ARE
7 HINDERED BY SOCIOECONOMIC CONSTRAINTS. THESE ARE IN
8 QUOTES BECAUSE THEY WERE LANGUAGE THAT WERE INCLUDED
9 IN THE APPLICATIONS AND THE REVIEW, AND A PORTION OF
10 THE LANGUAGE WAS ACTUALLY IN THE PROPOSITION. SO
11 INTENTIONAL INTERVENTION TO THIS POINT HAS LED TO
12 THIS SNAPSHOT OF REPRESENTATION. NEXT SLIDE PLEASE.

13 IN ADDITION, WITH THE LAUNCHING OF PROP
14 14, WHEN WE HAD UPGRADED THE EDUCATION PROGRAMS AS
15 WELL AS DEVELOPING NEW PROGRAMS, AGAIN, DR. SHEPARD
16 DESCRIBED THESE IN DETAIL AT THE LAST MEETING, DEI
17 PLANS WERE FURTHER DEVELOPED IN THE APPLICATION AND
18 REVIEW. THE DEI PLAN AND THE TRACK RECORD OF THE
19 PROGRAM TEAM LEADERSHIP WAS PART OF THE REVIEW. WE
20 INCREASED THE STIPENDS IN THE BUDGET TO HELP ATTRACT
21 AND RETAIN SOCIALLY ECONOMICALLY DISADVANTAGED
22 TRAINEES, ADDED AN ALUMNI TRACKING PLAN.

23 WHAT WE CAN'T MEASURE WE CANNOT UNDERSTAND
24 AND WE KNOW HOW WE ARE DOING. SO THAT'S IMPORTANT.
25 AND THE PROGRAMS ARE REQUIRED TO DEFINE METRICS,

BETH C. DRAIN, CA CSR NO. 7152

1 SELF-ASSESSMENTS, AND ADDRESS GAPS IN MITIGATION
2 PLANS, AND DEI PERFORMANCE AND ACCOUNTABILITY.

3 CIRM, ALONG WITH THE PROGRAM DIRECTORS,
4 ARE PROMOTING KNOWLEDGE SHARING OF INNOVATIONS AND
5 DEVELOPMENTS AND BEST PRACTICES AROUND DEI. THE
6 GRANTEES ARE COLLECTING DEMOGRAPHIC AND
7 SOCIOECONOMIC DATA, NOT ONLY ON THOSE STUDENTS THAT
8 THEY BROUGHT INTO THE PROGRAM, BUT ON THE TOTAL
9 APPLICANT POOL SO THAT IT CAN BE MEASURED IN TERMS
10 OF WHETHER THERE ARE DISPARITIES IN THOSE THAT ARE
11 APPLYING TO THOSE THAT ARE ACCEPTED AND, WHERE
12 NEEDED, ACTIVE COURSE CORRECTION.

13 THE GRANTEES HAVE ALSO BEEN RECRUITED TO
14 HELP US UNDERSTAND WHAT THE UNDERREPRESENTATION
15 BASELINE IS SO THAT WE CAN UNDERSTAND NOT JUST AT
16 THAT INSTITUTION BUT ACROSS THE STATE. NEXT SLIDE
17 PLEASE.

18 THAT CONCLUDES THIS PORTION OF THE
19 PRESENTATION. REALLY IMPORTANT IS THE SPOTLIGHT
20 PRESENTATION BY DR. SAMBRANO WHO IS GOING TO GIVE AN
21 UPDATE ON HOW WE HAVE APPROACHED DEI IN THE GRANT
22 REVIEW PROCESS. AS I MENTIONED EARLIER, THIS IS
23 WHERE IT ALL STARTS. THIS IS WHERE WE CAN IMPACT
24 HOW THE PROGRAMS ARE DESIGNED, HOW THEY DO
25 INCORPORATE DEI. IT IMPACTS HOW WE CAN THEN TRACK

BETH C. DRAIN, CA CSR NO. 7152

1 AND WORK WITH THE GRANTEES TO ENSURE THAT WE DO THE
2 BEST IN TERMS OF IMPROVING AND DEVELOPING THESE
3 PLANS.

4 BUT MEANWHILE I'D LIKE TO JUST PAUSE AND
5 PLEASE FEEL FREE TO ASK ANY QUESTIONS, RENDER ADVICE
6 TO US, FEEDBACK, INPUT. WE WELCOME THAT BOTH AT
7 THIS MEETING AS WELL AS ALWAYS. SO I'LL JUST PAUSE
8 THERE, MR. CHAIRMAN.

9 CHAIRMAN THOMAS: THANK YOU, MARIA, FOR
10 THAT COMPREHENSIVE REVIEW.

11 MARIA B, I'M NOT SEEING EVERYBODY ON THE
12 SCREEN. DO YOU SEE ANY HANDS RAISED AT THIS POINT
13 WITH QUESTIONS OR COMMENTS FROM MEMBERS OF THE
14 BOARD?

15 MS. BONNEVILLE: THERE ARE NO HANDS RAISED
16 RIGHT NOW.

17 CHAIRMAN THOMAS: OKAY. I SEE A HAND.
18 MARVIN.

19 DR. SOUTHARD: I'M GOING TO HAVE TO LEAVE
20 PART OF THE MEETING TODAY BECAUSE I'M AT A POLICY
21 FORUM FOR THE BEHAVIORAL HEALTH SYSTEMS IN
22 CALIFORNIA, BOTH THE PRIVATE AND THE NONPROFIT AND
23 SO FORTH. AND OUR THEME IS ACTUALLY ON DEI SORTS OF
24 ISSUES. AND SO I WILL TAKE THE OPPORTUNITY TO
25 COMMUNICATE CERTAIN EFFORTS IN THIS REGARD TO OUR

BETH C. DRAIN, CA CSR NO. 7152

1 GROUP, AND I THINK THERE MAY BE SOME AREAS IN
2 CALIFORNIA WHERE THE GROUPS I'M A PART OF HERE AND
3 CIRM CAN COLLABORATE SPECIFICALLY ON THESE DEI
4 MATTERS.

5 CHAIRMAN THOMAS: THANK YOU, MARV.
6 YSABEL.

7 MS. DURON: CLAPPING HANDS, J.T. GOOD ON
8 MARVIN. THE MORE WE SPREAD THE GOSPEL, THE BETTER
9 WE'RE GOING TO WIN THE RACE. THANK YOU.

10 DR. SOUTHARD: JUST AS A CONTINUATION, WE
11 GAVE AN AWARD TO RACHEL GUERRERO FOR HER WORK IN
12 THIS AREA. AND SO MANY OF YOU MAY KNOW RACHEL WHO
13 WAS IN CHARGE FOR THE STATE OF CALIFORNIA AT TIMES
14 PAST. AND SHE WAS VERY GRATEFUL TO HEAR OF OUR
15 WORK.

16 CHAIRMAN THOMAS: THANK YOU VERY MUCH.
17 OTHER COMMENTS FROM MEMBERS OF THE BOARD? OKAY.
18 THANK YOU.

19 GIL, IF YOU'D LIKE TO DO PART 2 PLEASE
20 HERE OF THIS VERY IMPORTANT PRESENTATION.

21 DR. SAMBRANO: ABSOLUTELY. THANK YOU VERY
22 MUCH, MR. CHAIRMAN. AND THANK YOU FOR THE
23 OPPORTUNITY TO PRESENT ON THIS. LET ME JUST SHARE
24 MY SCREEN.

25 SO WHEN I WAS PUTTING THIS TOGETHER, I HAD

BETH C. DRAIN, CA CSR NO. 7152

1 ABOUT 50 SLIDES AT LEAST THAT I WAS THINKING OF
2 PRESENTING. OKAY. I ONLY HAVE TEN. I'M MAKING
3 THIS A MUCH BRIEFER PRESENTATION GIVEN THE TIME
4 LIMITATIONS. BUT IT'S JUST TO SAY THAT WE DO HAVE A
5 LOT TO SAY ABOUT THIS IN OUR EFFORT TO MAKE DEI A
6 KEY PART OF THE REVIEW PROCESS. SO LET ME START
7 WITH THIS.

8 CIRM FUNDING OPPORTUNITIES, AS YOU KNOW,
9 CUT ACROSS DIFFERENT PILLARS FROM DISCOVERY,
10 TRANSLATION, AND CLINICAL, WHICH ARE THE FOUR OF OUR
11 RESEARCH OPPORTUNITIES, BUT WE ALSO DO EDUCATION AND
12 INFRASTRUCTURE PROGRAMS, AS YOU JUST HEARD FROM DR.
13 MILLAN.

14 CONSIDERATION OF DEI BY BOTH APPLICANTS
15 AND REVIEWERS HAS NOW BEEN INCORPORATED INTO ALL
16 CIRM FUNDING OPPORTUNITIES. I JUST WANT TO START
17 WITH THAT. EVERYTHING THAT WE SUPPORT, EVERY
18 APPLICATION THAT COMES IN, EVERY PROGRAM WE HAVE HAS
19 A DEI ELEMENT ASSOCIATED WITH IT. BECAUSE THEY'RE
20 QUITE DIFFERENT, THE APPLICATIONS ARE TAILORED TO
21 THE TYPE AND STAGE OF FUNDING OPPORTUNITY. SO
22 THEY'RE GOING TO ALL LOOK A LITTLE BIT DIFFERENT.
23 AND THEN WE HAVE DEVELOPED VERY SPECIFIC SCORING
24 CRITERIA TO EMPHASIZE THE IMPORTANCE OF DEI ONCE IT
25 GETS TO REVIEW.

BETH C. DRAIN, CA CSR NO. 7152

1 SO WHAT I'M GOING TO BRIEFLY DESCRIBE
2 TODAY IS WHAT WE ASK FOR FROM APPLICANTS AND THEN
3 HOW IT IS THAT WE EVALUATE IT.

4 SO BEGINNING WITH WHAT IT IS THAT WE ASK
5 FOR. AND LET ME JUST GIVE YOU SOME CONTEXT OF WHY
6 I'M SHOWING YOU THIS VERY BUSY SLIDE. OUR EFFORT TO
7 INCORPORATE DEI IN A MUCH MORE DELIBERATE WAY, AS
8 WAS MENTIONED BY DR. MILLAN, WAS IN THE REVIEW
9 PROCESS STARTING WITH OUR COVID FUNDING OPPORTUNITY
10 IN 2020. SINCE THEN WE'VE BEEN FOCUSING INITIALLY
11 ON DEVELOPING THESE ELEMENTS WITHIN OUR CLINICAL
12 PROGRAMS. WE, IN PART, WANTED TO MAKE SURE THAT THE
13 APPLICANTS WERE ADDRESSING EFFORTS TO PERFORM
14 OUTREACH AND PARTICIPATION BY UNDERSERVED GROUPS IN
15 CLINICAL TRIALS. IT ALSO SEEMED A PRETTY
16 STRAIGHTFORWARD PLACE TO START WHERE WE HAD AT LEAST
17 A CLEAR SET OF OBJECTIVES.

18 AND WHAT I'M SHOWING YOU HERE ARE THE DEI
19 SECTIONS OF OUR APPLICATION. SO YOU SEE SEVEN PAGES
20 HERE. AND THIS ORIGINALLY STARTED AS A ONE-PAGE
21 SECTION IN OUR APPLICATION, WHICH HAS NOW EVOLVED
22 INTO THESE SEVEN PAGES THAT INCLUDES INSTRUCTIONS,
23 TABLES, AND GUIDANCE TO THE APPLICANTS TO COMPLETE.
24 WE WANT TO PROVIDE AS MUCH INFORMATION AS WE CAN
25 ABOUT WHAT IT IS THAT WE ARE LOOKING FOR, WHAT WE

BETH C. DRAIN, CA CSR NO. 7152

1 ARE ASKING ABOUT, AND AN OPPORTUNITY FOR THEM TO
2 PROVIDE US AS COMPREHENSIVE OF A PLAN AS POSSIBLE
3 THAT ADDRESSES DIFFERENT ELEMENTS OF THESE.

4 SO THIS IS A SUMMARY OF WHAT IT IS THAT WE
5 ASK FOR ACROSS THE SEVEN DIFFERENT PAGES. WE ASK
6 FOR A DESCRIPTION OF THE KNOWN DEMOGRAPHIC
7 DISPARITIES AND DISEASE BURDEN, CARE AND HEALTH
8 OUTCOMES IN THE AFFECTED POPULATION; THAT IS,
9 WHATEVER THE DISEASE OR CONDITION THAT THE
10 APPLICANTS ARE ADDRESSING. WE ASK THEM TO COMPLETE
11 A POPULATION TABLE THAT PROVIDES THE PROPOSED GOALS
12 FOR ENROLLMENT ACROSS RACE, ETHNICITY, GENDER AND
13 AGE RELATIVE TO THE DEMOGRAPHICS OF THE POPULATION
14 THAT IS AFFECTED BY THAT DISEASE OR CONDITION AS
15 WELL AS PROVIDE A JUSTIFICATION FOR THE GOALS AND
16 WHY THERE ARE DIFFERENCES, MAYBE DUE TO THE SIZE OF
17 THE TRIAL OR THE STAGE OF THE TRIAL AND SO ON.

18 WE ASK THEM TO PROVIDE THEIR PLANS FOR
19 OUTREACH, ENGAGEMENT, ENROLLMENT, AND RETENTION OF
20 TRIAL PARTICIPANTS FROM UNDERSERVED GROUPS. FOR
21 EXAMPLE, DIFFERENT TRIAL SITES AND TESTING AREAS,
22 ALLIANCES THAT THEY'VE DEVELOPED WITH COMMUNITY
23 CLINICS AND/OR NAVIGATION SERVICES AS A FEW
24 EXAMPLES.

25 WE ASK FOR AN OUTLINE OF THE DEI-ORIENTED

BETH C. DRAIN, CA CSR NO. 7152

1 EXPERTISE AND EXPERIENCE OF THE TEAM MEMBERS AS WELL
2 AS ACTIVITIES THAT SUPPORT THE DEVELOPMENT OF
3 CULTURAL SENSITIVITY ON THE TEAM AND ANY PARTNERING
4 INSTITUTIONS IN CARRYING OUT THE PROJECT.

5 THIS IS NOW FOCUSED ON THE CLINICAL
6 PROGRAM, AND WE IMAGINE THE DISCOVERY STAGE OR
7 EDUCATION PROGRAMS ARE GOING TO ASK FOR SLIGHTLY
8 DIFFERENT THINGS. SO THIS IS JUST AN EXAMPLE OF THE
9 CLINICAL. AND JUST FOR REFERENCE, THE DISCOVERY
10 STAGE, THE QUESTIONS THAT WE ASK ARE A BIT MORE
11 FOCUSED ON HOW THE APPLICANTS HAVE CONSIDERED THE
12 POTENTIAL INFLUENCE OF RACE, ETHNICITY, SEX
13 DIFFERENCES, AGE WITHIN THEIR PLAN AND DESIGN.
14 AGAIN, AN EXAMPLE.

15 NOW LET ME TELL YOU ABOUT HOW IT IS THAT
16 WE EVALUATE DEI. WE HAVE, AS YOU KNOW, IN OUR
17 GRANTS WORKING GROUP TWO TYPES OF MEMBERS. WE HAVE
18 THE SCIENTIFIC MEMBERS AS WELL AS OUR GRANTS WORKING
19 GROUP PATIENT ADVOCATE OR NURSE MEMBERS WHO SERVE ON
20 THE ICOC AS WELL. THE SCIENTISTS PROVIDE A
21 SCIENTIFIC EVALUATION AND GIVE A SCIENTIFIC SCORE,
22 AND I'LL EXPLAIN IN THE NEXT SLIDE HOW IT IS THAT
23 THAT SCIENTIFIC SCORE ALSO INCORPORATES DEI. AND
24 THEN THE PATIENT ADVOCATE NURSE MEMBERS, DEPENDING
25 ON THE TYPE OF OPPORTUNITY FOR THE CLINICAL AND

BETH C. DRAIN, CA CSR NO. 7152

1 TRANSLATION APPLICATIONS, PROVIDE AN ADDITIONAL DEI
2 SCORE IN ADDITION TO THEIR ROLE IN PROVIDING
3 OVERSIGHT AND PROVIDING A PATIENT PERSPECTIVE ON THE
4 SIGNIFICANCE AND IMPACT OF A PROPOSED PROJECT.

5 THESE ARE THE SCIENTIFIC REVIEW CRITERIA
6 THAT WE UTILIZE AS THE BASIS FOR THE SCIENTIFIC
7 SCORE. SO THIS IS THE SCORE THAT THE SCIENTIFIC
8 MEMBERS USE TO SCORE AN APPLICATION. AND GENERALLY
9 THESE CRITERIA AT THIS HIGH LEVEL ARE MOSTLY THE
10 SAME FOR ALL OF OUR RESEARCH-TYPE PROJECTS. THEY'RE
11 GOING TO BE A LITTLE BIT DIFFERENT FOR EDUCATION AND
12 INFRASTRUCTURE PROGRAMS, BUT ALL OF THEM WILL
13 INCORPORATE NOW A CRITERION RELATED TO DEI. IN THIS
14 CASE DOES THE PROPOSAL UPHOLD THE PRINCIPLES OF
15 DIVERSITY, EQUITY, AND INCLUSION VIS-A-VIS DOES THE
16 CRITERIA HAVE SUBBULLETS THAT I'M NOT GOING TO GO
17 THROUGH IN DETAIL THAT ARE TAILORED, AGAIN, TO THE
18 SPECIFIC FUNDING OPPORTUNITY?

19 SO THE CRITERIA AS SHOWN HERE ARE INTENDED
20 TO BE THE MOST CRITICAL ELEMENTS SUCH THAT FAILURE
21 IN ANY OF THESE, IN GENERAL OR IDEALLY, COULD RESULT
22 IN A NONFUNDABLE SCORE. THESE ARE THE MOST
23 IMPORTANT ELEMENTS. SO DEI, THEREFORE, IS
24 HIGHLIGHTED AS ONE OF THOSE.

25 NOW, IN ADDITION TO THE FACT THAT THE

BETH C. DRAIN, CA CSR NO. 7152

1 SCIENTIFIC SCORES THAT YOU SEE INCORPORATE THAT DEI
2 ELEMENT, FOR A CLINICAL PROGRAM AS WELL AS NOW IN
3 OUR TRANSLATIONAL PROGRAM, WE HAVE AN ADDITIONAL DEI
4 SCORE THAT OUR PATIENT ADVOCATE AND NURSE MEMBERS
5 PROVIDE. THE SCALE IS ZERO TO TEN. AND THE
6 CRITERIA THAT ARE USED TO COME UP WITH THIS SCORE IS
7 BASED ON THESE THREE ELEMENTS: A COMMITMENT TO DEI,
8 HOW WELL THEY JUDGE THE PROJECT SEEMS TO DEMONSTRATE
9 COMMITMENT, DEVELOPING A THERAPY THAT SERVES AN
10 UNMET NEED OF CALIFORNIA POPULATION UNDERSERVED
11 GROUPS. THEY ARE ASKED TO DESCRIBE DISPARITIES THAT
12 WOULD ULTIMATELY UTILIZE THEIR PRODUCT, RECENT TRIAL
13 ENROLLMENT TARGETS, AND SO ON. THEY ALSO ASSESS THE
14 PROJECT PLANS IN TERMS OF ACTIVITIES THAT THEY WOULD
15 PROPOSE WOULD BE INCLUSION AND OUTREACH, ENGAGEMENT,
16 ENROLLMENT, AND RETENTION, AND HOW THEY WILL DEVELOP
17 CULTURAL SENSITIVITY. SO THIS COULD BE THROUGH
18 TRAINING OR THROUGH OTHER METHODS.

19 AND TO HELP GUIDE THE SCORING FOR OUR
20 BOARD MEMBERS, WE'VE DEVELOPED THIS RUBRIC, WHICH
21 YOU DON'T NEED TO SEE THE DETAILS OF, BUT THAT
22 SPLITS OUT THESE BASIC CRITERIA AND PROVIDE ACROSS
23 THE DIFFERENT SCORES HOW IT IS THAT A GOOD
24 APPLICATION THAT SCORES A 9 OR 10 COMPARES TO
25 SOMETHING THAT MIGHT SCORE A 0 OR 2. SO WE HAVE

BETH C. DRAIN, CA CSR NO. 7152

1 BEEN USING THAT AS A TOOL. EVEN THIS HAS GONE
2 THROUGH SEVERAL ITERATIONS AS WE CONTINUE TO DEVELOP
3 THIS ON THE PROGRAM.

4 I JUST WANT TO SHOW YOU SOMETHING THAT NOW
5 THAT WE HAVE TWO SCORES THAT ARE COMING FROM THE
6 GRANTS WORKING GROUP AND SOME OF OUR PROGRAMS, FOR
7 EXAMPLE, WITH THE CLINICAL PROGRAM, WE'VE DEVELOPED
8 A PROCESS TO ENSURE THAT APPLICATIONS THAT RECEIVE
9 EITHER A LOW DEI SCORE OR A NEEDS TO IMPROVE
10 SCIENTIFIC SCORE ARE REVISED AND REEVALUATED BY THE
11 GRANTS WORKING GROUP PRIOR TO GOING TO THE BOARD FOR
12 FINAL FUNDING. SO THIS THEN CREATES THOSE TWO
13 REVIEW CYCLES. SO EACH ARROW IS A REVIEW CYCLE. AN
14 APPLICANT SUBMITS, WE ASSES ELIGIBILITY, THEY GO TO
15 THE GRANTS WORKING GROUP REVIEW. AND COMING OUT OF
16 THAT GRANTS WORKING GROUP, IF THE RECOMMENDATION
17 FROM THAT PANEL IS A SCIENTIFIC SCORE OF 2 OR A DEI
18 SCORE BELOW 6, WE PROVIDE THE APPLICANT WITH A
19 SUMMARY OF CONCERNS AND HAVE THEM ADDRESS THOSE
20 CONCERNS AND REVISE THE APPLICATION THAT COMES OUT
21 OF THIS CYCLE AND WE BRING IT BACK TO THE GRANTS
22 WORKING GROUP AT A SUBSEQUENT CYCLE FOR EVALUATION.
23 AND IF ALL OKAY, THEN IT GOES TO THE ICOC FOR A
24 FINAL. WE JUST WANTED TO SHARE THAT PROCESS.

25 AND THEN, LASTLY, WE DO STILL HAVE SOME

BETH C. DRAIN, CA CSR NO. 7152

1 CHALLENGES IN PUTTING TOGETHER A COMPLETE DEI SET OF
2 ELEMENTS IN OUR APPLICATIONS AND THE PROCESS FOR
3 REVIEW. AND IT'S ONE THAT WE WORK WITH, BUT ALSO
4 ONE THAT WE NEED TO MAKE SURE THAT WE EXPLAIN TO THE
5 REVIEWERS AS THEY GO ABOUT THEIR EVALUATION. SO IT
6 IS BASICALLY THAT REVIEWERS ARE ALLOWED TO COMMENT
7 ON VIRTUALLY ALL ASPECTS OF DEI; FOR EXAMPLE,
8 DEMOGRAPHIC DATA THAT PRESENTS THE NUMBER OF WOMEN
9 OR INDIVIDUALS FROM SPECIFIC RACIAL OR ETHNIC
10 BACKGROUNDS AS PART OF THE APPLICATION, THEIR PLAN
11 TO RECRUIT PATIENTS FROM DIVERSE BACKGROUNDS, OR
12 THEIR TRACK RECORD IN PROMOTING DIVERSITY, EQUITY,
13 AND INCLUSION. HOWEVER, THERE IS STILL CALIFORNIA
14 PROP 209 RESTRICTIONS WHERE REVIEWERS AND CIRM
15 CANNOT SPECIFICALLY USE THE CHARACTERISTICS OF RACE,
16 ETHNICITY, GENDER, OR NATIONAL ORIGIN IN EVALUATING
17 THE APPLICANT TEAM PERSONNEL. WE PRESENT THIS AS WE
18 START THESE REVIEWS TO ENSURE THAT, WHEN WE DO THE
19 REVIEW, THAT WE FOCUS THE REVIEWERS ON THE ELEMENTS
20 THAT ARE ALLOWABLE. AND WE ALSO ADVISE APPLICANTS
21 ABOUT THIS TO ENSURE THAT THEY DEVELOP THEIR DEI
22 PLANS WITH THAT IN MIND.

23 AND SO AS I MENTIONED, THERE ARE OTHER
24 THINGS THAT I COULD EXPAND ON AND TALK TO YOU ABOUT,
25 BUT I WILL END IT HERE AND TAKE ANY QUESTIONS,

BETH C. DRAIN, CA CSR NO. 7152

1 KNOWING THAT THIS IS AN ONGOING PROCESS FOR US, THAT
2 WE WILL CONTINUE TO EVOLVE AND DEVELOP WITH THE HOPE
3 OF CREATING A MUCH BETTER PROCESS AS WE GO ALONG.
4 SO THANK YOU.

5 CHAIRMAN THOMAS: THANK YOU VERY MUCH,
6 GIL. AND I THINK THAT THIS IS A MOST IMPORTANT
7 PRESENTATION BY BOTH YOU AND MARIA. AND I WANTED TO
8 HIGHLIGHT ONE OF GIL'S SLIDES IN PARTICULAR BECAUSE
9 IT GETS TO THE ESSENCE OF THE LEVEL OF IMPORTANCE
10 THAT WE PLACE ON DEI, WHICH WAS THE SLIDE THAT SAID
11 THAT IF WE GET A DEI SCORE IN GWG OF LESS THAN 6,
12 EVEN IF THE GRANT RECEIVED A FUNDING SCORE ON THE
13 SCIENCE SIDE, THAT WE WILL SEND IT BACK FOR THEM TO
14 REVISE AND REVIEW.

15 THAT'S VERY IMPORTANT AND A REAL MILESTONE
16 DEVELOPMENT FOR THE AGENCY, WHICH WE'VE ACTUALLY
17 SEEN IN PRACTICE IN THE GWG. AND IT GETS TO THE
18 ESSENCE OF HOW MUCH WE DO EMPHASIZE DEI AND THE
19 SERIOUSNESS TO WHICH WE TAKE THE WHOLE ISSUE. SO I
20 JUST WANTED TO MAKE SURE THE BOARD FOCUSED ON THAT
21 BECAUSE THAT'S A BIG DEAL.

22 GIL AND HIS TEAM AND MARIA AND THE CIRM
23 TEAM WRIT LARGE HAVE SPENT A HUGE AMOUNT OF TIME
24 WITH THE BOARD IN DEVELOPING THE DEI POLICIES TO THE
25 STAGE WE ARE AT RIGHT NOW. AND I THINK WE REALLY

BETH C. DRAIN, CA CSR NO. 7152

1 HAVE A MODEL SYSTEM HERE FOR HOW THAT VERY IMPORTANT
2 ISSUE SHOULD BE TREATED IN THE CONTEXT OF THINGS
3 LIKE THOSE THAT WE DO. SO THANK YOU TO GIL, THANK
4 YOU TO MARIA, THANK YOU TO YSABEL, TO ALL MEMBERS OF
5 THE BOARD AND THE TEAM. I THINK THIS IS SOMETHING
6 WE CAN BE REALLY PROUD OF.

7 OTHER COMMENTS FROM MEMBERS OF THE BOARD?

8 MS. BONNEVILLE: WE HAVE SEVERAL HANDS
9 RAISED, J.T.

10 CHAIRMAN THOMAS: WILL YOU CALL THEM?

11 MS. BONNEVILLE: I SURE WILL. YSABEL.

12 MS. DURON: THANK YOU VERY MUCH, MR.
13 CHAIR. I AM SO THRILLED WE ARE AT THIS STAGE.
14 THANK YOU VERY MUCH TO GIL AND MARIA AND, YES, THE
15 CIRM STAFF AND TEAM FOR REALLY, REALLY GETTING
16 BEHIND THIS AND BEING INTENTIONAL.

17 THE ONLY THING I HAVE TO SAY, GIL, AND
18 MAYBE I'M GETTING AHEAD OF MYSELF, IS ARE WE
19 DEVELOPING OR DO WE HAVE METRICS IN PLACE TO
20 EVALUATE AFTER THAT, IN FACT, THEY ARE MEETING THESE
21 GOALS DOWN THE ROAD, THAT THEY ARE SEEING PROGRESS
22 IN OUR INSTITUTIONS, AND THAT THEY ARE MOVING IN THE
23 DIRECTION WE HOPE DEI AND THESE GUIDELINES ARE MEANT
24 FOR THEM TO GO? SO DO YOU HAVE METRICS AND
25 EVALUATIONS IN PLACE FOR MAYBE SIX MONTHS OR A YEAR

BETH C. DRAIN, CA CSR NO. 7152

1 IN OR TWO YEARS, HOWEVER YOU WANT TO MEASURE
2 SUCCESS?

3 DR. SAMBRANO: YES, WE DO. AND I FOCUSED
4 MY PRESENTATION ONLY ON THE REVIEW PROCESS ITSELF.
5 BUT DR. ABLA CREASEY AND JENNIFER LEWIS ARE
6 DEVELOPING AND HAVE PUT IN PLACE ELEMENTS TO TRACK
7 ONCE AN AWARD IS MADE WITH MILESTONES THEIR PROGRESS
8 ON DEI. AND SO THESE ARE PAYMENT-BASED MILESTONES.
9 SO DEFINITELY MAKING SURE THAT OUR GRANTEES ARE
10 FOLLOWING UP. SO THANKS FOR THE QUESTION.

11 MS. BONNEVILLE: LARRY.

12 MR. GOLDBERG: YES, THANK YOU. I JUST
13 WANTED TO ADD THAT I SERVED ON AN FDA ADVISORY PANEL
14 LAST WEEK EVALUATING A LICENSING APPLICATION. AND
15 THE APPLICATION GOT INTO SERIOUS TROUBLE, PROBABLY
16 LETHAL TROUBLE, BECAUSE THE CLINICAL TRIAL
17 POPULATION WAS NOT ADEQUATELY DIVERSE. SO IT'S NOT
18 JUST AT THE RESEARCH LEVEL. THIS MAY BECOME
19 IMPORTANT AT THE LICENSING LEVEL AS WELL AS THIS
20 SPREADS.

21 MS. BONNEVILLE: THANK YOU. GEORGE.

22 DR. BLUMENTHAL: THREE QUICK POINTS.
23 FIRST, I WANT TO THANK YOU, GIL AND MARIA. I THINK
24 I'M REALLY PLEASED AT THE PROGRESS THAT'S MADE IN A
25 RELATIVELY SHORT TIME OF DEI ISSUES. AND I THINK IT

BETH C. DRAIN, CA CSR NO. 7152

1 IS A CREDIT TO THE TEAM THAT YOU'VE GONE AS FAR AS
2 YOU HAVE. THAT'S GREAT.

3 SECOND, I WANT TO SECOND WHAT YSABEL SAID
4 EARLIER. I THINK IT IS IMPORTANT ALSO TO MEASURE
5 SUCCESS AND BASICALLY TO HAVE NUMERICAL MEASURES OF
6 SUCCESS AND TO FOLLOW THAT ALONG OVER TIME. SO I
7 HOPE EVERY EFFORT WILL BE MADE TO KEEP STATISTICS ON
8 HOW WE ARE DOING, ET CETERA, SO THAT WE CAN MEASURE,
9 NOT JUST AT A GIVEN TIME, OVER TIME HOW THINGS ARE
10 GOING.

11 AND THE THIRD POINT I WOULD MAKE CONCERNS
12 YOUR POINT ABOUT PROPOSITION 209. I THINK YOU'RE
13 RIGHT. IT IS NOT APPROPRIATE TO USE DIVERSITY
14 WITHIN THE TEAM AS A CRITERIA BASED ON PROPOSITION
15 209, BUT I DON'T BELIEVE THAT THERE IS ANY
16 RESTRICTION ON USING THE APPROACHES THAT THE TEAM
17 MAY USE TO ENSURE THEIR OWN DIVERSITY IF THEY HAVE
18 OUTREACH PROGRAMS TO TRY TO BRING IN DIVERSE
19 INDIVIDUALS TO THEIR TEAM. I THINK THAT IS
20 SOMETHING THAT IS APPROPRIATE TO LOOK AT AND DOESN'T
21 RUN AFOUL OF THE PROPOSITION 209 PROHIBITION. SO I
22 JUST WANT TO ENCOURAGE YOU TO THINK ABOUT THAT.

23 MS. BONNEVILLE: THANK YOU, GEORGE. KIM.

24 DR. BARRETT: ALSO I'M VERY APPRECIATIVE,
25 GIL, OF YOUR PRESENTATION AND ALSO MARIA'S. J.T.

BETH C. DRAIN, CA CSR NO. 7152

1 CALLED THIS A MODEL SYSTEM. AND I THINK THAT'S
2 PRECISELY WHAT IT IS, AND I WOULD HOPE THAT WE COULD
3 SEE THIS EMULATED IN OTHER FUNDING BODIES. I'M
4 PARTICULARLY STRUCK BY THE CRITERIA THAT YOU TALKED
5 ABOUT IN TERMS OF THE CLINICAL TRIALS AND ESPECIALLY
6 THE REQUIREMENT THAT APPLICANTS DOCUMENT THEIR
7 ACTIVITIES TO SUPPORT THE DEVELOPMENT OF CULTURAL
8 SENSITIVITY AMONG THE TEAM. WE WILL NOT BE ABLE TO
9 RECRUIT AND RETAIN PARTICIPANTS IF THEY DON'T FEEL
10 COMFORTABLE PARTICIPATING. SO THAT'S, I THINK,
11 ALMOST A UNIQUE FEATURE. I'VE NEVER SEEN THAT
12 ADDRESSED AS PART OF A GRANT REVIEW PROCESS. SO
13 CONGRATULATIONS.

14 MS. BONNEVILLE: THANK YOU, KIM. CHRIS.

15 DR. MIASKOWSKI: THANKS, MARIA. I'D LIKE
16 TO COMMENT AS A MEMBER OF THE GRANTS WORKING GROUP,
17 PUTTING THESE GUIDELINES INTO OPERATION. AND I
18 REALLY, REALLY WANT TO COMMEND THE STAFF FOR THE WAY
19 THE APPLICATION HAS CHANGED. I'VE BEEN DOING THIS
20 WORK FOR ABOUT A YEAR NOW, AND I WANT TO MAKE TWO
21 POINTS.

22 WITH THE CHANGES IN THE APPLICATION, IT'S
23 MUCH EASIER FOR US WHO ARE WORKING TO RATE THE DEI
24 COMPONENTS OF THE GRANT TO SEE IT ALL IN ONE PLACE.
25 BUT THE OTHER PART I WAS STRUCK WITH WITH THE ROUND

BETH C. DRAIN, CA CSR NO. 7152

1 I JUST DID, AND YOU ALLUDED TO THIS, GIL, BUT I
2 THINK WE COULD CALL IT OUT IN RELATIONSHIP TO THE
3 INSTRUCTIONS THAT ARE GIVEN TO THE APPLICANTS. I
4 BELIEVE WHAT WE ARE DOING IN THAT SPACE IS PROMPTING
5 PEOPLE TO THINK ABOUT THESE VARIOUS AREAS OF DEI,
6 AND IT'S EXCEEDINGLY WELL-WORDED. I DON'T THINK WE
7 SHOULD CUT THAT SHORT.

8 THE OTHER PIECE IN TERMS OF THE METRICS,
9 IN SOME OF THE AREAS, AND I'M NOT GOING TO REMEMBER
10 ALL OF THEM, THE APPLICANTS ARE ACTUALLY PROMPTED TO
11 INCLUDE METRICS THAT THEY'RE GOING TO USE TO
12 EVALUATE THEIR OWN OBJECTIVES. SO WE'VE BUILT IN
13 SOMEWHAT OF AN EVALUATION SYSTEM AS WELL. SO I JUST
14 WANT YOU TO KNOW AND APPLAUD THE STAFF FOR THIS
15 WORK. IT'S REALLY, REALLY WONDERFUL TO SEE IT.
16 THANKS SO MUCH.

17 MS. BONNEVILLE: THANKS, CHRIS. AL.

18 MR. ROWLETT: THANK YOU. I AM ALSO AT THE
19 SAME CONFERENCE THAT MARV SOUTHARD IS ATTENDING AND
20 WILL BE SHARING THE SENTIMENTS REGARDING DEI.

21 MARIA, J.T., I WANT TO COMPLIMENT THE
22 STAFF ON THE INCLUSIVE NATURE OF THIS PROCESS. THE
23 PATIENT ADVOCATES' NOT ONLY PERSPECTIVE, BUT CHANGES
24 TO THE SCORING MECHANISMS SPECIFICALLY, AND I'LL
25 CALL OUT THE SOCIAL DETERMINANTS OF HEALTH AS ONE

BETH C. DRAIN, CA CSR NO. 7152

1 EXAMPLE, SOMETHING THAT I HAVE BEEN CHAMPIONING THAT
2 WE PAY ATTENTION TO AS NOT ONLY A REFERENCE ONCE,
3 NOT TWICE, BUT THREE TIMES DURING THIS PRESENTATION,
4 WHICH, AGAIN, IS REPRESENTATIVE OF THE WORK THAT HAS
5 BEEN DONE FROM THE BEGINNING TO NOW.

6 AND I ALSO AGREE WITH THE FELLOW BOARD
7 MEMBERS. THIS IS A WORK THAT IS GOING TO CONTINUE.
8 IDEALLY THIS WILL BECOME THE BENCHMARK FOR EVERY
9 ORGANIZATION THAT PROVIDES -- THAT DOES WORK LIKE
10 THIS IN TERMS OF DIVERSITY, EQUITY, INCLUSION, AND
11 ACCESS. AND WE ARE MAKING ACCESS FOR PATIENTS A
12 REALITY, AND I AM THRILLED TO SEE THIS PRESENTATION.

13 MS. BONNEVILLE: THANK YOU, AL. THANKS
14 FOR EVERYTHING YOU DID TO GET US HERE. YSABEL.

15 MS. DURON: KIM SIMPLY REMINDED ME EVEN AS
16 WE TALK ABOUT CULTURALLY APPROPRIATENESS, I THINK WE
17 NEED TO ADD LANGUAGE APPROPRIATENESS AS WELL. THAT
18 IS ONE OF THE NO. 1 BARRIERS FOR A PERCENTAGE OF OUR
19 POPULATION NOT ONLY TO BE RECRUITED INTO, BUT TO BE
20 MAINTAINED IN RESEARCH. SO WE NEED TO MAKE SURE
21 THAT IS A VERY CRITICAL POINT OF ACCESS, AND THAT IS
22 LANGUAGE. SO IT'S NOT CULTURAL SENSITIVITY. IT'S
23 LANGUAGE APPROPRIATENESS. SO I CHALLENGE YOU, GIL,
24 TO ADD THAT INTO THE SLIDE.

25 MS. BONNEVILLE: THANKS, YSABEL.

BETH C. DRAIN, CA CSR NO. 7152

1 MOHAMMED.

2 DR. ABOUSALEM: I'D LIKE TO THANK MARIA
3 AND HER TEAM FOR ALL THIS GREAT WORK. I CAN SEE THE
4 PROGRESS THERE. I AM CONVINCED THAT YOU WILL
5 ACHIEVE THE GOAL THAT WE WANT TO ACHIEVE HERE,
6 ESPECIALLY IF YOU DEFINE THOSE SUCCESS METRICS AND
7 STATISTICS AND KEEP MONITORING THEM OVER TIME.

8 THE THOUGHT THAT I'D LIKE TO LEAVE YOU
9 WITH IS CONSIDER -- GIVEN THE GOAL, THAT WE WANT
10 THIS TO BE A BENCHMARK FOR SOCIETY OR SIMILAR
11 ORGANIZATIONS, CONSIDER THE OPPORTUNITY FOR
12 LAUNCHING A MARKETING CAMPAIGN AROUND WHAT CIRM IS
13 DOING IN THIS AREA. SO ACTUALLY DON'T WAIT FOR
14 COMPANIES TO APPLY OR PARTNERS TO APPLY AND ACTUALLY
15 SEE THAT WORK IN THE APPLICATION, BUT ACTUALLY SPEAK
16 IT OUT, PUSH IT OUT ACROSS ALL MEDIA TO INVITE
17 PEOPLE TO LEARN FROM CIRM AND SEE WHAT YOU'RE DOING
18 IN THIS AREA EVEN IF THEY'RE NOT APPLICANTS FOR OUR
19 PROGRAMS.

20 MS. BONNEVILLE: THANK YOU. DEBORAH.

21 DR. DEAS: YES. I'D LIKE TO THANK MARIA,
22 GIL, AND THE TEAM FOR THE EXCELLENT WORK IN THIS
23 AREA. I CAN'T HELP BUT THINK BACK TO THE TIME WHEN
24 WE WERE DISCUSSING ALL THIS SEVERAL YEARS AGO. AND
25 I'M SO PLEASED THAT EVERYTHING THAT WE DISCUSSED HAS

1 BEEN IMPLEMENTED.

2 THE ONE POINT THAT I'D LIKE TO ALSO
3 HIGHLIGHT IS, AS WE LOOK AT DEI, AND I LIKE THAT WE
4 ARE DOING THIS, IS THAT IT'S IMPORTANT TO FOLLOW THE
5 OUTCOMES AND TO TRACK THOSE OUTCOMES OVER TIME.
6 BECAUSE WHEN WE DON'T DO IT, THERE'S THE TENDENCY TO
7 REGRESS BACK TO WHAT WE DID PREVIOUSLY OR WHAT WE
8 WEREN'T DOING. SO I WOULD LIKE TO SEE THIS
9 FOLLOWING THE DATA AND EVALUATING THE OUTCOMES OVER
10 TIME, AND I'D LIKE US TO REVISIT ON OCCASION TO MAKE
11 SURE WHERE WE'RE GOING ON THAT.

12 ALSO I REFER BACK TO WHAT YSABEL STATED AS
13 WELL. WHEN WE HAVE INVESTIGATORS, HAVING THEM DO
14 THEIR PROGRESS REPORT WITH THOSE OUTCOMES AND
15 DETERMINING WHAT IS THEIR PROGRESS IN DEI AS WELL.

16 MS. BONNEVILLE: THANK YOU, DEBORAH.
17 YSABEL.

18 MS. DURON: DID EVERYBODY ELSE GET THEIR
19 TIME IN? I WANTED TO MAKE SURE. VERY GOOD. I JUST
20 WANTED TO SAY TO MOHAMMED'S POINT, IN FACT, WE WILL
21 BE TALKING ABOUT THIS VIRTUALLY NATIONALLY TOMORROW
22 MORNING WHEN THE LATINO CANCER INSTITUTE HOSTS ITS
23 FOURTH ANNUAL FORUM. MARIA HAS BEEN INVITED TO THE
24 TABLE BECAUSE I WANT THE WORLD TO KNOW WHAT THE HECK
25 CIRM IS DOING AND TO START SHOWING THIS MODEL OUT

BETH C. DRAIN, CA CSR NO. 7152

1 THERE. I'VE BEEN TALKING ABOUT IT AT MY VARIOUS
2 TABLES AS WELL FOR SOME TIME NOW BECAUSE I JUST
3 THINK IT IS A MODEL AND IT'S EVOLVING AND GIL AND
4 MARIA AND THE TEAM ARE REALLY GETTING THE NUANCES.
5 SO I'M THRILLED. I'M ABSOLUTELY THRILLED.

6 AND, IN FACT, PULLING OUT SOME OF YOUR
7 SLIDES ALREADY, I'LL OWN IT IN PUBLIC, GIL. I
8 PULLED OUT A COUPLE OF YOUR SLIDES. I'M GOING TO
9 SEND THEM ON TO THE NATIONAL BREAST CANCER
10 ROUNDTABLE. WE ARE IN PUBLIC. I CAN DO THAT. AND
11 LET THEM KNOW, HERE, LET US NOT REINVENT THE WHEEL.
12 HERE ARE SOME BENCHMARKS WHERE WE CAN START.

13 SO DON'T WORRY, MOHAMMED. I AM THE TOWN
14 CRIER, AND I TALK ABOUT IT WHEREVER I GO AS WELL AS
15 HAVING A COMMS PLAN. I'M SURE WE'LL DO THAT BECAUSE
16 WE GOT A GREAT COMMS TEAM TOO.

17 MS. BONNEVILLE: THANK YOU, YSABEL.
18 MARVIN HAS HIS HAND RAISED. MARVIN.

19 DR. SOUTHARD: WANT TO ALSO SAY THAT AL
20 AND I WILL BE SHARING THIS INFORMATION AT THE
21 MEETING WE ARE TOO.

22 MS. BONNEVILLE: J.T.

23 CHAIRMAN THOMAS: WELL, THANK YOU FOR ALL
24 OF YOUR COMMENTS, MEMBERS OF THE BOARD. AND, AGAIN,
25 CONGRATULATIONS TO MARIA, GIL, AND THE ENTIRE TEAM.

BETH C. DRAIN, CA CSR NO. 7152

1 THIS TOOK A HUGE AMOUNT OF WORK, PIONEERING WORK,
2 AND WE CAN ALL BE VERY PROUD OF WHERE WE ARE.

3 OKAY. WE ARE NOW GOING TO MOVE TO THE
4 ACTION ITEMS. WE'RE GOING TO TAKE ITEM 6 AND 7
5 FIRST. THEY COMPRISE ACTION ITEMS BEFORE THE
6 APPLICATION REVIEW SUBCOMMITTEE TO WHICH WE WILL NOW
7 MOVE.

8 SO WE'LL START WITH ITEM NO. 6,
9 CONSIDERATION OF APPLICATIONS SUBMITTED IN RESPONSE
10 TO CLINICAL TRIAL STAGE PROJECTS PROGRAM
11 ANNOUNCEMENTS CLIN1 OR 2. PRESENTATION BY DR.
12 SAMBRANO. GIL.

13 DR. SAMBRANO: THANK YOU, MR. CHAIRMAN.
14 ALL RIGHT. THESE ARE THE RECOMMENDATIONS FROM THE
15 GRANTS WORKING GROUP RELATED TO OUR LATEST REVIEW
16 CYCLE FOR OUR CLINICAL PROGRAM. AS ALWAYS, WE START
17 WITH OUR MISSION THAT WE SHOW YOU HERE, BUT ALSO TO
18 OUR PANEL TO MAKE SURE WE'RE ALL ON THE SAME PAGE OF
19 WHAT WE ARE TRYING TO ACHIEVE THROUGH THESE
20 PROGRAMS.

21 THIS INDICATES A SNAPSHOT OF WHERE WE ARE
22 ON OUR BUDGET FOR THIS FISCAL YEAR OF 22/23. WE
23 HAVE AN ANNUAL ALLOCATION OF 169 MILLION. THE
24 AMOUNT THAT HAS BEEN APPROVED SO FAR IS 14.7. THERE
25 ARE TWO APPLICATIONS UNDER CONSIDERATION TODAY THAT

BETH C. DRAIN, CA CSR NO. 7152

1 TOTAL 15.1. AND IF THESE ARE APPROVED, WE WOULD
2 HAVE A REMAINDER OF 132 LEFT IN OUR BUDGET.

3 THIS IS A REMINDER OF THE SCIENTIFIC SCORE
4 THAT IS USED TO ASSESS THE APPLICATIONS. THOSE THAT
5 RECEIVE A SCORE OF 1 HAVE BEEN DEEMED TO HAVE
6 EXCEPTIONAL MERIT AND WARRANT FUNDING. A SCORE OF 2
7 MEANS THEY NEED IMPROVEMENT AND ARE SPECIFICALLY
8 TAKEN BACK TO THE APPLICANT FOR REVISION AND
9 RESUBMISSION. A SCORE OF 3 MEANS THAT THEY'RE
10 SUFFICIENTLY FLAWED, THAT THEY DON'T WARRANT
11 FUNDING, AND THEY CANNOT RESUBMIT FOR SIX MONTHS.

12 THE REVIEW CRITERIA, AS WE JUST SAW, THAT
13 ARE USED FOR THE CLINICAL PROGRAMS ARE THE FIVE:
14 SIGNIFICANCE AND POTENTIAL FOR IMPACT, WHETHER THEY
15 HAVE A SOUND RATIONALE, WHETHER THE PROJECT IS WELL
16 PLANNED AND DESIGNED, IF IT'S FEASIBLE, INCLUDING
17 HAVING AN APPROPRIATE TEAM AND RESOURCES TO CARRY IT
18 OUT, AND, OF COURSE, WHETHER THE PROJECT UPHOLDS THE
19 PRINCIPLES OF DIVERSITY, EQUITY, AND INCLUSION.

20 THE COMPOSITION OF THE GRANTS WORKING
21 GROUP INCLUDES THE SCIENTIFIC MEMBERS, PATIENT
22 ADVOCATE AND NURSE MEMBERS, AS WELL AS SCIENTIFIC
23 SPECIALISTS WHO ARE NOT VOTING, BUT WE BRING IN TO
24 GIVE US EXPERTISE AND KNOWLEDGE IN AREAS THAT THE
25 FULL PANEL MAY NOT HAVE.

BETH C. DRAIN, CA CSR NO. 7152

1 OKAY. BEFORE I PRESENT EACH OF THE
2 APPLICATIONS, THIS IS JUST A REMINDER TO THE BOARD
3 MEMBERS THAT HAVE A CONFLICT WITH ONE OF THE
4 APPLICATIONS. WE HAVE THE NAMES UP HERE. JUST
5 REMEMBER TO REFRAIN FROM PARTICIPATING IN DISCUSSION
6 OR VOTING ON ANY OF THE APPLICATIONS THAT YOU HAVE A
7 CONFLICT WITH.

8 THE FIRST APPLICATION IS ENTITLED "A PHASE
9 1 STUDY OF MULTIPLE DOSES OF NSC-BASED ONCOLYTIC
10 VIRAL THERAPY ADMINISTERED INTRACEREBRALLY TO
11 PATIENTS WITH RECURRENT HIGH-GRADE GLIOMAS." SO
12 THIS IS A GENETICALLY ENGINEERED CELL THERAPY MADE
13 UP OF NEURAL STEM CELLS THAT HAVE IN THEM A VIRUS
14 THAT KILLS AND TARGETS BRAIN TUMOR CELLS. SO THE
15 CELLS HOME TO THE TUMOR AND RELEASE THE VIRUS, AND
16 THE VIRUS KILLS THOSE TUMORS.

17 THE INDICATION IS FOR HIGH-GRADE ADULT
18 GLIOMAS AND GLIOBLASTOMA. THEIR GOAL IS TO COMPLETE
19 A PHASE 1 CLINICAL TRIAL TO ASSESS SAFETY AND ARE
20 REQUESTING JUST UNDER 12 MILLION FOR THIS PROJECT.

21 AS BACKGROUND, GLIOBLASTOMA, AS WE ALL
22 KNOW, IS A CRITICAL UNMET NEED. AND IT IS THE MOST
23 COMMON MALIGNANT PRIMARY BRAIN TUMOR IN ADULTS, AND
24 EACH YEAR ABOUT 12,000 AMERICANS ARE DIAGNOSED WITH
25 A FIVE-YEAR SURVIVAL RATE OF ONLY ABOUT 10 PERCENT.

BETH C. DRAIN, CA CSR NO. 7152

1 AND THE CURRENT STANDARD OF CARE INVOLVES RESECTION
2 OF THE TUMOR FOLLOWED BY RADIATION, CHEMOTHERAPY,
3 ALTERNATING ELECTRIC FIELD THERAPY. AND DESPITE
4 THESE TREATMENTS, SURVIVAL STILL IS QUITE LOW.

5 THE PROPOSED THERAPY HAS THE POTENTIAL TO
6 IMPROVE SURVIVAL AND QUALITY OF LIFE FOR THOSE
7 PATIENTS.

8 WHY IS THIS A STEM CELL OR GENE THERAPY
9 PROJECT? WELL, THE THERAPEUTIC CANDIDATE IS
10 COMPOSED OF NEURAL STEM CELLS, MAKING THIS A STEM
11 CELL PROJECT.

12 THIS IS A SNAPSHOT OF WHAT WE HAVE IN OUR
13 CURRENT ACTIVE CIRM PORTFOLIO OF PROJECTS THAT ARE
14 ADDRESSING THE SIMILAR INDICATIONS, EITHER GLIOMAS
15 OR BRAIN TUMORS. ALL OF THOSE OTHER PROJECTS ARE
16 PHASE 1 CLINICAL TRIALS, BUT USING LARGELY DIFFERENT
17 VARIATIONS OF CAR-T OR APPROACH; WHEREAS, THE
18 CURRENT PROJECT IS USING AN ONCOLYTIC VIRUS
19 APPROACH. SO IT'S DIFFERENT FROM THOSE.

20 THE APPLICANT HAS RECEIVED CIRM FUNDING IN
21 THE PAST THROUGH A TRAN AWARD. IN THAT CASE THEY
22 WERE DEVELOPING A THERAPEUTIC THAT WAS SIMILAR THAT
23 USES ONCOLYTIC VIRUS TO TARGET OVARIAN CANCER. SO
24 THAT PROJECT IS STILL ACTIVE, BUT ON THE TAIL END
25 AND EXPECTED TO END DECEMBER OF THIS YEAR.

BETH C. DRAIN, CA CSR NO. 7152

1 THIS IS A SUMMARY OF THE RECOMMENDATIONS
2 FROM THE GRANTS WORKING GROUP ON THE APPLICATION.
3 THERE WERE 11 SCIENTIFIC MEMBERS THAT GAVE IT A
4 SCORE OF 1. THERE WERE FOUR MEMBERS THAT GAVE IT A
5 SCORE OF 2. THERE WERE NONE THAT GAVE IT A SCORE OF
6 3. THE DEI SCORE GIVEN BY OUR BOARD MEMBERS WAS AN
7 8 ON THE SCALE OF 1 TO 10. AND THE CIRM TEAM
8 RECOMMENDS FUNDING IN CONCURRENCE WITH THE GRANTS
9 WORKING GROUP FOR THE AWARD AMOUNT OF UNDER 12
10 MILLION. MR. CHAIRMAN.

11 CHAIRMAN THOMAS: THANK YOU VERY MUCH,
12 GIL. DO WE HAVE A MOTION TO APPROVE FROM THE BOARD?

13 DR. STAMOS: SO MOVED.

14 CHAIRMAN THOMAS: THANK YOU, MICHAEL.

15 MS. BONNEVILLE: MICHAEL CANNOT MOVE THE
16 MOTION. REMEMBER IT'S THE APPLICATION REVIEW
17 SUBCOMMITTEE THAT WE ARE IN RIGHT NOW. SO IT'S JUST
18 MEMBERS OF THE ARS THAT CAN MAKE MOTIONS, BUT OUR
19 OTHERS ARE FREE TO SPEAK IF THEY DO NOT HAVE A
20 CONFLICT.

21 DR. DULIEGE: HAPPY TO MOVE IT.

22 CHAIRMAN THOMAS: THANK YOU, ANNE-MARIE.

23 MR. BERNAL: I'LL SECOND.

24 CHAIRMAN THOMAS: SECONDED BY -- I THINK
25 DAN BEAT YOU, AL, SLIGHTLY BY A NOSE.

BETH C. DRAIN, CA CSR NO. 7152

1 MR. BERNAL: HAPPY TO GIVE IT TO AL IF HE
2 DESIRES.

3 MR. ROWLETT: AGAIN, I'LL GIVE IT TO DAN.
4 THANK YOU.

5 CHAIRMAN THOMAS: THANK YOU BOTH.
6 ARE THERE QUESTIONS OR COMMENTS FROM
7 MEMBERS OF THE BOARD? ANY COMMENTS BY MEMBERS OF
8 THE PUBLIC?

9 MS. BONNEVILLE: I SEE NO HANDS RAISED. I
10 SEE A HAND RAISED. JUST AS A -- FOR YOUR
11 INFORMATION, IT'S A THREE-MINUTE PUBLIC COMMENT. SO
12 IF THE CALLER WOULD LIKE TO START.

13 DR. HORTON: THIS IS JANIS HORTON. I'M
14 THE PRINCIPAL INVESTIGATOR OF THE GRANT APPLICATION,
15 AND I JUST WANTED TO START OFF BY SAYING THANK YOU
16 VERY MUCH TO THE REVIEWERS. WE GOT REALLY
17 INSIGHTFUL COMMENTS BACK. AND I KNOW THIS IS A
18 LARGE APPLICATION AND A LOT OF WORK, AND I JUST WANT
19 TO THANK THEM FOR THEIR SUPPORT.

20 AS THE PERSON WHO WAS TALKING AHEAD OF ME
21 WAS SAYING, WE ALL KNOW GLIOBLASTOMA IS A REALLY
22 DEVASTATING DISEASE, VERY DIFFICULT TO TREAT. WHEN
23 WE TALK ABOUT SURVIVAL, IT'S STILL LESS THAN TWO
24 YEARS. WE REALLY HAVEN'T MADE ANY ADVANCES.
25 THERE'S BEEN NO APPROVED TARGET AGENT OR

BETH C. DRAIN, CA CSR NO. 7152

1 IMMUNOTHERAPY FOR TREATING GLIOBLASTOMA. AND WE
2 REALLY HAVEN'T BEEN ABLE TO -- THESE WERE THE MAJOR
3 ADVANCES IN THE LAST 20 YEARS IN ONCOLOGY, BUT
4 PATIENTS WITH GLIOBLASTOMA HAVE NOT BENEFITED FROM
5 THOSE.

6 THIS RESEARCH, LOOKING AT THE NEURAL STEM
7 CELL-BASED ONCOLYTIC VIRUS THERAPY, SOMETHING THAT
8 WE'VE BEEN WORKING ON FOR A LONG TIME. AND ALSO
9 ONCOLYTIC VIRUSES HAVE BEEN STUDIED FOR A LONG TIME
10 IN GLIOBLASTOMA WITHOUT MUCH SUCCESS ALTHOUGH
11 RECENTLY THERE WAS AN ONCOLYTIC VIRUS DEVELOPED BY A
12 RESEARCH TEAM IN JAPAN WHERE THEY COULD SEE
13 IMPROVEMENT AND SURVIVAL GETTING MULTIPLE
14 INJECTIONS. THEY GAVE SIX INJECTIONS MONTHLY TO
15 THEIR PATIENTS. AND SO ONE WONDERS MAYBE THE
16 MULTIPLE INJECTIONS WERE THE REASON THAT THEY WERE
17 SEEN AS EFFICACY. AND THAT IS WHAT WE'RE TRYING TO
18 DO WITH OUR ONCOLYTIC VIRUS, BUT WE THINK OUR
19 APPROACH IS A LITTLE MORE PRACTICAL IN TERMS OF
20 WE'RE RELYING ON THE PROMISE OF NEURAL STEM CELLS TO
21 HELP DELIVER THE ONCOLYTIC VIRUS. AND BECAUSE
22 NEURAL STEM CELLS ARE USED AS VEHICLES OF DRUG
23 DELIVERY. AND SO WE ARE HOPING THAT, WHEREAS, THIS
24 OTHER STUDY DID SHOW EFFICACY, PATIENTS HAVE TO GO
25 BACK TO THE O.R. EVERY FOUR WEEKS, WE THINK THAT OUR

BETH C. DRAIN, CA CSR NO. 7152

1 APPROACH BY DELIVERING THE STEM CELL ONCOLYTIC VIRUS
2 DIRECTLY TO THE BRAIN WILL BE MORE PRACTICAL AND
3 MORE GENERALIZABLE.

4 WE ALSO HAVE SAFETY DATA FROM OUR
5 FIRST-IN-HUMAN STUDY OF THIS NEURAL STEM CELL-BASED
6 ONCOLYTIC VIRUS THERAPY AND EVEN SOME EVIDENCE OF
7 BIOLOGIC ACTIVITY. THIS STUDY THAT WE'RE PROPOSING
8 TO DO IS NO SMALL UNDERTAKING. WE HAVE FOUR SITES,
9 AND WE'VE CHOSEN THEM STRATEGICALLY IN TERMS OF
10 PROVIDING ACCESS TO UNDERSERVED POPULATIONS ACROSS
11 THE COUNTRY. AND THAT -- I'M PROBABLY RUNNING OUT
12 OF TIME. I JUST, AGAIN, WANTED TO SAY THANK YOU TO
13 CIRM FOR SUPPORTING OUR PREVIOUS RESEARCH WITH
14 NEURAL STEM CELLS, AND THANK YOU FOR YOUR INTEREST
15 IN THIS CURRENT RESEARCH PROJECT.

16 CHAIRMAN THOMAS: THANK YOU VERY MUCH FOR
17 YOUR COMMENT. IS THERE ANY OTHER PUBLIC COMMENT?

18 MS. BONNEVILLE: I DO NOT SEE ANY.

19 CHAIRMAN THOMAS: THANK YOU. IN THAT
20 CASE, MARIA, WILL YOU PLEASE CALL THE ROLL.

21 MS. BONNEVILLE: YES. DAN BERNAL.

22 MR. BERNAL: AYE.

23 MS. BONNEVILLE: JUDY CHOU.

24 DR. CHOU: AYE.

25 MS. BONNEVILLE: LEONDRA CLARK-HARVEY.

BETH C. DRAIN, CA CSR NO. 7152

1 ANNE-MARIE DULIEGE.
2 DR. DULIEGE: YES.
3 MS. BONNEVILLE: MARK FISCHER-COLBRIE.
4 DR. FISCHER-COLBRIE: YES.
5 MS. BONNEVILLE: FRED FISHER. ELENA
6 FLOWERS.
7 DR. FLOWERS: YES.
8 MS. BONNEVILLE: DAVID HIGGINS. STEVE
9 JUELSGAARD.
10 MR. JUELSGAARD: YES.
11 MS. BONNEVILLE: RICH LAJARA.
12 MR. LAJARA: YES.
13 MS. BONNEVILLE: CHRIS MIASKOWSKI.
14 DR. MIASKOWSKI: YES.
15 MS. BONNEVILLE: LAUREN MILLER-ROGEN.
16 MS. MILLER-ROGEN: YES.
17 MS. BONNEVILLE: ADRIANA PADILLA.
18 DR. PADILLA: YES.
19 MS. BONNEVILLE: JOE PANETTA. AL ROWLETT.
20 MR. ROWLETT: YES.
21 MS. BONNEVILLE: MARVIN SOUTHARD.
22 DR. SOUTHARD: YES.
23 MS. BONNEVILLE: JONATHAN THOMAS.
24 CHAIRMAN THOMAS: YES.
25 MS. BONNEVILLE: ART TORRES.

BETH C. DRAIN, CA CSR NO. 7152

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

MR. TORRES: AYE, EXCEPT FOR THOSE WITH
WHICH I HAVE A CONFLICT.

MS. BONNEVILLE: KAROL WATSON.

DR. WATSON: YES.

BETH C. DRAIN, CA CSR NO. 7152

1 MS. BONNEVILLE: THANK YOU. THANK YOU.
2 THE MOTION CARRIES.

3 CHAIRMAN THOMAS: THANK YOU. GIL, DO YOU
4 HAVE MORE OR DOES THAT CONCLUDE YOUR PRESENTATION?

5 DR. SAMBRANO: THERE IS ONE MORE
6 APPLICATION.

7 CHAIRMAN THOMAS: THERE IS A CLIN1, I
8 BELIEVE, CORRECT?

9 DR. SAMBRANO: YES, CORRECT.

10 ALL RIGHT. SO THE NEXT APPLICATION IS
11 ENTITLED "ALLOGENEIC MESENCHYMAL STEM CELLS LOADED
12 WITH ONCOLYTIC VIRUS FOR CANCER TREATMENT." SO,
13 INTERESTINGLY WE HAVE TWO ONCOLYTIC VIRUS RELATED
14 APPLICATIONS IN A ROW. THAT DOESN'T USUALLY HAPPEN,
15 BUT HERE WE ARE.

16 SO THIS IS AN ALLOGENEIC THERAPY OF
17 MESENCHYMAL STEM CELLS THAT HAVE, AGAIN, AN
18 ONCOLYTIC VIRUS THAT TARGETS CANCER IN THIS CASE.
19 THE APPLICANTS ARE TARGETING MELANOMA, BREAST
20 CANCER, AND HEAD AND NECK CANCER. THEIR GOAL IS TO
21 COMPLETE PRE-IND ENABLING STUDIES AND FILE AN IND.
22 SO THIS IS A MUCH EARLIER STAGE. AND THE FUNDS
23 REQUESTED ARE 3.1 MILLION AND PROVIDE CO-FUNDING OF
24 777,000 TO CO-FUND THE PROJECT.

25 SOME BACKGROUND ON THE SOLID TUMORS THAT

BETH C. DRAIN, CA CSR NO. 7152

1 ARE TARGETED BY THIS APPLICATION. MELANOMA CANCER,
2 BREAST CANCER, AND HEAD AND NECK CANCER ARE ALL
3 ASSOCIATED WITH SIGNIFICANT MORBIDITY, AND THERE ARE
4 VERY FEW TREATMENT OPTIONS AND POOR SURVIVAL RATES
5 IN MANY CASES. THE STANDARD OF CARE IS GOING TO
6 VARY BY TUMOR TYPE, BUT TYPICALLY INVOLVES
7 CHEMOTHERAPY, RADIATION, RESECTION, AND/OR OTHER
8 AVAILABLE DRUGS.

9 IF SUCCESSFUL, THE PROPOSED THERAPY WOULD
10 PROVIDE THE POTENTIAL FOR A SAFER AND MORE EFFECTIVE
11 THERAPEUTIC OPTION FOR PATIENTS WITH SOLID TUMORS
12 WHERE SOME APPROACHES, SUCH AS THE NOVEL CAR-T, HAVE
13 BEEN LESS SUCCESSFUL.

14 THIS IS A STEM CELL OR GENE THERAPY
15 PROJECT BECAUSE THE THERAPEUTIC CANDIDATE IS
16 COMPOSED OF MESENCHYMAL STEM CELLS.

17 WITHIN OUR PORTFOLIO WE HAVE ONE OTHER
18 PROJECT THAT IS USING ONCOLYTIC VIRUS TO INDUCE
19 KILLING OF TUMOR CELLS. IT IS A PHASE 1 CLINICAL
20 TRIAL IN ADDITION TO THE ONE THAT WAS JUST APPROVED.
21 SO WE NOW HAVE TWO. THIS APPLICANT HAS NOT
22 PREVIOUSLY RECEIVED A CIRM AWARD.

23 AND THE SUMMARY OF THE RECOMMENDATION IS
24 AS FOLLOWS. THERE WERE 12 MEMBERS THAT GAVE THIS A
25 SCORE OF 1, TWO SCIENTIFIC MEMBERS THAT GAVE IT A

BETH C. DRAIN, CA CSR NO. 7152

1 SCORE OF 2, AND NONE THAT GAVE IT A SCORE OF 3. THE
2 DEI SCORE IS A SCORE OF 7 ON A SCALE OF 1 TO 10.
3 AND THE CIRM TEAM RECOMMENDATION CONCURS WITH THE
4 GRANTS WORKING GROUP FOR AN AWARD AMOUNT OF 3.111
5 MILLION. MR. CHAIRMAN.

6 CHAIRMAN THOMAS: THANK YOU, GIL. DO WE
7 HEAR A MOTION TO APPROVE?

8 DR. ABDULHAQ: MOTION TO APPROVE.

9 MS. BONNEVILLE: HAIFAA, YOU CANNOT MAKE A
10 MOTION ON THIS.

11 DR. ABDULHAQ: SORRY.

12 CHAIRMAN THOMAS: MEMBERS OF THE
13 APPLICATION REVIEW SUBCOMMITTEE PLEASE. THANK YOU
14 THOUGH.

15 DR. SOUTHARD: SO MOVED.

16 MR. ROWLETT: SECOND.

17 CHAIRMAN THOMAS: MOVED BY MARV, SECONDED
18 BY AL. QUESTIONS OR COMMENTS FROM MEMBERS OF THE
19 BOARD? ANY PUBLIC COMMENT?

20 MS. BONNEVILLE: THERE IS NO PUBLIC
21 COMMENT.

22 CHAIRMAN THOMAS: MARIA, WILL YOU PLEASE
23 CALL THE ROLL.

24 MS. BONNEVILLE: YES. DAN BERNAL.

25 MR. BERNAL: AYE.

BETH C. DRAIN, CA CSR NO. 7152

1 MS. BONNEVILLE: JUDY CHOU.
2 DR. CHOU: AYE.
3 MS. BONNEVILLE: LEONDRA CLARK-HARVEY.
4 ANNE-MARIE DULIEGE.
5 DR. DULIEGE: AYE.
6 MS. BONNEVILLE: YSABEL DURON.
7 MS. DURON: AYE.
8 MS. BONNEVILLE: MARK FISCHER-COLBRIE.
9 DR. FISCHER-COLBRIE: YES.
10 MS. BONNEVILLE: FRED FISHER. ELENA
11 FLOWERS.
12 DR. FLOWERS: YES.
13 MS. BONNEVILLE: DAVID HIGGINS. STEVE
14 JUELSGAARD.
15 MR. JUELSGAARD: YES.
16 MS. BONNEVILLE: RICH LAJARA.
17 MR. LAJARA: YES.
18 MS. BONNEVILLE: CHRIS MIASKOWSKI.
19 DR. MIASKOWSKI: YES.
20 MS. BONNEVILLE: LAUREN MILLER-ROGEN.
21 MS. MILLER-ROGEN: YES.
22 MS. BONNEVILLE: ADRIANA PADILLA.
23 DR. PADILLA: YES.
24 MS. BONNEVILLE: JOE PANETTA. AL ROWLETT.
25 MR. ROWLETT: YES.

BETH C. DRAIN, CA CSR NO. 7152

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

MS. BONNEVILLE: MARVIN SOUTHARD.

DR. SOUTHARD: YES.

MS. BONNEVILLE: JONATHAN THOMAS.

CHAIRMAN THOMAS: YES.

MS. BONNEVILLE: ART TORRES.

MR. TORRES: AYE, EXCEPT FOR THOSE WITH
WHICH I HAVE A CONFLICT.

MS. BONNEVILLE: KAROL WATSON.

DR. WATSON: YES.

BETH C. DRAIN, CA CSR NO. 7152

1 MS. BONNEVILLE: THANK YOU. THE MOTION
2 CARRIES.

3 CHAIRMAN THOMAS: THANK YOU. AND, GIL,
4 THANK YOU VERY MUCH. I BELIEVE THAT NOW DOES
5 CONCLUDE THAT ACTION ITEM, CORRECT?

6 DR. SAMBRANO: IT DOES. THANK YOU.

7 CHAIRMAN THOMAS: THANK YOU. WE'RE GOING
8 TO MOVE ON NEXT TO ITEM NO. 7, CONSIDERATION OF
9 APPLICATIONS SUBMITTED IN RESPONSE TO THE ALPHA
10 CLINIC NETWORK EXPANSION, WHICH IS ONE OF OUR
11 INFRASTRUCTURE PROGRAMS. AGAIN, THIS IS APPLICATION
12 REVIEW SUBCOMMITTEE VOTING ONLY. SO, GIL, PLEASE
13 PROCEED.

14 DR. SAMBRANO: THANK YOU, MR. CHAIRMAN,
15 LET ME SHARE THESE SLIDES.

16 ALL RIGHT. SO ONCE AGAIN, IN OUR EFFORT
17 TO ACHIEVE THE CIRM MISSION, ONE OF THE THINGS THAT,
18 AS YOU ALL KNOW, WE DEVELOPED A STRATEGIC PLAN
19 LAYING OUT OUR PLANS FOR THE NEXT FIVE YEARS. AND
20 WITHIN THAT STRATEGIC PLAN, WE HAVE THREE SPECIFIC
21 THEMES THAT WE OFTEN REFER TO. ADVANCE WORLD-CLASS
22 SCIENCE TO DELIVER REAL-WORLD SOLUTIONS AND PROVIDE
23 OPPORTUNITY FOR ALL. WITHIN THE REAL-WORLD
24 SOLUTIONS, WE ARE DEVELOPING INFRASTRUCTURE PROGRAMS
25 AND RESOURCES THAT WILL HELP ENERGIZE AND BRING

BETH C. DRAIN, CA CSR NO. 7152

1 TOGETHER A LOT OF THE DIFFERENT ELEMENTS THAT WE
2 SUPPORT IN OUR RESEARCH TO ENHANCE THEM AND MAKE
3 THEM MORE BROADLY AVAILABLE.

4 PART OF WHAT WE ARE DOING IS CREATING A
5 MANUFACTURING PARTNERSHIP NETWORK, WHICH YOU'VE
6 HEARD ABOUT PREVIOUSLY IN A CONCEPT FORM. WE ARE
7 EXPANDING THE ALPHA CLINICS NETWORK, AS WE'RE GOING
8 TO SPEAK ABOUT TODAY, AND THEN IN THE FUTURE CREATE
9 COMMUNITY CARE CENTERS OF EXCELLENCE THAT WILL
10 PARTNER WITH THESE ALPHA CLINICS.

11 I'LL TELL YOU A LITTLE BIT ABOUT THE ALPHA
12 CLINICS AS THEY EXIST TODAY. WE HAVE AN ALPHA
13 CLINICS NETWORK CURRENTLY THAT SUPPORTS SIX SITES,
14 AND WE HAVE INVESTED 40 MILLION IN THE COMMUNITY
15 CARE CENTERS OF EXCELLENCE TRAINING ELEMENTS FOR THE
16 ALPHA CLINICS.

17 THE ALPHA CLINICS OVER THE LAST SEVERAL
18 YEARS, SINCE 2015, WHEN THEY WERE ESTABLISHED, HAVE
19 BEEN QUITE SUCCESSFUL IN ACCELERATING CELL AND GENE
20 THERAPY CLINICAL TRIALS, PROVIDING SERVICES TO HELP
21 NOT ONLY CIRM-SUPPORTED TRIALS, BUT ALSO TRIALS THAT
22 ARE CONDUCTING CELL AND GENE THERAPY AND OTHER TYPES
23 OF ADVANCED THERAPIES FROM INDUSTRY AND ELSEWHERE.
24 THEY HAVE GARNERED OVER A HUNDRED MILLION IN
25 INDUSTRY CONTRACTS AS A POINT OF REFERENCE.

BETH C. DRAIN, CA CSR NO. 7152

1 WITH AN EYE TO OUR STRATEGIC PLAN AND
2 THEMES, WE ARE CREATING A MORE INTEGRATED AND
3 NETWORK RESOURCE IN ORDER TO ENABLE INNOVATIVE
4 CLINICAL RESEARCH, INCREASE PATIENT ACCESS
5 THERAPIES, AND TRAIN OUR FUTURE WORKFORCE. PART OF
6 THIS BEGINS WITH THE EXPANSION OF THE ALPHA CLINICS
7 NETWORK AS A WHOLE AND, AS MENTIONED, TO PARTNER
8 EVENTUALLY WITH THE COMMUNITY CARE CENTERS SO THAT
9 WE CAN BRING WHAT WE DO IN TERMS OF CELL AND GENE
10 THERAPY TO EVERY CORNER OF CALIFORNIA, IF POSSIBLE.

11 THE OBJECTIVE OF THIS OPPORTUNITY IS TO
12 EXPAND EXISTING CAPACITY FOR DELIVERING STEM CELL
13 GENE THERAPIES AND OTHER ADVANCED TREATMENTS TO
14 PATIENTS FOR THE ALPHA CLINIC EXPANSION PROGRAM, AND
15 ALSO TO SERVE AS A COMPETENCY HUB FOR REGENERATIVE
16 MEDICINE TRAINING, CLINICAL RESEARCH, AND DELIVERY
17 OF APPROVED TREATMENTS.

18 AND BY EXPANSION HERE WE MEAN ESTABLISHING
19 ADDITIONAL ALPHA CLINIC SITES AS WELL AS EXPANDING
20 THE SERVICES AND REACH OF THE EXISTING SITES.

21 AND FOR ALL OF THESE PROGRAMS, THERE ARE
22 BASIC CORE ACTIVITIES THAT WE EXPECT APPLICANTS TO
23 ENGAGE IN. OBVIOUSLY THEY NEED TO HAVE A
24 DEMONSTRATED ABILITY TO CONDUCT FDA-AUTHORIZED
25 CLINICAL TRIALS THAT INVOLVE CELL AND/OR GENE

BETH C. DRAIN, CA CSR NO. 7152

1 THERAPIES. WE WANT THEM TO PARTICIPATE IN NETWORK
2 COORDINATION. PART OF WHAT HAPPENS WITH THIS
3 NETWORK IS THAT WE ARE ESTABLISHING A STEERING
4 COMMITTEE THAT INCLUDES CIRM STAFF MEMBERS AS WELL
5 AS THE PROGRAM DIRECTORS OF THESE PROGRAMS THAT
6 TOGETHER REFINE AND EXPAND THE NETWORK SYSTEM TO
7 ADDRESS EMERGING ISSUES OR NEEDS OF THE FIELD AS
8 THEY PROGRESS.

9 THEY SHOULD ALL PROPOSE REGENERATIVE
10 MEDICINE TRAINING TO SUPPORT CAREER DEVELOPMENT FOR
11 PHYSICIANS, NURSES, RESEARCH COORDINATORS, OR OTHER
12 MEDICAL PROFESSIONALS THAT ARE INTEGRAL TO THE
13 DELIVERY OF CLINICAL TRIALS, AND, DEPENDING ON THE
14 PROGRAM, THEY CAN FOCUS ON ONE AND DEVELOP A PROGRAM
15 AROUND THAT OR THEY CAN BE BROAD.

16 WE ALSO EXPECT THEM TO EXPAND NETWORK
17 CAPABILITIES THROUGH LEAD OFFERINGS. AND SO THE
18 LEAD OFFERINGS THAT THEY DEVELOP CAN BE UTILIZED BY
19 OTHER ALPHA CLINIC NETWORK SITES. AND THESE MAY BE
20 AREAS OF SPECIALTY THAT THEY HAVE WITHIN THEIR OWN
21 CLINICS AND AN ENHANCEMENT OF ELEMENTS THAT ARE
22 OFFERED MORE BROADLY.

23 HERE ARE SOME EXAMPLES OF WHAT APPLICANTS
24 MAY HAVE PROPOSED IN THEIR APPLICATIONS SUCH AS
25 DEVELOPING NOVEL CLINICAL TRIAL DESIGNS; PROVIDING

BETH C. DRAIN, CA CSR NO. 7152

1 TISSUE BANKING OR GENOMICS SERVICE; DEVELOPING OR
2 PROVIDING TOOLS, DEVICES, OR TECHNOLOGIES; FOR
3 EXAMPLE, IMAGING TO ASSESS ENGRAFTMENT OR SOME KIND
4 OF SPECIALIZED DEVICE FOR CELL DELIVERY; PROVIDING
5 OR DEVELOPING PROGRAMS FOR DECENTRALIZED POINT OF
6 CARE TREATMENTS; AND OTHER ELEMENTS, INCLUDING
7 PARTICIPATION OF UNDERSERVED POPULATIONS IN CLINICAL
8 RESEARCH OR PATIENT NAVIGATION TOOLS THAT WOULD
9 PROMOTE ACCESS AND INCLUSIVITY. AND ALSO THINGS
10 THAT PERHAPS WE HAVE NOT THOUGHT OF THAT APPLICANTS
11 PROVIDED AS A POSSIBLE LEAD OFFERING.

12 THERE ARE SOME OTHER CONSIDERATIONS THAT
13 WE HAD THE GRANTS WORKING GROUP THINK ABOUT IN
14 ASSESSING THESE APPLICATIONS. ONE OF THEM WAS
15 PARTNERSHIPS. WE ENCOURAGED APPLICANTS TO PROPOSE
16 PARTNERSHIPS WITH OTHER ALPHA CLINIC SITES, BUT ALSO
17 WITH OTHER ORGANIZATIONS, INCLUDING THE POTENTIAL
18 COMMUNITY CARE CENTERS IN THE FUTURE, TO SUPPORT
19 THEIR OFFERINGS AND EXTEND THEIR REACH AND
20 CAPABILITIES. THERE'S ALSO A BUSINESS AND
21 ORGANIZATIONAL INTEGRATION PLAN THAT WE ASK ALL
22 APPLICANTS TO PROVIDE IN DESCRIBING HOW THEY WILL
23 LEVERAGE THEIR CAPABILITIES SO THAT IT IS INTEGRAL
24 TO THE CLINICAL OPERATIONS OF THE ORGANIZATION
25 BEYOND THE AWARD PERIOD.

BETH C. DRAIN, CA CSR NO. 7152

1 WE DEFINITELY WANT THE ALPHA CLINICS TO
2 EXIST EVEN WHEN WE ARE NO LONGER ABLE TO SUPPORT
3 THEM THROUGH GRANT FUNDING. WE WANT THEM TO REALLY
4 BECOME AN ENGINE THAT DOESN'T STOP ONCE WE HAVE
5 BUILT IT.

6 KNOWLEDGE SHARING IS ANOTHER IMPORTANT
7 ELEMENT. APPLICANTS ARE EXPECTED TO DESCRIBE HOW
8 THEY'RE GOING TO FACILITATE THEIR DATA SHARING BOTH
9 FOR CLINICAL TRIALS THAT THEY SERVE AS WELL AS THEIR
10 OWN OPERATIONS. THIS MAY BE IN THE FORM OF BEST
11 PRACTICES OR THE REPLICATION OF CORE COMPETENCIES AS
12 THEY SHARE THEM WITH OTHER ALPHA CLINIC SITES OR
13 EVEN PERHAPS OTHER ORGANIZATIONS.

14 LASTLY, ALL OF THE APPLICANTS INCLUDE A
15 PLAN TO ADDRESS DEI. AND THIS MAY COME IN THE FORM
16 OF SUPPORTING AND FACILITATING OUTREACH AND STUDY
17 PARTICIPATION BY UNDERSERVED AND DISPROPORTIONATELY
18 AFFECTED POPULATIONS FOR THE CLINICAL TRIALS THAT
19 THEY SERVE.

20 AND, IN ADDITION, THE ALPHA CLINIC SITES
21 SHOULD PROPOSE TO BRING DIVERSE AND INCLUSIVE
22 PERSPECTIVES INTO THE OVERALL IMPLEMENTATION OF THE
23 PROPOSED ACTIVITIES THAT THEY TAKE ON, INCLUDING THE
24 TRAINING ACTIVITIES.

25 AND IF ALL THIS WORKS AS WE WOULD IDEALLY

BETH C. DRAIN, CA CSR NO. 7152

1 LIKE, WE WOULD HAVE HOPEFULLY A ROBUST COMPETENCY
2 HUB THAT IS CENTERED WITH THE ALPHA CLINICS NETWORK,
3 ALL OF THESE SITES PROVIDING BOTH CORE SERVICES AS
4 WELL AS SOME UNIQUE OFFERINGS THAT MAY BE AVAILABLE
5 AT ONE OR TWO THAT LEVERAGE THE EXPERTISE OF THE
6 INSTITUTION THAT THE SITE IS LOCATED AT FOR ALL CIRM
7 CLINICAL TRIALS AS WELL AS OTHER CLINICAL TRIALS.
8 OUR HOPE IS THAT EVEN BEYOND OUR EXISTENCE THAT THEY
9 CONTINUE TO SERVE CLINICAL TRIALS IN CELL AND GENE
10 THERAPY AND PERHAPS OTHER ADVANCED THERAPIES AS THEY
11 ARE DEVELOPED.

12 WE WANT THEM TO FORM PARTNERSHIPS WITH
13 HOSPITALS, INDUSTRY, OTHERS THAT CAN HELP ENHANCE
14 THEIR CAPABILITIES AS WELL AS, MENTIONED EARLIER,
15 THE COMMUNITY CARE CENTERS, AND TO ALSO HELP DEVELOP
16 A TRAINED WORKFORCE THAT IS DIVERSE AND CAN ADDRESS
17 THE NEEDS OF CELL AND GENE THERAPY.

18 THE AWARD ITSELF, THE CIRM BOARD ALLOCATED
19 UP TO 80 MILLION TO SUPPORT THIS FUNDING
20 OPPORTUNITY, WITH EACH AWARD PROVIDING UP TO 8
21 MILLION FOR FIVE YEARS. WE RECEIVED NINE
22 APPLICATIONS, AND ALL WERE ACCEPTED FOR REVIEW. OF
23 THEM, THERE WERE SIX THAT WERE EXISTING SITES AND
24 THREE THAT ARE PROPOSED NEW SITES. SO THE 80
25 MILLION WOULD EASILY COVER ALL THE APPLICATIONS THAT

1 WERE SUBMITTED.

2 THE SCORING MECHANISM THAT THE SCIENTIFIC
3 MEMBERS OF THE WORKING GROUP USED FOR THESE
4 APPLICATIONS IS BASED ON A SCALE OF 1, 2, AND 3. IT
5 LOOKS A LOT LIKE THE CLINICAL ONE, AND THIS LARGELY
6 IS EXCEPT FOR THE SCORE OF 2, WHICH IS A LITTLE
7 DIFFERENT IN TERMS OF THE LANGUAGE AND MEANING. A
8 SCORE OF 2 ALSO NEEDS IMPROVEMENT AND DOESN'T
9 WARRANT FUNDING AT THIS TIME, BUT IT LEAVES IT UP TO
10 THE APPLICATION REVIEW SUBCOMMITTEE TO DETERMINE
11 WHETHER IT GOES BACK TO THE GRANTS WORKING GROUP.
12 SO THIS RECOMMENDATION IS FOR THE APPLICANT TO
13 REVISE AND RESUBMIT, AND THE APPLICATION REVIEW
14 SUBCOMMITTEE MAY CHOOSE TO FUND IT, NOT FUND IT, OR
15 TO HAVE THE GRANTS WORKING GROUP REEVALUATE ANY
16 REVISIONS.

17 THE CRITERIA THAT WERE USED TO COME UP
18 WITH THE SCORE WERE BASED ON THESE FOUR QUESTIONS:
19 WHETHER THE PROPOSAL OFFERS A SIGNIFICANT VALUE
20 PROPOSITION THAT WOULD ENHANCE THE ABILITY OF THE
21 ALPHA CLINICS NETWORK AS A WHOLE TO ACCELERATE
22 CLINICAL RESEARCH CONSISTENT WITH CIRM'S MISSION;
23 WHETHER THE PROPOSAL WAS WELL-PLANNED AND DESIGNED;
24 WHETHER IT WAS FEASIBLE; AND WHETHER IT EFFECTIVELY
25 SERVES THE NEEDS OF UNDERSERVED AND

BETH C. DRAIN, CA CSR NO. 7152

1 DISPROPORTIONATELY AFFECTED COMMUNITIES.

2 THE REVIEW ITSELF WAS CONDUCTED IN A
3 SLIGHTLY UNIQUE WAY COMPARED TO OTHER REVIEWS. WE
4 ACTUALLY HAD THE APPLICANT PARTICIPATE IN PART OF
5 THE REVIEW. SO WE HAVE AN ADDENDA FOR THESE
6 REVIEWS. WE HAD AN INITIAL DISCUSSION BY THE GRANTS
7 WORKING GROUP, BUT THEN INVITED THE APPLICANT TO THE
8 CALL TO MAKE A TEN-MINUTE PITCH ABOUT THEIR PROGRAM
9 AND HIGHLIGHT KEY ELEMENTS. THERE WAS A QUESTION
10 AND ANSWER PERIOD THAT ALLOWED THEM TO GET
11 CLARIFICATION FROM THE APPLICANTS ON ANY CONCERNS
12 AND QUESTIONS THEY MAY HAVE HAD. AND THEN THERE WAS
13 A WRAP-UP DISCUSSION. WE DID THIS FOR EACH GIVEN
14 APPLICATION.

15 SO THIS IS A SUMMARY, THEN, OF THE
16 RECOMMENDATIONS THAT CAME OUT OF THAT GRANTS WORKING
17 GROUP REVIEW MEETING. WE HAD EIGHT APPLICATIONS
18 THAT RECEIVED A SCORE OF 1 AND WERE RECOMMENDED FOR
19 FUNDING. THE TOTAL APPLICANT REQUEST FOR THOSE
20 EIGHT APPLICATIONS IS 63.9 MILLION.

21 THERE IS ONE APPLICATION THAT WAS
22 RECOMMENDED FOR REVISION WITH A SCORE OF 2, AND THAT
23 APPLICANT REQUEST IS EIGHT MILLION. THERE WERE NO
24 APPLICATIONS THAT WERE NOT RECOMMENDED FOR FUNDING.

25 AS YOU KNOW, THERE ARE MINORITY REPORTS

BETH C. DRAIN, CA CSR NO. 7152

1 THAT ACCOMPANY APPLICATIONS THAT UNDER PROP 14
2 DEFINE THOSE THAT HAVE 35 PERCENT OR MORE OF THE
3 MEMBERS SCORING TO FUND THE APPLICATION. THE
4 MINORITY REPORT IS INCLUDED WITHIN THE REVIEW
5 SUMMARY AND PROVIDES A BRIEF SYNOPSIS OF THE
6 OPINIONS OF THOSE REVIEWERS THAT SCORE THE
7 APPLICATION, NOT 85 OR ABOVE IN THIS CASE, BUT THAT
8 SCORED A 1.

9 SO WE HAVE ONE MINORITY REPORT FOR ONE OF
10 THE APPLICATIONS, THE ONE THAT GOT A SCORE OF 2.
11 THE VOTE FOR THE SCORING FROM THE SCIENTIFIC MEMBERS
12 WAS SIX WHO GAVE IT A SCORE OF 1 AND EIGHT WHO GAVE
13 IT A SCORE OF 2. NO ONE SCORED IT A 3.

14 THE HIGHLIGHTS AS QUICKLY BULLETED. YOU
15 CAN SEE IN THE REVIEW SUMMARY OF WHAT THE MINORITY
16 POSITION WAS WAS THAT THEY HAVE A QUALITY TEAM, THAT
17 IT HAS WELL-ESTABLISHED EXPERTISE IN STEM CELL
18 BIOLOGY AND REGENERATIVE MEDICINE. THEY HAVE STRONG
19 CLINICAL TRIAL MANAGEMENT AND THE CAPACITY TO
20 DELIVER SYSTEMS THAT MAY BENEFIT THE NETWORK.
21 SUPPORT FOR A BROAD SCOPE OF REGENERATIVE MEDICINE
22 PROJECTS, THEY FELT, WOULD ULTIMATELY BE MORE LIKELY
23 TO FURTHER CIRM GOALS AND BENEFIT CALIFORNIA
24 CITIZENS. THE APPLICANTS PRESENTED A PRETTY BROAD
25 SET OF PROJECTS THAT EXTEND BEYOND CELL AND GENE

BETH C. DRAIN, CA CSR NO. 7152

1 THERAPY EXCLUSIVELY. AND SO THEY THOUGHT THAT THAT
2 WAS ACTUALLY AN ADVANTAGE. AND, OF COURSE, THEY
3 ALSO OFFER SIGNIFICANT MATCHING AND IN-KIND FUNDS.

4 SO THE RECOMMENDATION FROM THE CIRM TEAM
5 IS THAT WE CONCUR WITH THE GRANTS WORKING GROUP
6 RECOMMENDATION FOR FUNDING; BUT, IN ADDITION, THE
7 CIRM TEAM SUPPORTS THE MINORITY POSITION FOR
8 APPLICATION 13597, AND WE RECOMMEND FUNDING OF THIS
9 APPLICATION AS WELL.

10 AND BECAUSE THIS PARTICULAR APPLICATION IS
11 FROM AN EXISTING SITE, AND PART OF THE REASON WHY WE
12 ARE RECOMMENDING IT IS THAT WE KNOW, THROUGH OUR
13 MANAGEMENT OF THAT GRANT AWARD, THAT THIS IS A SITE
14 THAT HAS BEEN QUITE SUCCESSFUL IN SUPPORTING CELL
15 AND GENE THERAPY TRIALS. AND THE CRITICISM FROM THE
16 WORKING GROUP WAS A LACK OF STEM CELL/GENE THERAPY
17 TRIALS WITHIN THE APPLICATION. BUT WHAT HAPPENS,
18 THE APPLICANT CHOSE TO ONLY HIGHLIGHT CIRM-FUNDED
19 TRIALS RATHER THAN THEIR FULL SCOPE OF TRIALS THAT
20 THEY SUPPORT. WE KNOW FOR A FACT THAT THE APPLICANT
21 HAS A VERY HEALTHY PORTFOLIO OF STEM CELL AND GENE
22 THERAPY TRIALS. AND WE DO BELIEVE THAT THIS WAS A
23 KEY FACTOR IN GIVING THIS APPLICATION A SCORE OF 2.

24 I WANT TO HIGHLIGHT A COUPLE OF ELEMENTS
25 THAT UNDER PROP 14 SHOULD BE CONSIDERED

BETH C. DRAIN, CA CSR NO. 7152

1 PROGRAMMATICALLY. ONE IS THE INSTITUTE
2 SELF-PRIORITIZED APPLICATION FOR ALPHA STEM CELL
3 CLINICS AND COMMUNITY CARE CENTERS OF EXCELLENCE
4 THAT OFFER MATCHING FUNDS OR VERIFIED IN-KIND
5 SUPPORT CONSISTENT WITH THE HIGHEST MEDICAL
6 STANDARDS AS ESTABLISHED BY THE GOVERNING BOARD.
7 AND THIS ONE IS A LITTLE MORE TANGENTIAL, BUT THE
8 INSTITUTE SHALL PRIORITIZE THE FUNDING OF
9 APPLICATIONS FOR COMMUNITY CARE CENTERS OF
10 EXCELLENCE -- THAT'S NOT WHAT THIS IS -- AND
11 ENHANCES GEOGRAPHIC DISTRIBUTION OF THE CENTERS
12 ACROSS THE STATE, BUT CONSIDERATION AS A LOCATION OF
13 THE ALPHA STEM CELL CLINICS TO PROMOTE PATIENT
14 ACCESS.

15 SO THERE IS A RELATIONSHIP IN TERMS OF
16 GEOGRAPHY. THERE'S A GOAL TO SPREAD THE GEOGRAPHY
17 BOTH OF THE ALPHA CLINICS AND THEN EVEN FURTHER WITH
18 THE COMMUNITY CARE CENTERS OF EXCELLENCE. SO TO THE
19 EXTENT THAT THERE IS SOME GEOGRAPHIC DISTRIBUTION
20 UNDER PROP 14, THAT IS SOMETHING THAT IS HOPED THAT
21 WE ACCOMPLISH.

22 THIS IS A REMINDER OF THOSE THAT HAVE A
23 CONFLICT OF INTEREST THAT WAS DECLARED FOR AT LEAST
24 ONE OF THE APPLICATIONS. SO A REMINDER, AGAIN, THAT
25 IF YOUR NAME IS UP HERE, LOOK TO MAKE SURE WHAT

BETH C. DRAIN, CA CSR NO. 7152

1 APPLICATION YOU MAY HAVE A CONFLICT WITH. AND IF
2 YOU HAVE A CONFLICT WITH THAT APPLICATION, TO
3 REFRAIN FROM DISCUSSING OR VOTING ON THAT
4 APPLICATION.

5 LET ME THEN SHOW YOU THE SPREADSHEET,
6 WHICH IS ALSO IN YOUR MATERIALS. IT SHOWS EACH OF
7 THE APPLICATIONS. WITHIN THAT ARE ALSO INFORMATION
8 ABOUT THE GENERAL GEOGRAPHY AND THE MATCHING AND
9 IN-KIND THAT WAS PROVIDED BY THE APPLICANT. MR.
10 CHAIRMAN.

11 CHAIRMAN THOMAS: CAN YOU JUST ENLARGE
12 THAT A BIT, GIL, PLEASE.

13 DR. SAMBRANO: YES, ABSOLUTELY.

14 CHAIRMAN THOMAS: OKAY. I'M SEEING IT.
15 THAT'S NOT THE ENTIRE...

16 DR. SAMBRANO: HOLD ON.

17 CHAIRMAN THOMAS: OKAY. THANK YOU. ALL
18 RIGHT. GIL, THANKS VERY MUCH FOR THAT.

19 SO I'M GOING TO FIRST THING HERE
20 PERSONALLY MOVE THAT WE MOVE THE ONE APPLICATION
21 THAT'S LISTED IN TIER II, FOR PURPOSES OF
22 DISCUSSION, UP TO TIER I. DO I HAVE A SECOND FOR
23 THAT?

24 DR. DULIEGE: I SECOND.

25 CHAIRMAN THOMAS: THANK YOU, ANNE-MARIE.

BETH C. DRAIN, CA CSR NO. 7152

1 OKAY.

2 SO THIS APPLICATION WHICH IS FROM UCSD,
3 LET ME JUST MAKE SOME COMMENTS ON THIS. FIRST OF
4 ALL, THE APPLICATION ITSELF, AS EVIDENCED BY THE
5 MATERIALS THAT WERE PROVIDED TO THE BOARD ONLINE,
6 DID GENERATE A NUMBER OF COMMENTS ON THE NEGATIVE
7 SIDE DEALING WITH VARIOUS ASPECTS OF THE
8 APPLICATION. ALTHOUGH I WILL NOTE, INTERESTINGLY,
9 THAT THERE WAS THE SLIDE GIL HAD WHICH LISTED THE
10 FOUR CRITERIA, WHICH WERE YES/NO QUESTIONS THAT
11 MEMBERS OF THE GWG WERE ASKED. AND FOR ALL FOUR OF
12 THOSE QUESTIONS, THE GWG HAD MORE YESES THAN NOS.
13 SO HOW THEY ENDED UP WITH A VOTE OF SIX TO EIGHT
14 FAVORING TIER II I'M NOT ENTIRELY CLEAR. BUT
15 NONETHELESS, THERE WERE A SUBSTANTIAL NUMBER OF
16 COMMENTS.

17 HAVING SAT IN ON THE REVIEW, THERE ARE A
18 COUPLE THINGS THAT I WANTED TO HIGHLIGHT. THE
19 APPLICANT, WHICH THE PRESENTATION WAS LED VERY
20 CAPABLY BY DR. CAT JAMIESON, TALKED IN TERMS OF WHAT
21 THEY HAD, AND GIL ALLUDED TO THIS ALREADY, TALKED IN
22 TERMS OF WHAT THEY HAD AT THE ALPHA CLINICS, A
23 CONSIDERABLE AMOUNT ABOUT A CIRM-FUNDED PROJECT
24 WHICH YIELDED A MONOCLONAL ANTIBODY FOR CANCER
25 TREATMENT CALLED CIRMTUZAMAB WHICH HAS HAD A

BETH C. DRAIN, CA CSR NO. 7152

1 CONSIDERABLE DEGREE OF SUCCESS, AND WAS DESCRIBED --
2 IT'S AN ANTIBODY WHICH LOOKS TO INHIBIT THE ACTIVITY
3 OF CANCER STEM CELLS AND, THEREFORE, HAD A STEM CELL
4 ELEMENT TO IT.

5 THE DISCUSSION ABOUT THAT, DR. JAMIESON IS
6 VERY PROUD OF THAT WORK, VERY PROUD OF WHAT CIRM HAS
7 DONE TO ENABLE IT, SPENT A LOT OF TIME ON THAT, AND
8 DID NOT SPEND MUCH TIME ON OTHER PROJECTS THAT DEAL
9 SPECIFICALLY WITH CELL AND GENE THERAPY. AS GIL
10 JUST MENTIONED, THAT'S LARGELY BECAUSE SHE CHOSE TO
11 HIGHLIGHT THAT PARTICULAR PROJECT BECAUSE IT WAS A
12 CIRM-FUNDED PROJECT AND DID NOT TALK ABOUT THE
13 OTHERS. BUT THEY HAVE A GREAT MANY CELL AND GENE
14 THERAPY PROJECTS IN THEIR ALPHA STEM CELL CLINIC
15 THAT WERE NOT MENTIONED, BUT ARE VERY IMPORTANT AND
16 EVIDENCE THEIR FOCUS ON CELL AND GENE THERAPY ITSELF
17 IN ADDITION TO THE PROJECT THAT WAS HIGHLIGHTED.

18 SO TO ME THAT WAS STRICTLY A MATTER OF HOW
19 THE GRANT WAS PRESENTED IN THE ORAL PRESENTATION AND
20 NOT AT ALL BACKED UP BY EMPIRICAL EVIDENCE, FOR
21 THOSE THAT WERE CONCERNED, THAT THERE WAS NO FOCUS
22 ON CELL AND GENE THERAPY.

23 THE SECOND THING THAT WAS OF CONSIDERABLE
24 DISCUSSION WAS DR. JAMIESON IN HER PRESENTATION
25 SPENT MOST OF THE TIME TALKING ABOUT THE WORK THAT'S

BETH C. DRAIN, CA CSR NO. 7152

1 BEING DONE AT THE STEM CELL CLINIC ITSELF AT UCSD
2 AND DID NOT SPEND A PARTICULARLY LARGE AMOUNT OF
3 TIME DEALING WITH HOW THE UCSD WORK NETWORKS WITH
4 THE OTHER INSTITUTIONS IN THE ALPHA STEM CELL
5 CLINIC. AND YOU WILL SEE A NUMBER OF COMMENTS TO
6 THAT EFFECT IN THE NEGATIVE COMMENT COMPONENT OF
7 WHAT'S ONLINE THERE.

8 IN FACT, I'M VERY FAMILIAR WITH THE UCSD
9 PROGRAM. THEY HAVE MANY COLLABORATIONS WITH OTHER
10 INSTITUTIONS IN THE NETWORK. AS AN EXAMPLE, AS IT
11 HAPPENS, LAST WEEK -- WAS IT LAST WEEK OR EARLIER
12 THIS WEEK? I LOSE TRACK SO MANY DIFFERENT THINGS
13 GOING ON -- THERE WAS A SYMPOSIUM AT UCSD THAT I
14 WENT DOWN TO SEE. ONE OF THE SEGMENTS FEATURED A
15 PANEL VERY CAPABLY EMCEED BY DR. MILLAN ON ALPHA
16 STEM CELL CLINICS, AT WHICH WERE REPRESENTATIVES
17 FROM UCSD, UCI, UCLA, AND OTHERS. AND IN THE COURSE
18 OF THAT DISCUSSION, THERE WAS A NUMBER OF COMMENTS
19 DR. JAMIESON MADE TO THE EXTENT OF ABOUT HOW MUCH
20 THEY DO COLLABORATE WITH OTHER MEMBERS OF THE ALPHA
21 STEM CELL CLINIC AND INDEED THE IMPORTANCE OF THAT
22 COLLABORATION AS IT IS NOT JUST IMPORTANT IN AND OF
23 ITSELF, BUT FUNDAMENTAL TO THE WHOLE NOTION OF ALPHA
24 STEM CELL CLINICS.

25 SO THOSE TWO THINGS WHICH GOT A LOT OF

BETH C. DRAIN, CA CSR NO. 7152

1 PLAY IN THE COMMENTS, I THOUGHT, WERE, AGAIN, A
2 FUNCTION OF WHAT WAS HIGHLIGHTED IN THE PRESENTATION
3 AND NOT IN SORT OF THE WAY THINGS ACTUALLY ARE.

4 NORMALLY WHEN WE GIVE COMMENTS TO
5 APPLICANTS, THEY'RE RESPONDED TO EITHER TO A
6 CONSIDERABLE EXTENT OR NOT SO MUCH. IN THIS CASE
7 DR. JAMIESON HAS SUBMITTED, WHICH ALL OF YOU
8 RECEIVED, A LETTER EXHAUSTIVELY POINTING OUT HOW
9 THEY ARE DEALING WITH ALL OF THE POINTS THAT WERE
10 RAISED IN THE NEGATIVE COMMENTS AND, HAVING READ
11 THAT, FOUND IT TO BE VERY PERSUASIVE AND INDICATIVE
12 OF THE FACT THAT THEY HEARD THE COMMENTS OF THE GWG,
13 THEY'VE HEARD THE COMMENTS OF OUR TEAM, AND HAVE
14 GIVEN A GREAT DEAL OF THOUGHT ON HOW TO WORK IN
15 THEIR RESPONSE TO THOSE COMMENTS, AND TO HOW THEIR
16 STEM CELL CLINIC WILL PROCEED GOING FORWARD IF
17 FUNDED.

18 THIS IS AN ORIGINAL STEM CELL CLINIC THAT
19 WE FUNDED IN THE ALPHA CLINIC PROGRAM. IT'S, VERY
20 IMPORTANTLY, IN THE SOUTHERNMOST PART OF THE STATE
21 AND, AS SUCH, DEALS WITH PATIENTS IN THAT MOST
22 IMPORTANT AREA, WERE THEY NOT TO BE FUNDED GOING
23 FORWARD AND TO THE EXTENT THAT THAT HAD A NEGATIVE
24 IMPACT ON WHAT THEY'RE ABLE TO DO GOING BEYOND NOW,
25 THAT WOULD BE, IN MY OPINION, A REAL SHAME. I THINK

BETH C. DRAIN, CA CSR NO. 7152

1 THAT DR. JAMIESON AND HER TEAM ARE ABSOLUTELY
2 FIRST-RATE AND HAVE PRODUCED MANY EXCELLENT PROJECTS
3 THAT CIRM HAS FUNDED OVER THE YEARS.

4 IN ANY EVENT, IN SUM, IN SPITE OF THE FACT
5 THAT THERE WAS OPPOSITION, I STRONGLY AM IN FAVOR OF
6 ELEVATING THEM UP TO TIER I TO BE CONSIDERED AS PART
7 OF THE OTHER VERY EXCELLENT PROGRAMS THAT HAVE
8 ALREADY BEEN RECOMMENDED FOR FUNDING. THAT
9 CONCLUDES MY COMMENTS.

10 ARE THERE COMMENTS FROM OTHER MEMBERS OF
11 THE APPLICATION REVIEW SUBCOMMITTEE ON THIS
12 PARTICULAR MOTION?

13 MS. BONNEVILLE: MARK HAS HIS HAND RAISED.

14 DR. FISCHER-COLBRIE: J.T., THANK YOU FOR
15 YOUR EXTREMELY ARTICULATE COMMENTS IN LAYING OUT THE
16 DISCUSSION AND THE CLEAR OPPORTUNITIES RELATED TO UC
17 SAN DIEGO AND ADDRESSING THE ELEMENTS WHERE PEOPLE
18 HAD EXPRESSED CONCERN.

19 I WANTED TO AMPLIFY AND SUPPORT YOUR
20 RECOMMENDATION FROM THE CONTEXT OF, IF YOU DO LOOK
21 AT THE VOTE, MORE SPECIFICALLY IF YOU LOOK AT THE
22 FOUR CATEGORIES IN TERMS OF THE KEY ELEMENTS AND
23 FEASIBILITY, 13 TO 1; VALUE PROPOSITION TO THE STATE
24 OF CALIFORNIA, 9 TO 5; SERVING THE NEEDS OF THE
25 UNDERSERVED, 9 TO 5; WELL PLANNED, 8 TO 6, DESPITE

BETH C. DRAIN, CA CSR NO. 7152

1 THE PHENOMENON OF ELEMENTS, THE COMMUNICATION THAT
2 DIDN'T NECESSARILY BRING OUT ALL THE STRENGTHS OF
3 THE SAN DIEGO PLATFORM. I THINK REALLY IN
4 CONJUNCTION, IF WE LOOK AT THIS ORGANIZATION IN SAN
5 DIEGO, NOT ONLY IS IT A POWERHOUSE WITH DEMONSTRATED
6 SUCCESS, BUT THERE IS THE PHENOMENON OF THE LOSS OF
7 THAT CAPABILITY IN THAT PARTICULAR REGION WOULD BE
8 DETRIMENTAL, IN MY VIEW, RELATED TO CONTINUATION
9 AROUND THE UNDERSERVED COMMUNITY AND TO OTHER AREAS.

10 SO OBVIOUSLY I DON'T COUNT FOR A VOTE ON
11 THIS COUNT; BUT DURING THE COURSE OF THE PROCESS, I
12 THINK IT'S IMPORTANT TO SUPPORT THIS KIND OF
13 DEMONSTRATED PERFORMANCE. AND I THINK IT'S A
14 SITUATION WHERE I AGREE WITH THE STAFF'S
15 RECOMMENDATION, THAT THIS SHOULD BE MOVED FROM A 2
16 TO A 1, AND THAT WE PROGRESS WITH THE FUNDING FOR
17 THIS TERRIFIC PROGRAM.

18 CHAIRMAN THOMAS: THANK YOU, MARK. OTHER
19 COMMENTS BY MEMBERS OF THE BOARD?

20 MS. BONNEVILLE: ANNE-MARIE.

21 DR. DULIEGE: SO I'M GOING TO SUPPORT WHAT
22 BOTH OF YOU MENTIONED. AND IT SEEMS MERELY SORT OF
23 A MISUNDERSTANDING BETWEEN WHAT WAS ACTUALLY
24 PRESENTED VERSUS WHAT WAS INTENDED TO BE PRESENTED,
25 A MORE GLOBAL DESCRIPTION OF THE WORK WHICH DR.

BETH C. DRAIN, CA CSR NO. 7152

1 JAMIESON, I THINK, ELOQUENTLY PUT IN HER LETTER.

2 I JUST WANT TO SAY THERE'S SOMETHING THAT
3 DOESN'T COMPUTE WELL IN MY MIND, WHICH IS WHEN YOU
4 LOOK AT ALL THE ANSWERS OF THE GWG IN THE DOCUMENT
5 WE HAVE, THEY ARE ALL MOSTLY POSITIVE TO EACH OF THE
6 QUESTIONS. AND YET AT THE END, WE HAVE A TOTAL
7 SCORE THAT IS MOSTLY NEGATIVE. I'M NOT SURE EXACTLY
8 HOW THAT CAN HAPPEN; NONETHELESS, I SUPPORT WHAT
9 BOTH OF YOU SUGGESTED AND WHAT THE CIRM TEAM ALSO
10 SUGGESTED.

11 CHAIRMAN THOMAS: THANK YOU, ANNE-MARIE.
12 OTHER QUESTIONS OR COMMENTS FROM MEMBERS OF THE
13 BOARD?

14 MS. BONNEVILLE: THERE ARE NO OTHER HANDS
15 RAISED.

16 CHAIRMAN THOMAS: OKAY. DO WE HAVE PUBLIC
17 COMMENT ON THIS MOTION?

18 MS. BONNEVILLE: I BELIEVE WE WILL HAVE
19 PUBLIC COMMENT. YES, THERE IS A HAND RAISED. IF
20 YOU COULD UNMUTE YOURSELF AND YOU WILL HAVE THREE
21 MINUTES.

22 THE CALLER THAT IS CALLING IN FROM
23 858-246-1453, IF YOU COULD UNMUTE YOURSELF AND START
24 YOUR PUBLIC COMMENT.

25 DR. JAMIESON: HELLO THERE. IT'S CATRIONA

BETH C. DRAIN, CA CSR NO. 7152

1 JAMIESON.

2 MS. BONNEVILLE: THANKS, CATRIONA. YOU
3 HAVE THREE MINUTES.

4 DR. JAMIESON: THANK YOU SO MUCH, CHAIRMAN
5 THOMAS AND MEMBERS OF THE INDEPENDENT CITIZENS
6 OVERSIGHT COMMITTEE, FOR YOUR VERY THOUGHTFUL AND
7 COMPREHENSIVE REVIEW OF OUR PROPOSAL. WE REALLY
8 APPRECIATE THIS OPPORTUNITY TO HIGHLIGHT THE DECADES
9 OF EXPERIENCE IN STEM CELL AND GENE THERAPY CLINICAL
10 TRIALS DEVELOPMENT AND ADMINISTRATION THAT OUR TEAM
11 BRINGS TO THE ALPHA STEM CELL CLINIC NETWORK AS WELL
12 AS TO THE PATIENTS THAT ARE WITHIN OUR 3.3 MILLION
13 CATCHMENT AREA, WITH 30 PERCENT BEING LATIN-X AND
14 UNDERFUNDED SOCIOECONOMICALLY DISADVANTAGED. SO I
15 REALLY APPRECIATE THIS OPPORTUNITY TO CLARIFY THREE
16 KEY ASPECTS OF OUR PROPOSAL AND ESPECIALLY
17 APPRECIATE THE POSITIVE COMMENTS FROM THE ICOC IN
18 THIS REVIEW AND GIL SAMBRANO FOR HIS THOUGHTFUL
19 ATTENTION.

20 SO NO. 1 IS TRAINING PROGRAMS. SO WE
21 RECEIVED A RECENT GIFT FROM T. DENNY SANFORD WITH A
22 THIRD OF THAT LARGE GIFT GOING TO TRAINING OF
23 FELLOWS AND FACULTY. SO WE WILL BE INVESTING MORE
24 IN EARLY CAREER INVESTIGATORS AND SPECIFICALLY IN
25 THE CIRM CLINICAL FELLOWSHIP PROGRAM, WHICH WE WILL

BETH C. DRAIN, CA CSR NO. 7152

1 BE VERY HAPPY TO INTERACT WITH FOR THE OTHER ALPHA
2 CLINIC SITES. SO WE WILL BE TRAINING FOUR ELIGIBLE
3 FELLOWS A YEAR ON OUR SERVICE.

4 WE HAVE A TRANSLATIONAL REGENERATIVE
5 MEDICINE COURSE ALREADY THAT IS ABLE TO BE TAKEN,
6 AND THEY WILL BE TRAINING WITHIN OUR ADVANCED CELL
7 THERAPY LAB, OUR NEW SANFORD STEM CELL INNOVATION
8 CENTER, AND THEN WE HAVE OUR SANFORD STEM CELL BASIC
9 AND TRANSLATIONAL LAB TRAINING PROGRAM WHERE WE GOT
10 A CIRM AWARD. SO WE ARE VERY GRATEFUL TO CIRM FOR
11 THE SPARK PROGRAM, THE BRIDGES PROGRAM, AND THEN
12 MORE RECENT TRAINING PROGRAM, AND WILL BE ADDING A
13 VERY ROBUST FELLOWSHIP PROGRAM WITH ADDITIONAL
14 REGULATORY AND CLINICAL TRIALS TRAINING. WE
15 CONTINUE TO TRAIN STAFF NURSES AND RESEARCH
16 COORDINATORS AND INVESTIGATORS TO MAKE SURE THAT WE
17 ARE PERFORMING FDA REGULATORY COMPLIANCE TRAINING
18 FOR OUR TEAM.

19 NO. 2, WITH REGARDS TO THE VALUE ADD TO
20 THE ALPHA STEM CELL CLINIC NETWORK, IN OUR CELL AND
21 GENE THERAPY, AS CHAIRMAN THOMAS MENTIONED, WE DID
22 HIGHLIGHT SOMETHING THAT WE WERE VERY PROUD TO WORK
23 WITH CIRM ON, AND THAT'S CIRMTUZAMAB THAT IS NOW
24 CALLED ZILOVERTAMAB AND IS TRANSITIONING TO CAR-T
25 CELL THERAPY FOR A NUMBER OF SOLID TUMORS AS WELL AS

BETH C. DRAIN, CA CSR NO. 7152

1 LIQUID TUMORS WITH AN EMPHASIS ON BREAST CANCER AND
2 OTHER RECALCITRANT MALIGNANCIES.

3 SO WE DID HIGHLIGHT THE 30 CLINICAL TRIALS
4 THAT WERE SUPPORTED BY THE ALPHA STEM CELL CLINIC
5 NETWORK, BUT WE DIDN'T ACTUALLY TALK ABOUT THAT
6 WE'VE DONE 59 TRIALS IN TOTAL, ENROLLED 553
7 PATIENTS, 54 PERCENT OF OUR TRIALS ARE CELL AND GENE
8 THERAPY TRIALS. AND WHAT REALLY CHANGED OUR ACCRUAL
9 METRIC IS WHEN WE ADDED AN INPATIENT CELL AND
10 REGENERATIVE MEDICINE SERVICE. IT'S A DEDICATED
11 SERVICE SO THAT WE CAN ENSURE THAT WE GET CELL AND
12 GENE THERAPY TRIALS INTO OUR PORTFOLIO. SO WE
13 BASICALLY DOUBLED THE NUMBER OF TRIALS AND WENT FROM
14 30 TO 59 SINCE WE STARTED THAT SERVICE IN 2018. SO
15 THAT'S A BIG PROPORTION OF WHAT WE DO. WITH THIS
16 BIOTECH HUB, OVER 600 BIOTECH AND PHARMA COMPANIES
17 ACTUALLY INVESTING IN CELL AND GENE THERAPY LOCALLY,
18 I THINK THAT WE ARE IN A UNIQUE POSITION TO BE ABLE
19 TO ACCELERATE IMPLEMENTATION OF CLINICAL TRIALS.

20 I GAVE FOUR EXAMPLES IN OUR WRITE-UP. ONE
21 IS --

22 MS. BONNEVILLE: DR. JAMIESON, IF YOU
23 COULD JUST WRAP IT UP PLEASE.

24 DR. JAMIESON: I'M WRAPPING IT UP. BY
25 BASICALLY ANGIOCRINE, SWITCHABLE CAR-T CELLS, THE

BETH C. DRAIN, CA CSR NO. 7152

1 FIRST-IN-HUMAN IPS-DERIVED NK CELLS, CAR-T CELLS
2 TARGETING CANCER STEM CELL PROPERTIES SUCH AS
3 CARSGEN, HEMATOPOIETIC STEM CELL AND GENE THERAPY
4 TRIAL FOR CYSTINOSIS. SO OUR LEAD-OFF OFFERINGS IN
5 ADDITION TO THE FELLOWSHIP PROGRAM INCLUDE OUR
6 STRATEGIC RESEARCH ADVISING TEAM.

7 AND, FINALLY, WITH DEIA, WE HAVE A SYSTEM
8 IN OUR ALPHA STEM CELL CLINICS --

9 MR. TORRES: YOU'RE LOSING VOTES.

10 DR. JAMIESON: -- ENROLLED 533 RACIALLY
11 AND SOCIOECONOMICALLY DIVERSE PATIENTS. WE WILL
12 EXPAND THAT ACCRUAL BY ENHANCING OUR OUTREACH TO
13 HILLCREST HOSPITAL WITH FOUR COORDINATORS AND THEN
14 TO EL CENTRO.

15 SO THANK YOU VERY MUCH FOR PROVIDING THE
16 OPPORTUNITY TO PROVIDE THIS PUBLIC COMMENT. WE
17 REALLY APPRECIATE YOUR THOUGHTFUL REVIEW OF OUR
18 APPLICATION AND THE PROPOSAL TO MOVE IT TO A TIER I.
19 THANK YOU.

20 CHAIRMAN THOMAS: THANK YOU, DR.
21 JAMIESON. OKAY.

22 WE WANT TO GET TO A VOTE ON THIS. WE MAY
23 BE LOSING PEOPLE. IS THAT THE EXTENT OF PUBLIC
24 COMMENT, MARIA?

25 MS. BONNEVILLE: THOSE -- YES, THAT WAS

BETH C. DRAIN, CA CSR NO. 7152

1 THE ONLY HAND RAISED.

2 CHAIRMAN THOMAS: OKAY. ALL RIGHT. THANK
3 YOU, EVERYBODY, FOR YOUR THOUGHTFUL COMMENTS ON
4 THIS. MARIA, WILL YOU PLEASE CALL THE ROLL ON THIS
5 MOTION, WHICH IS SPECIFICALLY JUST TO MOVE THIS UP
6 TO TIER I.

7 MS. BONNEVILLE: DAN BERNAL.

8 MR. BERNAL: AYE.

9 MS. BONNEVILLE: JUDY CHOU.

10 DR. CHOU: AYE.

11 MS. BONNEVILLE: LEONDRAL CLARK-HARVEY.

12 ANNE-MARIE DULIEGE.

13 DR. DULIEGE: AYE.

14 MS. BONNEVILLE: YSABEL DURON.

15 MS. DURON: AYE.

16 MS. BONNEVILLE: MARK FISCHER-COLBRIE.

17 DR. FISCHER-COLBRIE: AYE.

18 MS. BONNEVILLE: FRED FISHER. ELENA

19 FLOWERS.

20 DR. FLOWERS: YES.

21 MS. BONNEVILLE: DAVID HIGGINS. STEVE

22 JUELGAARD.

23 MR. JUELGAARD: YES.

24 MS. BONNEVILLE: RICH LAJARA.

25 MR. LAJARA: YES.

BETH C. DRAIN, CA CSR NO. 7152

1 MS. BONNEVILLE: CHRIS MIASKOWSKI.
2 DR. MIASKOWSKI: YES.
3 MS. BONNEVILLE: LAUREN MILLER-ROGEN.
4 MS. MILLER-ROGEN: YES.
5 MS. BONNEVILLE: ADRIANA PADILLA.
6 DR. PADILLA: YES.
7 MS. BONNEVILLE: JOE PANETTA. AL ROWLETT.
8 MR. ROWLETT: YES.
9 MS. BONNEVILLE: MARVIN SOUTHARD.
10 DR. SOUTHARD: YES.
11 MS. BONNEVILLE: JONATHAN THOMAS.
12 CHAIRMAN THOMAS: YES.
13 MS. BONNEVILLE: KAROL WATSON.
14 DR. WATSON: YES.

BETH C. DRAIN, CA CSR NO. 7152

1 MS. BONNEVILLE: THANK YOU. THE MOTION
2 CARRIES.

3 CHAIRMAN THOMAS: OKAY. IF EVERYBODY CAN
4 HANG ON JUST FOR ONE QUICK SECOND TO FINISH THIS
5 OUT. SO NOW DO I HEAR A MOTION TO APPROVE ALL OF
6 TIER I RECOMMENDED PROJECTS?

7 MS. BONNEVILLE: AND JUST AS A REMINDER,
8 IF YOU HAVE A CONFLICT WITH THIS, YOU CANNOT MAKE OR
9 SECOND THE MOTION.

10 MR. BERNAL: SO MOVED.

11 MR. ROWLETT: SECOND.

12 CHAIRMAN THOMAS: MOVED BY DAN, SECONDED
13 BY AL. ARE THERE QUESTIONS OR COMMENTS FROM MEMBERS
14 OF THE BOARD? ANY PUBLIC COMMENT?

15 MS. BONNEVILLE: THERE IS NO PUBLIC
16 COMMENT.

17 CHAIRMAN THOMAS: HEARING NONE, MARIA,
18 WILL YOU PLEASE CALL THE ROLL.

19 MS. BONNEVILLE: YES. AND AS A REMINDER,
20 IF YOU COULD SAY YEA OR NAY, YES OR NO, EXCEPT FOR
21 THOSE WITH WHICH I HAVE A CONFLICT. THANK YOU.

22 DAN BERNAL.

23 MR. BERNAL: AYE.

24 MS. BONNEVILLE: JUDY CHOU.

25 DR. CHOU: AYE.

BETH C. DRAIN, CA CSR NO. 7152

1 MS. BONNEVILLE: LEONDRA CLARK-HARVEY.
2 ANNE-MARIE DULIEGE.

3 DR. DULIEGE: AYE.

4 MS. BONNEVILLE: YSABEL DURON.

5 MS. DURON: AYE, EXCEPT FOR THOSE WITH
6 WHICH I HAVE A CONFLICT.

7 MS. BONNEVILLE: MARK FISCHER-COLBRIE.

8 DR. FISCHER-COLBRIE: YES.

9 MS. BONNEVILLE: FRED FISHER. ELENA
10 FLOWERS.

11 DR. FLOWERS: YES, EXCEPT THOSE FOR WHICH
12 I HAVE A CONFLICT.

13 MS. BONNEVILLE: DAVID HIGGINS. STEVE
14 JUELSGAARD.

15 MR. JUELSGAARD: YES.

16 MS. BONNEVILLE: RICH LAJARA.

17 MR. LAJARA: YES.

18 MS. BONNEVILLE: CHRIS MIASKOWSKI, EXCEPT
19 FOR THOSE WITH WHICH I HAVE A CONFLICT.

20 DR. MIASKOWSKI: YES.

21 MS. BONNEVILLE: LAUREN MILLER-ROGEN.

22 MS. MILLER-ROGEN: YES.

23 MS. BONNEVILLE: ADRIANA PADILLA.

24 DR. PADILLA: YES.

25 MS. BONNEVILLE: JOE PANETTA. AL ROWLETT.

BETH C. DRAIN, CA CSR NO. 7152

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

MR. ROWLETT: YES.
MS. BONNEVILLE: MARVIN SOUTHARD.
DR. SOUTHARD: YES.
MS. BONNEVILLE: JONATHAN THOMAS.
CHAIRMAN THOMAS: YES.
MS. BONNEVILLE: ART TORRES.
MR. TORRES: AYE, EXCEPT FOR THOSE WITH
WHICH I HAVE A CONFLICT.
MS. BONNEVILLE: KAROL WATSON.
DR. WATSON: YES.

BETH C. DRAIN, CA CSR NO. 7152

1 MS. BONNEVILLE: EXCEPT FOR THOSE, CAN YOU
2 ADD THAT? YOU HAVE A CONFLICT OF INTEREST.

3 DR. WATSON: EXCEPT FOR THOSE WITH WHICH I
4 HAVE A CONFLICT.

5 MS. BONNEVILLE: THANK YOU. THE MOTION
6 CARRIES.

7 CHAIRMAN THOMAS: OKAY. THANK YOU. THANK
8 YOU ALL FOR THAT. CONGRATULATIONS TO ALL ALPHA STEM
9 CELL CLINIC GRANT RECIPIENTS. WE LOOK FORWARD TO
10 CONTINUED EXCELLENCE AND BIGGER AND BETTER THINGS AS
11 WE PROCEED DOWN THE ROAD.

12 MR. BERNAL: J.T., I APOLOGIZE. WE HAVE A
13 MANDATORY FIRE DRILL HAPPENING IN THE BUILDING RIGHT
14 NOW. SO I'M GOING TO HAVE TO SIGN OFF.

15 CHAIRMAN THOMAS: THANK YOU, DAN. SO
16 MARIA TELLS ME WE MAY HAVE QUORUM ISSUES. WE HAVE
17 TWO VERY MINOR -- LET'S SEE.

18 MS. BONNEVILLE: J.T., WE SHOULD GO TO THE
19 SHARED LABS. I DON'T KNOW IF BETH NEEDS A BREAK,
20 BUT WE SHOULD DEFINITELY DO SHARED LABS. IT WAS
21 QUORUM ON THE ARS. I THINK WE ARE GOOD FOR
22 EVERYTHING ELSE.

23 CHAIRMAN THOMAS: OKAY. BETH, DO YOU NEED
24 A SHORT BREAK HERE?

25 THE REPORTER: I'M GOOD, MR. CHAIRMAN.

BETH C. DRAIN, CA CSR NO. 7152

1 THANK YOU.

2 CHAIRMAN THOMAS: I SHOULD NOTE, FOR THOSE
3 JUST RELEVANT TO THE ALPHA CLINICS, THAT THE MEMBERS
4 OF THE MEDICAL AFFAIRS TEAM HELD THE FIRST MEETING
5 IN CONNECTION WITH THE COMMUNITY CARE CENTERS OF
6 EXCELLENCE THIS WEEK IN FRESNO OR CLOVIS, I SHOULD
7 SAY, THAT WAS ATTENDED BY MANY OF THE STAKEHOLDERS
8 IN THAT AREA TO TALK ABOUT WHAT WOULD BE GOOD
9 ELEMENTS GOING INTO THE COMMUNITY CARE CENTERS OF
10 EXCELLENCE CONCEPT PLAN.

11 THE DISCUSSION WAS ABLY EMCEED BY GEOFF
12 LOMAX, SEAN TURBEVILLE, AND MEMBERS OF HIS TEAM WERE
13 THERE, AS WELL AS DR. PADILLA AND MYSELF
14 REPRESENTING THE BOARD, MARIA BONNEVILLE AND KEVIN
15 MCCORMACK REPRESENTING THE COMMUNICATIONS TEAM AND
16 PATIENT OUTREACH TEAM. IT WAS A VERY ROBUST
17 DISCUSSION WITH LOTS OF GREAT INPUT BY THE
18 STAKEHOLDER GROUP.

19 EVERYBODY GOT A TOUR OF THE COMMUNITY
20 CANCER INSTITUTE THERE, WHICH IS MOST IMPRESSIVE, AS
21 PART OF A LARGER CAMPUS OF MEDICAL FACILITIES. AND
22 IT WAS A GREAT DAY AND THE FIRST OF SEVERAL SUCH
23 MEETINGS THAT WILL BE HELD AROUND THE STATE OVER THE
24 COURSE OF THE COMING MONTHS TO INFORM THAT COMMUNITY
25 CARE CENTERS OF EXCELLENCE CONCEPT PLAN. SO STAY

BETH C. DRAIN, CA CSR NO. 7152

1 TUNED FOR THAT AS IT PROCEEDS ITS WAY DOWN THE ROAD.
2 THANK YOU TO EVERYBODY WHO MADE THAT HAPPEN. IT WAS
3 AN EXCELLENT EVENT.

4 SINCE BETH IS STILL ABLE TO GO HERE
5 WITHOUT A BREAK, THANK YOU, BETH, WE'RE GOING TO GO
6 NEXT TO ITEM 5, CONSIDERATION OF SHARED LABS
7 RESOURCES CONCEPT PLAN, WHICH WILL BE PRESENTED BY
8 DR. GRIESHAMMER AND CANET-AVILES. UTA, I THINK
9 WE'RE GOING TO GO RIGHT TO YOU.

10 DR. GRIESHAMMER: THANK YOU, MR. CHAIR.
11 AND I'M HOPING TO SET UP MY SLIDES HERE.

12 GOOD MORNING, EVERYONE, AND THANK YOU FOR
13 THE OPPORTUNITY TO PRESENT THE CONCEPT FOR SHARED
14 RESOURCE LABORATORIES FOR STEM CELL-BASED MODELING.

15 SO THIS IS AN INFRASTRUCTURE PROGRAM
16 DESIGNED TO ALIGN WITH CIRM'S MISSION TO ACCELERATE
17 WORLD-CLASS SCIENCE TO DELIVER TRANSFORMATIVE
18 REGENERATIVE MEDICINE TREATMENTS IN AN EQUITABLE
19 MANNER TO A DIVERSE CALIFORNIA AND WORLD.

20 SHARED RESOURCE LABORATORIES, IF APPROVED,
21 WILL REPRESENT A FORM OF COMPETENCY HUBS ENVISIONED
22 IN OUR STRATEGIC PLAN UNDER ADVANCING WORLD-CLASS
23 SCIENCE. THIS PROGRAM ALSO TOUCHES ON BUILDING
24 KNOWLEDGE NETWORKS AND ON BUILDING A DIVERSE AND
25 HIGHLY SKILLED WORKFORCE IN CALIFORNIA.

BETH C. DRAIN, CA CSR NO. 7152

1 BEFORE I INTRODUCE YOU TO THE CONCEPT FOR
2 THE SHARED RESOURCE LABS FOR STEM CELL-BASED
3 MODELING AND GO OVER THE OPPORTUNITIES AND NEEDS WE
4 INTEND TO ADDRESS, I'D LIKE TO PROVIDE SOME
5 HISTORICAL CONTEXT FOR THE STEM CELL-BASED MODELING
6 FIELD.

7 IN 1998 THE DERIVATION OF HUMAN EMBRYONIC
8 STEM CELLS WAS FIRST REPORTED. A FEW YEARS LATER IN
9 2001, FEDERAL FUNDING FOR HUMAN EMBRYONIC STEM CELL
10 RESEARCH WAS AFFIRMED; HOWEVER, IT WAS RESTRICTED TO
11 HUMAN EMBRYONIC STEM CELL LINES THAT ALREADY EXISTED
12 AT THE TIME.

13 IN 2004 CALIFORNIA VOTERS APPROVED
14 PROPOSITION 71, LEADING TO THE CREATION OF CIRM.
15 ONE OF THE INFRASTRUCTURE PROGRAMS CIRM PUT IN PLACE
16 TO PROVIDE CALIFORNIA RESEARCHERS WITH ACCESS TO
17 CRITICAL FUNDING FOR HUMAN EMBRYONIC STEM CELL
18 RESEARCH WAS THE SHARED LABS PROGRAM, PROVIDING
19 ACCESS TO DEDICATED RESEARCH SPACE, TO SPECIALIZED
20 INSTRUMENTATION TO HUMAN EMBRYONIC STEM CELL LINES,
21 AND TRAINING AND EDUCATION FOR RESEARCHERS AND
22 STUDENTS. AND MAKING THE EMERGING FIELD OF HUMAN
23 EMBRYONIC STEM CELL RESEARCH AT THE TIME MORE
24 ACCESSIBLE TO CALIFORNIA RESEARCHERS.

25 DURING THE TIME THE SHARED LAB AWARDS WERE

BETH C. DRAIN, CA CSR NO. 7152

1 ACTIVE, THERE WERE TWO IMPORTANT EVENTS THAT
2 OCCURRED. IN 2007 THE DERIVATION OF IPSC CELL LINES
3 WAS FIRST PUBLISHED. I SHOULD SAY HUMAN INDUCED
4 PLURIPOTENT STEM CELL LINES WAS FIRST PUBLISHED.
5 AND IN 2009 THE FEDERAL GOVERNMENT LIFTED ITS LIMITS
6 ON FUNDING FOR HUMAN EMBRYONIC STEM CELL RESEARCH.

7 ONE OF THE MAIN APPLICATIONS OF HUMAN
8 PLURIPOTENT STEM CELLS, EMBRYONIC STEM CELLS, AND
9 INDUCED PLURIPOTENT STEM CELLS COMBINED, JUST
10 CALLING THEM HUMAN PLURIPOTENT STEM CELLS, ONE OF
11 THE MAIN APPLICATIONS LIES IN THE USE OF THESE CELLS
12 FOR DISEASE MODELING BY DIFFERENTIATING THE CELLS
13 INTO THE CELL TYPES RELEVANT FOR THE DISEASE THAT IS
14 BEING STUDIED.

15 OVER THE LAST TWO DECADES, MUCH PROGRESS
16 HAS BEEN MADE IN REFINING THE DIFFERENTIATION
17 PROTOCOLS AND CREATING MODELS IN A DISH, MUCH MORE
18 COMPLEX MODELS IN A DISH SUCH AS ORGANOIDS AND
19 TISSUES ON CHIPS. BUT CHALLENGES REMAIN, AND I'LL
20 GO OVER THAT IN THE NEXT SLIDE.

21 ANOTHER GROUNDBREAKING DISCOVERY WAS
22 REPORTED IN 2012, DEMONSTRATING THAT A GENOME
23 EDITING SYSTEM THAT EVOLVED IN BACTERIA CAN BE USED
24 AS A GENOME EDITING TOOL IN OTHER CELLS SUCH AS
25 HUMAN CELLS. THIS CRISPR-CAS9 GENOME EDITING SYSTEM

BETH C. DRAIN, CA CSR NO. 7152

1 MAKES STEM CELL-BASED MODELING AN EVEN MORE POWERFUL
2 TOOL FOR STUDYING DISEASE MECHANISMS FOR DISCOVERING
3 NEW BIOMARKERS AND THERAPEUTIC TARGETS.

4 SO WITH THE PASSAGE OF PROPOSITION 14, WE
5 NOW HAVE AN OPPORTUNITY TO LEVERAGE EXISTING
6 CAPABILITIES AND ADDRESS NEEDS IN THE FIELD AND TO
7 HELP ADVANCE WORLD-CLASS SCIENCE BY ESTABLISHING
8 CORE RESOURCES ACROSS THE STATE.

9 SO WHAT ARE THE OPPORTUNITIES AND WHAT ARE
10 THE NEEDS WE INTEND TO ADDRESS WITH THE SHARED
11 RESOURCE LABORATORIES CONCEPT? THERE IS ABUNDANT
12 SCIENTIFIC STRENGTH, INNOVATION, AND EXPERTISE IN
13 CALIFORNIA TO CAPITALIZE ON THE PROMISE OF STEM
14 CELL-BASED MODELING. AND WE CAN ALSO LEVERAGE SOME
15 OF THE INFRASTRUCTURE CIRM ALREADY SUPPORTED UNDER
16 PROPOSITION 71 WITH THE SHARED LABS, THEN, AS CORE
17 LABS AND PROVIDERS OF TRAINING AND COURSES GOING
18 FORWARD.

19 BASED ON STAKEHOLDER INPUT WE'VE GATHERED
20 THROUGH VARIOUS MEANS, SUCH AS TOWN HALLS, SURVEYS,
21 WE HAD A WORKSHOP EARLIER THIS YEAR, WE LEARNED
22 ABOUT IMPORTANT NEEDS THAT CAN BE ADDRESSED WITH A
23 SHARED RESOURCE LABS PROGRAM. THERE ARE MANY
24 LABORATORIES THAT DO NOT YET USE STEM CELL-BASED
25 MODELS, BUT ARE INTERESTED IN ACQUIRING THAT

1 EXPERTISE.

2 ON THE OTHER HAND, THERE ARE LABORATORIES
3 THAT ARE WELL VERSED ALREADY IN STEM CELL-BASED
4 MODELING AND ARE ALREADY SHARING THE EXPERTISE, BUT
5 CAN'T REALLY MEET THE DEMAND AS IT IS TIME-CONSUMING
6 AND COSTLY TO DIVERT RESOURCES TO TRAINING OTHER
7 RESEARCHERS AND EDUCATING STUDENTS IN THIS
8 TECHNOLOGY.

9 SO IN ADDITION TO THESE INFRASTRUCTURE
10 NEEDS, THERE ARE ALSO SCIENTIFIC CHALLENGES THE
11 FIELD IS FACING RELATED TO THE LIMITED
12 REPRODUCIBILITY OF FINDINGS ACROSS LABS AND MODELS
13 USED. AND THERE'S A NEED TO BETTER UNDERSTAND THE
14 PREDICTIVE VALUE OF STEM CELL-BASED MODELS FOR HUMAN
15 BIOLOGY AND DISEASE.

16 SO BASED ON THESE NEEDS, WE ARE PROPOSING
17 TO FUND A SHARED RESOURCE LABS PROGRAM THAT WOULD
18 PROVIDE THESE FUNCTIONS THAT ARE LISTED HERE.

19 FIRST, WE ENVISION THIS WOULD PROVIDE RESEARCHERS
20 LOCALLY AT GRANTEE INSTITUTIONS, ALSO REGIONALLY AT
21 NEIGHBORING INSTITUTIONS, WITH ACCESS TO A CELL
22 CULTURE FACILITY FOR CONDUCTING STEM CELL-BASED
23 MODELING EXPERIMENTS. AND IT WILL ALSO PROVIDE
24 THOSE RESEARCHERS WITH ACCESS TO HIGHLY SPECIALIZED
25 TECHNOLOGIES THAT ARE NEEDED FOR THE ANALYSES OF

BETH C. DRAIN, CA CSR NO. 7152

1 THESE MODELS.

2 FURTHER, THIS PROGRAM WOULD PROVIDE
3 RESEARCHERS, AGAIN LOCALLY, BUT ALSO ACROSS
4 CALIFORNIA, ACCESS TO WELL-CHARACTERIZED, UNMODIFIED
5 AND MODIFIED HUMAN PLURIPOTENT STEM CELL
6 COLLECTIONS, PARTIALLY OR FULLY DIFFERENTIATED STEM
7 CELL-BASED MODELS, AND TRAINING OF RESEARCHERS IN
8 CONDUCTING STEM CELL-BASED MODELING EXPERIMENTS.

9 THE SHARED RESOURCE LABS PROGRAM IS ALSO
10 INTENDED TO SUPPORT EDUCATORS, INCLUDING THOSE IN
11 CIRM'S EDUCATION PROGRAMS, BY OFFERING FORMAL
12 TECHNIQUES COURSES FOR STUDENT EDUCATION. AND WE'D
13 ASK APPLICANTS TO BE CREATIVE AND OFFER OTHER
14 STUDENT EXPERIENCES FOR STEM CELL-BASED MODELING TO
15 ATTRACT STUDENTS INTO THE STEM CELL FIELD.

16 AND, FINALLY, WE EXPECT FUNDED SHARED
17 RESOURCE LABORATORIES TO BECOME SELF-SUSTAINING BY
18 THE END OF THE AWARD PERIOD.

19 NOT ALL LABORATORIES WITH RESEARCH AGENDAS
20 AND HYPOTHESES THAT COULD BE ADDRESSED USING STEM
21 CELL-BASED MODELS CURRENTLY HAVE ACCESS TO RELEVANT
22 LOCAL INFRASTRUCTURE AND EXPERTISE. SO TO ENSURE
23 BROAD ACCESS TO STEM CELL-BASED MODELS ACROSS
24 CALIFORNIA, WE, THEREFORE, ENVISION TWO TYPES OF
25 SHARED RESOURCE LABS, WHICH I'LL REFER TO GOING

BETH C. DRAIN, CA CSR NO. 7152

1 FORWARD OFTEN AS SRL'S, SHARED RESOURCE LABS.

2 THE ESTABLISHING SRL'S WILL PROVIDE ACCESS
3 TO STEM CELL-BASED MODELING EXPERTISE IN GEOGRAPHIC
4 AREAS WHERE ACCESS TO MODELS IS CURRENTLY LIMITED
5 WHILE THE ENHANCING EXPANSION SRL'S TARGET
6 INSTITUTIONS THAT HAVE ALREADY CUTTING-EDGE STEM
7 CELL-BASED MODELING EXPERTISE AND ASK THEM TO SHARE
8 BROADLY.

9 ESTABLISHING SRL'S WOULD BE FUNDED TO
10 RENOVATE SPACE FOR A CORE FACILITY AND THEN EQUIP IT
11 WHILE ENHANCING EXPANSION SRL'S WILL BE FUNDED TO
12 EQUIP EXISTING CORE SPACE. BOTH TYPES OF SHARED
13 RESOURCE LABS WOULD THEN BE EXPECTED TO ESTABLISH
14 THE EXPERTISE IN STEM CELL-BASED MODELS THAT THEY
15 INTEND TO OFFER IN THEIR CORE FACILITIES. AND THEN
16 THEY WOULD OPERATE THESE CORES BY PROVIDING ACCESS
17 TO THE FACILITY AND THE SPECIALIZED SERVICES AND
18 EQUIPMENT THEY OFFER BY SHARING THEIR MODELS AND
19 EXPERTISE AND RESOURCES FOR RESEARCH BROADLY, BY
20 TRAINING RESEARCHERS AND PROVIDING EDUCATIONAL
21 RESOURCES AND ACTIVITIES, A FORMAL TECHNIQUES COURSE
22 TO BE OFFERED THAT WOULD BE OPTIONAL WITH EXTRA
23 FUNDS.

24 SINCE THE TWO SHARED RESOURCE LAB TYPES
25 DIFFER IN FOCUS AND SCOPE, APPLICATIONS WILL BE

BETH C. DRAIN, CA CSR NO. 7152

1 SOLICITED THROUGH TWO SEPARATE RFA'S. SO ONCE
2 FUNDED, ALL SHARED RESOURCE LABS ARE EXPECTED TO
3 FUNCTION AS PART OF A NETWORK. CIRM WILL COORDINATE
4 A STEERING COMMITTEE THAT WILL DRIVE THE NETWORK
5 FUNCTIONS, WHICH I'LL INTRODUCE IN A FEW SLIDES
6 DOWN. BUT THE INDIVIDUAL SRL'S AND THE NETWORK AS A
7 WHOLE WILL WORK TO ACHIEVE THE OVERALL OBJECTIVE OF
8 THIS FUNDING OPPORTUNITY TO PROVIDE ACCESS TO
9 MODELS, TO STEM CELL-BASED MODELS, ACROSS
10 CALIFORNIA, TO ADVANCE STANDARDS AND REPRODUCIBILITY
11 OF STEM CELL-BASED MODELS, TO PROVIDE ACCESS TO
12 EDUCATIONAL OPPORTUNITIES, AND TO DEVELOP
13 SUSTAINABLE STEM CELL CORE INFRASTRUCTURE IN
14 CALIFORNIA.

15 THE FUNDING WE WOULD OFFER PER AWARD IS
16 LISTED IN THE TOP ROW. THE TWO AWARD AMOUNTS WITHIN
17 AN SRL TYPE REFLECT FUNDS NEEDED FOR OFFERING A
18 FORMAL STEM CELL TECHNIQUES COURSE, WHICH IS
19 OPTIONAL. AND THE DIFFERENCE BETWEEN THE TWO SHARED
20 RESOURCE LAB TYPES REFLECTS THE RENOVATION FUNDS
21 PROVIDED FOR ESTABLISHING SRL'S.

22 THE AWARD DURATION WILL BE FIVE YEARS, AND
23 THE MAIN GOAL, AS I MENTIONED, OF ESTABLISHING SRL'S
24 IS TO ESTABLISH NEW RESOURCES AND EXPERTISE, TO HAVE
25 A NOVEL IMPACT IN THE LOCAL SCIENTIFIC COMMUNITY,

BETH C. DRAIN, CA CSR NO. 7152

1 AND THE MAIN GOAL OF ENHANCING EXPANSION SRL'S IS TO
2 SHARE EXISTING EXPERTISE LOCALLY AND ACROSS
3 CALIFORNIA.

4 CO-FUNDING WILL BE REQUIRED FROM ENHANCING
5 EXPANSION SRL'S, AT LEAST 20 PERCENT OF THE
6 OPERATIONAL COSTS, BUT WON'T BE REQUIRED FOR THE
7 ESTABLISHING SRL'S. AND THE TOTAL BUDGET REQUESTED
8 FOR THIS PROGRAM WOULD BE \$50 MILLION WITH 26
9 MILLION FOR BUILD AND EQUIP FUNDS, AND 24 MILLION
10 FOR OPERATIONAL FUNDS. AND THEN THE ANTICIPATED
11 NUMBER OF AWARDS WE'RE THINKING COULD BE FOUR
12 ESTABLISHING SRL'S AND TEN ENHANCING EXPANSION
13 SRL'S, HALF EACH, WITH A TECHNIQUES COURSE.

14 SO WE'RE PROPOSING TO DIVIDE THESE
15 FIVE-YEAR AWARDS INTO THREE PHASES. SHOWN HERE ARE
16 THE OUTCOME METRICS FOR EACH OF THE PHASES FOR THE
17 ESTABLISHING SHARED RESOURCE LABS. SO BY THE END OF
18 PHASE A, WHICH SHOULD LAST ABOUT 18 MONTHS, THE
19 SHARED RESOURCE LABS CORE FACILITY SHOULD BECOME
20 OPERATIONAL AND SHOULD BE RENOVATED AND EQUIPPED.
21 STEM CELL-BASED MODELS AND THE RESEARCHER TRAINING
22 AND STUDENT EDUCATIONAL PROGRAMS SHOULD BE
23 ESTABLISHED IN PHASE B, WHICH LASTS TWO YEARS.

24 CIRM-SUPPORTED OPERATIONS WILL OCCUR THAT
25 ARE MEASURED BY THE UTILIZATION OF THE CORE FACILITY

BETH C. DRAIN, CA CSR NO. 7152

1 WITH A FOCUS ON LABORATORIES THAT HAVE CURRENTLY
2 LIMITED ACCESS TO STEM CELL-BASED MODELING
3 EXPERTISE. IT WILL BE MEASURED BY SUSTAINED
4 ENROLLMENT AND RESEARCHER TRAINING AND STUDENT
5 EDUCATIONAL PROGRAMS. AND WE'LL LOOK AT THE SUCCESS
6 RATE OF PROJECTS THAT ARE UTILIZING THE CORE, SUCH
7 AS THIS DATA THAT GET GENERATED, SOME EARLY
8 INDICATIONS OF PUBLICATIONS, AND LEVERAGED FUNDING.
9 AND WE'D EXPECT A DELIVERY OF A PLAN FOR OPERATIONS
10 AT 50 PERCENT OPERATIONAL FUNDING HALFWAY FOR PHASE
11 C.

12 THE FINAL 18 MONTHS, PHASE C, WILL THEN
13 CONTINUE OPERATIONS WITH 50 PERCENT CIRM OPERATIONAL
14 FUNDING, THE SAME SUCCESS METRICS FROM PHASE B WOULD
15 APPLY, PLUS WE'D EXPECT THE DELIVERY OF A PLAN FOR
16 INDEPENDENT OPERATIONS HALFWAY THROUGH AND
17 CONTRIBUTIONS TO SHARED RESOURCE LAB NETWORK
18 FUNCTIONS.

19 I'D LIKE TO MENTION THAT, BASED ON
20 FEEDBACK WE RECEIVED FROM THE BOARD'S SCIENCE
21 SUBCOMMITTEE A FEW WEEKS AGO EXPRESSING CONCERN THAT
22 PHASE A, THE RENOVATION PHASE, MAY NOT BE LONG
23 ENOUGH, ESPECIALLY SINCE THERE ARE STILL PANDEMIC
24 SUPPLY CHAIN ISSUES THAT CAN SLOW DOWN SUCH
25 RENOVATIONS, WE HAVE ADDED A STATEMENT TO THE

BETH C. DRAIN, CA CSR NO. 7152

1 CONCEPT PROPOSAL THAT FOR FUNDED APPLICATIONS, CIRM
2 WILL WORK WITH THE AWARDEES TO MAKE ADJUSTMENTS TO
3 THE TIMING OF THESE PHASES AS NEEDED.

4 THE TIMING, I WON'T GO INTO THE SAME
5 DETAIL ON THIS SLIDE. IT'S VERY SIMILAR TO THE
6 PREVIOUS SLIDE, BUT THE TIMING OF THE PHASES FOR
7 ENHANCING EXPANSION SHARED RESOURCE LABS DIFFER FROM
8 THOSE FOR THE ESTABLISHING SHARED RESOURCE LABS, BUT
9 THE OUTCOME METRICS ARE VERY SIMILAR. PHASE A IS
10 SHORTER, LASTING SIX MONTHS SINCE THERE IS NO
11 RENOVATION PHASE; BUT AGAIN, WE EXPECT THESE SHARED
12 RESOURCE LABS TO BE OPERATIONAL AT THE END OF THIS
13 PHASE. PHASE B, WHICH LASTS TWO AND A HALF YEARS
14 FOR CIRM-SUPPORTED OPERATIONS, MEASURED, AGAIN, BY
15 VERY SIMILAR METRICS EXCEPT HERE WE'VE ADDED THAT WE
16 WOULD LOOK AT THE SUCCESS RATE OF THE PROJECTS, NOT
17 ONLY UTILIZING THE CORE, BUT ALSO OF THE MODELS THAT
18 HAVE BEEN SHARED ACROSS THE STATE.

19 AND THE FINAL TWO YEARS, PHASE C, AGAIN,
20 IS TAPERED DOWN OPERATIONAL FUNDING WITH THE GOAL OF
21 GETTING READY FOR SELF-SUSTAINED OPERATIONS AT THE
22 END OF THE AWARDS.

23 I'D LIKE TO GO OVER SOME OF THE
24 ELIGIBILITY REQUIREMENTS FOR THE SHARED RESOURCE
25 LABS PROGRAM AND SOME OF THE PROP 14 STIPULATIONS

BETH C. DRAIN, CA CSR NO. 7152

1 THAT ARE ADDRESSED BY THIS PROGRAM. THE MODELING
2 EXPERTISE THAT WE EXPECT TO BE OFFERED IN THE SHARED
3 RESOURCE LABS IS LIMITED TO IN VITRO MODELS USING
4 HUMAN STEM OR PROGENITOR CELLS. CALIFORNIA
5 NONPROFIT RESEARCH INSTITUTIONS ARE ELIGIBLE TO
6 APPLY WITH ONE APPLICATION PER INSTITUTION. THE
7 PROGRAM DIRECTORS MUST COMMIT AT LEAST 20 PERCENT
8 EFFORT TO THIS PROGRAM. AND PURSUANT TO PROPOSITION
9 14, SHARED RESOURCE LABS ARE INTENDED TO BE
10 OPERATIONAL IN THE FIRST FIVE YEARS FOLLOWING THE
11 EFFECTIVE DATE OF THE INITIATIVE. IN THIS CASE THE
12 PROPOSITION IS MEANT. SO THAT WOULD BE BY
13 DECEMBER -- WHICH WAS DECEMBER 2020. AND,
14 THEREFORE, THE APPLICATIONS MUST PROPOSE PLANS THAT
15 ARE ACHIEVABLE WITHIN THE PHASES THAT I OUTLINED ON
16 THE PREVIOUS SLIDE.

17 CIRM, FURTHER, SHALL PRIORITIZE
18 APPLICATIONS FOR SHARED RESOURCE LABS THAT ENHANCE
19 GEOGRAPHIC DISTRIBUTION OF RESOURCES ACROSS THE
20 STATE AND SHALL PRIORITIZE APPLICATIONS THAT OFFER
21 MATCHING FUNDS OR VERIFIED IN-KIND SUPPORT.

22 APPLICATIONS MUST INCLUDE PLANS TO ADDRESS
23 DIVERSITY, EQUITY, AND INCLUSION IN THEIR PROGRAM.
24 THESE PLANS SHOULD DESCRIBE HOW THE PROPOSED
25 ACTIVITIES WILL ENSURE THAT USERS OF THE SHARED

BETH C. DRAIN, CA CSR NO. 7152

1 RESOURCE LAB COURSE AND THE RECIPIENTS OF STEM
2 CELL-BASED MODELS AND EXPERTISE REPRESENT DIVERSE
3 GOALS, APPROACHES, PERSPECTIVES, AND BACKGROUNDS.
4 THEY SHOULD DESCRIBE HOW ANY PROPOSED EDUCATIONAL
5 ACTIVITIES WILL ENSURE PARTICIPATION BY UNDERSERVED
6 POPULATIONS. THEY SHOULD DESCRIBE HOW THE SHARED
7 RESOURCE LABS TEAM AND OTHER CONTRIBUTORS WILL BRING
8 DIVERSE AND INCLUSIVE PERSPECTIVES AND EXPERIENCES
9 TO THE IMPLEMENTATION OF THE PROPOSED ACTIVITIES.
10 AND THEY'LL DESCRIBE HOW THE SHARED RESOURCE LABS
11 WILL OFFER STEM CELL LINES WITH ANCESTRAL AND SEX
12 DIVERSITY THAT MAY INCREASE THE APPLICABILITY OF THE
13 RESEARCH OUTCOMES TO DIVERSE POPULATIONS.

14 I'M ALMOST DONE. THE SHARED RESOURCE LAB
15 APPLICATIONS MUST INCLUDE A KNOWLEDGE SHARING PLAN
16 TO DESCRIBE PROCESSES AND SYSTEMS. THE APPLICANT
17 SHOULD PROPOSE FOR ADVERTISING ACCESS TO THEIR
18 MODELS, FOR SHARING BEST PRACTICES FOR CREATING AND
19 USING MODELS, AND FOR SHARING THE KNOWLEDGE AND
20 OTHER RESOURCES. AND THEY SHOULD ALSO DESCRIBE
21 APPROACHES TOWARDS STANDARDIZING CELL LINES AND
22 REAGENTS, HOW THEY WOULD GO ABOUT IT, AND
23 IMPLEMENTING QUALITY CONTROL AND VALIDATION
24 APPROACHES FOR THEIR MODELS, THEIR STEM CELL-BASED
25 MODELS.

BETH C. DRAIN, CA CSR NO. 7152

1 SHARED RESOURCE LAB APPLICATIONS MUST ALSO
2 INCLUDE A DATA SHARING AND MANAGEMENT PLAN. SINCE
3 THE DATA THAT ARE GENERATED DURING SHARED LAB
4 OPERATIONS, SUCH AS OMICS AND FAQ'S DATA, FOR CELL
5 MODEL QUALITY CONTROL AND VALIDATION MAY ACTUALLY BE
6 USEFUL FOR DEVELOPING APPROACHES. TOWARD IMPROVING
7 REPRODUCIBILITY OF STEM CELL-BASED MODELS, WE'D
8 EXPECT THAT THESE KIND OF DATA GENERATED DURING
9 OPERATIONS WILL BE EFFECTIVELY SHARED. I SHOULD
10 EMPHASIZE THE DATA GENERATED BY THE RESEARCH
11 PROJECTS THAT TAKE PLACE AT THE CORES AND THAT ARE
12 FUNDED EITHER BY CIRM OR OTHER AGENCIES SHOULD BE
13 COMPLYING WITH THEIR OWN DATA SHARING AND MANAGEMENT
14 PLANS.

15 THE KNOWLEDGE AND DATA SHARING PLANS THAT
16 ARE DESCRIBED ON THE PREVIOUS SLIDE WILL BE THE
17 STARTING POINT FOR SHARED RESOURCE LAB NETWORK
18 FUNCTIONS. CIRM WILL COORDINATE A STEERING
19 COMMITTEE OF AWARDEES AND EXTERNAL STAKEHOLDERS TO
20 FACILITATE THE DEVELOPMENT OF PROCESSES AND SYSTEMS
21 FOR SHARING NETWORKWIDE OFFERINGS, BEST PRACTICES,
22 KNOWLEDGE, AND RESOURCES, AND FACILITATE
23 IMPLEMENTATION OF QUALITY STANDARDS, MATERIALS, AND
24 CELL LINES ACROSS THE NETWORK, AND THE DEVELOPMENT
25 OF COLLABORATIVE APPROACHES TOWARD IMPROVING

BETH C. DRAIN, CA CSR NO. 7152

1 REPRODUCIBILITY OF STEM CELL-BASED MODELS. AND THIS
2 COULD INCLUDE WELL-CHARACTERIZED HUMAN PLURIPOTENT
3 STEM CELL LINES AS A BASIS FOR EXPERIMENTS ACROSS
4 SHARED RESOURCE LABS OR AS CONTROLS ACROSS
5 EXPERIMENTS, CHARACTERIZATION AND QC ASSAYS, QUALITY
6 CONTROL ASSAYS FOR THE STEM CELL-BASED MODELS AND
7 POSSIBLY METADATA STANDARDS.

8 SO THIS IS MY LAST SLIDE, PROVIDING A
9 SUMMARY OF THE CONCEPT FOR SHARED RESOURCE LABS FOR
10 STEM CELL-BASED MODELING. THE TOTAL PROGRAM BUDGET
11 IS \$50 MILLION WITH BUILD AND EQUIP FUNDS OF 26
12 MILLION AND OPERATIONAL FUNDS OF \$24 MILLION. FOR
13 THE INDIVIDUAL AWARDS, THE AWARD CAPS FOR
14 ESTABLISHING SRL'S OF 5.4 MILLION IF THEY OFFER A
15 TECHNIQUES COURSE, \$4.4 MILLION IF THEY DON'T OFFER
16 A TECHNIQUES COURSE, WHILE THE ENHANCING SRL'S RANGE
17 FROM 4.3 WITH AND 3 MILLION WITHOUT A TECHNIQUES
18 COURSE.

19 THE ALLOWABLE COSTS ARE THE BUILD OR
20 RENOVATION FUNDS FOR THE ESTABLISHING SRL'S, DIRECT
21 PROJECT COSTS, FACILITIES COSTS, AND INDIRECT COSTS,
22 AND CO-FUNDING IS REQUIRED FROM THE ENHANCING
23 EXPANSION SHARED RESOURCE LABS AT 20 PERCENT ON
24 THEIR OPERATIONAL COSTS. AS A REMINDER, CALIFORNIA
25 NONPROFIT RESEARCH INSTITUTIONS ARE ELIGIBLE TO

BETH C. DRAIN, CA CSR NO. 7152

1 APPLY.

2 SO I'D NOW LIKE TO ASK THAT THE BOARD
3 APPROVE THIS CONCEPT PLAN, AND I'M HAPPY TO ANSWER
4 QUESTIONS YOU MIGHT HAVE. THANK YOU.

5 CHAIRMAN THOMAS: THANK YOU, UTA, FOR THAT
6 EXTREMELY COMPREHENSIVE AND WELL THOUGHT OUT
7 PRESENTATION.

8 MEMBERS OF THE BOARD, IT SHOULD BE OBVIOUS
9 THAT THIS CONCEPT PLAN, AS WITH ALL OF OUR CONCEPT
10 PLANS, TOOK AN EXTRAORDINARY AMOUNT OF WORK TO GET
11 TO THIS POINT. AND I THINK THAT THE LEVEL OF DETAIL
12 HERE IS JUST OUTSTANDING, AND ALL ASPECTS SHOW
13 EXTREME THOUGHT AS TO WHAT WILL MAKE THIS PROGRAM
14 WORK BEST.

15 DO I HEAR A MOTION TO APPROVE?

16 DR. BARRETT: MOVE APPROVAL.

17 CHAIRMAN THOMAS: MOVED BY KIM. IS THERE
18 A SECOND?

19 DR. ABDULHAQ: SECOND.

20 CHAIRMAN THOMAS: THANK YOU. ARE THERE
21 COMMENTS OR QUESTIONS FROM MEMBERS OF THE BOARD?

22 DR. ABOUSALEM: THANK YOU, UTA, FOR THIS
23 GREAT PRESENTATION. I SUPPORT THE INITIATIVE, GREAT
24 INITIATIVE, AND IT'S GOOD TO SEE THAT WE CAN USE THE
25 FUNDING TO PROVIDE ACCESS THROUGH A PROGRAM LIKE

BETH C. DRAIN, CA CSR NO. 7152

1 THIS. I HAVE THREE QUESTIONS FOR YOU.

2 THE FIRST ONE IS I SEE THAT COST MATCHING
3 IS PREFERRED, BUT NOT REQUIRED. AND I WOULD LIKE
4 FOR YOU TO COMMENT ON WHY IT WOULD NOT BE REQUIRED
5 KNOWING THAT WHEN THERE'S COST MATCHING, THERE IS A
6 COMMITMENT FROM THE INSTITUTION OR THE APPLICANT,
7 NOT ONLY DURING THE GRANT PERIOD, BUT ALSO IT'S A
8 COMMITMENT FOR LONG-TERM OPERATION OF THE FACILITY,
9 WHICH TAKES ME TO THE SECOND QUESTION.

10 I DON'T QUITE UNDERSTAND THE 20 PERCENT ON
11 OPERATIONAL COSTS, BUT THE QUESTION IS IF YOU CAN
12 EXPLAIN THAT. AND THE QUESTION IS WHAT HAPPENS
13 AFTER THE GRANT PERIOD? ARE YOU REQUIRING THE
14 APPLICANT TO SHOW A PLAN FOR THEIR ABILITY TO
15 CONTINUE OPERATING THE FACILITIES AFTER THE GRANT
16 PERIOD RUNS?

17 AND THEN THE THIRD QUESTION, WHEN YOU
18 APPROVE THE APPLICATIONS, YOU MAY GET REQUESTS FOR
19 GEOGRAPHICAL LOCATIONS THAT ARE ALMOST TOO CLOSE
20 THAT COULD CREATE A REDUNDANCY IN THE SERVICES, OR
21 IN THOSE AREAS YOU MAY NEED DOUBLE CAPACITY AS
22 OPPOSED TO JUST ONE LAB, BUT YOU MAY NEED TWO. HOW
23 ARE YOU GOING TO ASSESS CAPACITY VERSUS COVERAGE
24 GEOGRAPHICALLY? THANK YOU.

25 DR. GRIESHAMMER: VERY GOOD QUESTIONS. SO

BETH C. DRAIN, CA CSR NO. 7152

1 LET ME START WITH THE COST MATCHING BEING PREFERRED,
2 NOT REQUIRED. JUST TO CLARIFY, WE ARE REQUIRING
3 THAT THE ESTABLISHING ENHANCING SHARED RESOURCE LABS
4 DO PROVIDE 20 PERCENT OF THE OPERATIONAL COSTS. AND
5 WE -- BUT THAT MEANS THAT THE ESTABLISHING SRL'S ARE
6 NOT REQUIRED TO PROVIDE MATCHING FUNDS ALTHOUGH THEY
7 ARE, OF COURSE, VERY WELCOME AND WOULD LEAD TO
8 PRIORITIZATION.

9 THE RATIONALE BEHIND THAT WAS WE REALLY
10 WANTED TO MAKE SURE TO BE ABLE -- THE ASSUMPTION IS
11 THAT THE ESTABLISHING SHARED RESOURCE LABS ARE
12 BEHIND IN OFFERING THESE MODELS AND MIGHT NEED JUST
13 MORE SUPPORT FROM CIRM OVERALL TO GET GOING. AND WE
14 DIDN'T -- WE DECIDED TO PROPOSE TO THEM AND NOT
15 REQUIRE, FOR THAT REASON, OPERATIONAL FUNDS FROM THE
16 INSTITUTION. THAT'S THE RATIONALE BEHIND THAT.

17 YOU ASKED ABOUT THE PLAN FOR OPERATIONS
18 ONCE THE AWARDS ARE COMPLETED. SO WE DO -- WE WILL
19 ASK OUR APPLICANTS TO PROVIDE -- THERE'S TWO ANSWERS
20 TO THAT. THE FIRST IS THE TAPERING THE PHASES OF
21 THE AWARD AND THE TAPERING OF FUNDING IN THE LAST
22 PHASE, WHICH IS MEANT TO ALREADY HAVE THE SHARED
23 RESOURCE LABS OPERATING UNDER ONLY HALF OF CIRM
24 OPERATIONAL SUPPORT IN PREPARATION FOR THE END OF
25 THE AWARD WHERE THEY THEN ARE EXPECTED TO FUNCTION

BETH C. DRAIN, CA CSR NO. 7152

1 INDEPENDENTLY. YES, WE DO EXPECT THEM IN THE
2 APPLICATION TO PROVIDE A BUSINESS PLAN FOR HOW THIS
3 WILL WORK FOR THEM, HOW THEY ANTICIPATE THAT. AND
4 THEN DURING THE AWARD, WE'LL HAVE AS A MILESTONE AN
5 UPDATED PLAN THAT MIGHT BE INFORMED BY WHAT HAPPENED
6 DURING THE AWARD PERIOD. BUT, YES, WE WILL EXPECT
7 THEM TO PROVIDE TO US AN UPDATED PLAN FOR OPERATIONS
8 AFTER THE AWARD.

9 NOW, THE REDUNDANCY OF THE SERVICES, YOUR
10 QUESTION ABOUT HOW TO DISTRIBUTE THESE FACILITIES
11 ACROSS THE STATE IN THE MOST OPTIMAL MANNER IS A
12 TRICKY ONE. SINCE WE DO REVIEW APPLICATIONS
13 INDEPENDENTLY FOR THEIR MERIT AND NOT AS A GROUP,
14 AND MAYBE OTHERS FROM CIRM CAN CHIME IN, BUT ONE
15 COMMENT I WANTED TO MAKE IS THAT SOME REDUNDANCY IN
16 THE SYSTEM, I THINK, WILL BE HIGHLY APPRECIATED
17 ACTUALLY. SO, FOR INSTANCE, IN THE CONTEXT OF
18 ADDRESSING REPRODUCIBILITY ISSUES. SO IF SIMILAR
19 MODELS ARE BEING OFFERED NEARBY OR MORE BROADLY
20 DISTRIBUTED, IT GIVES AN OPPORTUNITY FOR RESEARCHERS
21 TO TEST THE HYPOTHESES USING THESE TWO DIFFERENT
22 OFFERINGS. IT MIGHT HELP WITH UNDERSTANDING BETTER
23 THE TRUE REPRODUCIBILITY OF THE FINDINGS. SO THAT
24 COULD BE ACTUALLY A STRENGTH IF THERE'S SOME
25 REDUNDANCY.

BETH C. DRAIN, CA CSR NO. 7152

1 AND THE OTHER THING I WILL SAY IS THAT A
2 PART OF WHAT WE WANTED, ESPECIALLY THE ENHANCING
3 EXPANSION SHARED RESOURCE LABS, TO THINK ABOUT IS
4 NOT ONLY TO SERVE THE GRANTEE INSTITUTION AND THEIR
5 LOCAL COMMUNITY, BUT HOW CAN THEY REALLY SHARE THEIR
6 HIGHLY SPECIALIZED TECHNOLOGIES ACROSS THE STATE?
7 SO WE'LL LOOK FOR THAT IN THE APPLICATIONS AS WELL.
8 IT MIGHT NOT BE THAT EVERYBODY CAN COME TO THE CORE,
9 BUT THERE MIGHT BE OTHER WAYS OF MORE BROADLY
10 SHARING. SO THAT MIGHT ADDRESS SOME OF YOUR
11 CONCERNS. I'LL STOP THERE.

12 DR. ABOUSALEM: THANK YOU.

13 DR. ABDULHAQ: YES. THANK YOU SO MUCH FOR
14 A VERY THOROUGH PRESENTATION. I AM VERY MUCH IN
15 SUPPORT OF THIS PROPOSAL. IT HAS A BIG UNMET NEED.

16 MY QUESTION IS DO YOU SEE -- HOW DO YOU
17 SEE THIS INTERACTING WITH THE ALPHA CLINICS IN THE
18 FUTURE? AND HOW CAN IT BE IN SUPPORT OF THE ALPHA
19 CLINICS?

20 MY OTHER QUESTION IS ARE THESE LABS GOING
21 TO BE ONLY FOR STEM CELL MODELS, OR WOULD YOU
22 CONSIDER EXPANDING THIS TO HAVING THESE LABS FOR
23 STEM CELL PRESERVATION AND PROCESSING, AND MAYBE
24 ALTHOUGH THAT WOULD BE A TOTALLY DIFFERENT AREA, BUT
25 IN MY MIND THIS IS ANOTHER BIG UNMET NEED IN

BETH C. DRAIN, CA CSR NO. 7152

1 CALIFORNIA THAT POTENTIALLY CAN HELP OTHER SMALLER
2 CENTERS PARTICIPATING IN STEM CELL TRIALS.

3 DR. GRIESHAMMER: THANK YOU FOR THOSE
4 QUESTIONS. ALPHA STEM CELL CLINIC CONNECTIONS, IT
5 WAS A GREAT QUESTION. I HAVEN'T REALLY THOUGHT
6 ABOUT THAT. WHAT COMES TO MIND IS THAT I, FOR
7 INSTANCE, ASSUME THAT AS PART OF ANY CLINICAL
8 RESEARCH THAT'S RELATED TO STEM CELL AND GENE
9 THERAPY, QUESTIONS ARISE IN THE BACKWARDS FROM THE
10 BENCH -- FROM THE BEDSIDE TO THE BENCH DIRECTION OF
11 RESEARCH. AND SO THE CLINICAL RESEARCHERS WHO ARE
12 DOING THE WORK IN THE ALPHA STEM CELL CLINICS WOULD
13 HAVE ACCESS THROUGH THEIR MORE BASIC RESEARCH FUNDS
14 TO BRING QUESTIONS THAT ARISE TO THE STEM CELL
15 MODELING FIELD. SO THAT WOULD BE A REALLY EXCITING
16 WAY OF SUPPORTING RESEARCH WITHIN THESE BASIC
17 RESEARCH CORES ADDRESSING QUESTIONS THAT ARISE AT
18 THE BEDSIDE. SO THAT MIGHT BE A GREAT WAY OF
19 THINKING ABOUT THAT.

20 AND THEN YOU ASKED ABOUT WHETHER THESE
21 SHARED LABORATORIES COULD ALSO BE IN THE BUSINESS,
22 SO TO SPEAK, OF PRESERVING STEM CELL LINES AND ET
23 CETERA. AND I THINK THAT IS NOT CURRENTLY PART OF
24 THE WAY WE ENVISION THESE STEM CELL LABS TO
25 FUNCTION. NOW, THEY WILL, AS PART OF THE

BETH C. DRAIN, CA CSR NO. 7152

1 OPERATIONS, BE OFFERING WHATEVER THAT THEY OFFER.
2 IF YOUR QUESTION ABOUT WOULD THEY ALSO BE TAKING IN
3 CELL LINES THAT GET GENERATED AND DISTRIBUTE THEM,
4 ET CETERA, I THINK THAT WOULD BE ASKING, THAT'S MY
5 OPINION, IT WOULD BE ASKING TOO MUCH FROM THIS KIND
6 OF CORE OPERATION TO BE ALSO A BANKER.

7 NOW, I UNDERSTAND YOUR CONCERN ABOUT THIS
8 BEING A GREAT NEED, AND SO IT'S SOMETHING THAT
9 SHOULD BE THOUGHT ABOUT IN GENERAL IS MY QUESTION TO
10 THAT ANSWER.

11 DR. ABDULHAQ: THANK YOU.

12 MS. BONNEVILLE: ART, YOU HAVE YOUR HAND
13 RAISED.

14 MR. TORRES: THANK YOU TO THE WONDERFUL
15 STAFF, UTA AND OTHERS, WHO PUT THIS PROPOSAL
16 TOGETHER. IT WAS ALMOST NOT INCLUDED IN PROP 14
17 WHEN BOB KLEIN AND I WERE WRITING IT ALONG WITH
18 JAMES HARRISON. IT WAS ADDED ALMOST NOT THE LAST
19 MINUTE, BUT IT WAS JUST A VERY CONTROVERSIAL ISSUE
20 BECAUSE, AS YOU KNOW, THERE WAS SOME CONTROVERSY IN
21 THE PAST WHERE PEOPLE WERE NOT SUPPORTIVE OF SHARED
22 LABS. SO I'M GLAD WE PUT IT IN, AND YOU PROVED TO
23 US THAT WE WERE RIGHT TO PUT IT IN BECAUSE THE
24 PROJECT YOU PROPOSE, I THINK, IS TERRIFIC, AND I
25 LOOK FORWARD TO SEEING IT.

BETH C. DRAIN, CA CSR NO. 7152

1 DR. GRIESHAMMER: THANK YOU FOR THAT
2 PERSPECTIVE. I SEE KEITH HAS HIS HAND RAISED.

3 DR. YAMAMOTO: YES. HI, UTA. THANK YOU
4 FOR THE PRESENTATION. IT'S GOOD TO SEE YOU.

5 I DON'T THINK THERE'S ANY DOUBT THAT THERE
6 IS A NEED FOR FACILITIES LIKE THIS, THAT GOOD THINGS
7 WOULD COME FROM PROVIDING THESE KINDS OF RESOURCES
8 TO THE COMMUNITY. MY QUESTION, THOUGH, IS RELATED
9 TO THAT. AND THAT IS HOW YOU DECIDED TO SCALE THESE
10 EFFORTS. HOW MANY SUCH FACILITIES TO BUILD, WHICH
11 REALLY ASKS WHETHER YOU DID ESSENTIALLY A MARKET
12 ANALYSIS TO DETERMINE WHETHER THE COMMUNITY SENSES
13 THE NEED IN SUCH A WAY THAT THEY WOULD BE HAPPY TO
14 PAY FEE FOR SERVICE TO PARTICIPATE AND WORK IN THESE
15 FACILITIES.

16 SO GOING INTO THIS AND THEN SCALING THE
17 MODEL, DID YOU BASE THAT ON ESSENTIALLY A MARKET
18 ANALYSIS?

19 DR. GRIESHAMMER: TO SORT OF ANSWER YOUR
20 QUESTION, WE CERTAINLY HAVE EXPERIENCE WITH PREVIOUS
21 SHARED LABORATORIES THAT WERE FUNDED UNDER
22 PROPOSITION 71. AND WE WERE GUIDED BY THE SET ASIDE
23 IN THE PROPOSITION 14 OF THE BUILD AND EQUIP FUNDS
24 FOR SHARED RESOURCE LABORATORIES. SO THAT'S ONE
25 GUIDING SET OF GUIDING PRINCIPLES THAT WE USED. AND

BETH C. DRAIN, CA CSR NO. 7152

1 I SEE ROSA WOULD LIKE TO COMMENT.

2 DR. CANET-AVILES: THANK YOU, UTA. THANK
3 YOU, KEITH, FOR YOUR QUESTION. ACTUALLY SO THE
4 MARKET ANALYSIS THAT WE'VE DONE BESIDES WHAT UTA WAS
5 JUST MENTIONING HAS BEEN THROUGH ALL THESE
6 STAKEHOLDER MEETINGS, TOWN HALLS, ALSO INFORMATION
7 FROM OUR WORKSHOP THAT WE HAD IN FEBRUARY. WE SPOKE
8 TO MANY OF THE USERS OF SHARED RESOURCE LABS, AND
9 THE LEADS OF MOST SHARED RESOURCE LABS, AND ALSO THE
10 POTENTIAL USERS FOR THEM, THE ESTABLISHING SHARED
11 RESOURCE LABS. SO WE DID KIND OF A LANDSCAPE
12 ANALYSIS INTERNALLY AT CIRM WITHIN THE STAFF, AND
13 THEN WE REACHED OUT TO ALL OF THEM, AND UTA AND I
14 HAVE HAD MANY CONVERSATIONS WITH MANY POTENTIAL
15 APPLICANTS AND PEOPLE THAT HAVE REACHED OUT TO US.
16 SO THAT'S HOW WE WORKED IT OUT. IT WASN'T A
17 FORMALIZED PROCESS, BUT IT WAS IN RESPONSE TO HOW WE
18 WERE DEVELOPING THESE CONCEPTS AND GATHERING INPUT.

19 DR. YAMAMOTO: THANK YOU.

20 CHAIRMAN THOMAS: MARIA --

21 MS. BONNEVILLE: NO MORE HANDS RAISED.

22 CHAIRMAN THOMAS: OKAY. DO WE HAVE ANY
23 PUBLIC COMMENT?

24 MS. BONNEVILLE: I DON'T SEE ANY PUBLIC
25 COMMENT.

BETH C. DRAIN, CA CSR NO. 7152

1 CHAIRMAN THOMAS: OKAY. THEN, MARIA, WILL
2 YOU PLEASE CALL THE ROLL.
3 MS. BONNEVILLE: HAIFAA ABDULHAQ.
4 DR. ABDULHAQ: YES.
5 MS. BONNEVILLE: MOHAMMED ABOUSALEM.
6 DR. ABOUSALEM: YES.
7 MS. BONNEVILLE: KIM BARRETT.
8 DR. BARRETT: AYE.
9 MS. BONNEVILLE: DAN BERNAL.
10 MR. BERNAL: AYE.
11 MS. BONNEVILLE: GEORGE BLUMENTHAL.
12 DR. BLUMENTHAL: YES.
13 MS. BONNEVILLE: MICHAEL BOTCHAN. LINDA
14 BOXER.
15 DR. BOXER: YES.
16 MS. BONNEVILLE: JUDY CHOU.
17 DR. CHOU: YES.
18 MS. BONNEVILLE: LEONDRA CLARK-HARVEY.
19 DEBORAH DEAS.
20 DR. DEAS: YES.
21 MS. BONNEVILLE: ANNE-MARIE DULIEGE.
22 DR. DULIEGE: YES.
23 MS. BONNEVILLE: YSABEL DURON.
24 MS. DURON: YES.
25 MS. BONNEVILLE: MARK FISCHER-COLBRIE.

BETH C. DRAIN, CA CSR NO. 7152

1 DR. FISCHER-COLBRIE: YES.
2 MS. BONNEVILLE: FRED FISHER. ELENA
3 FLOWERS.
4 DR. FLOWERS: YES.
5 MS. BONNEVILLE: JUDY GASSON.
6 DR. GASSON: YES.
7 MS. BONNEVILLE: LARRY GOLDSTEIN.
8 DR. GOLDSTEIN: YES.
9 MS. BONNEVILLE: DAVID HIGGINS. STEPHEN
10 JUELSGAARD.
11 MR. JUELSGAARD: YES.
12 MS. BONNEVILLE: RICH LAJARA.
13 MR. LAJARA: YES.
14 MS. BONNEVILLE: PAT LEVITT.
15 DR. LEVITT: YES.
16 MS. BONNEVILLE: LINDA MALKAS.
17 DR. MALKAS: YES.
18 MS. BONNEVILLE: SHLOMO MELMED.
19 DR. MELMED: YES.
20 MS. BONNEVILLE: CHRISTINE MIASKOWSKI.
21 DR. MIASKOWSKI: YES.
22 MS. BONNEVILLE: LAUREN MILLER-ROGEN.
23 MS. MILLER-ROGEN: YES.
24 MS. BONNEVILLE: ADRIANA PADILLA.
25 DR. PADILLA: YES.

BETH C. DRAIN, CA CSR NO. 7152

1 MS. BONNEVILLE: JOE PANETTA. AL ROWLETT.
2 MARVIN SOUTHARD. MICHAEL STAMOS. JONATHAN THOMAS.
3 CHAIRMAN THOMAS: YES.
4 MS. BONNEVILLE: ART TORRES.
5 MR. TORRES: AYE.
6 MS. BONNEVILLE: KAROL WATSON.
7 DR. WATSON: YES.
8 MS. BONNEVILLE: KEITH YAMAMOTO.
9 DR. YAMAMOTO: YES.
10 MS. BONNEVILLE: THE MOTION CARRIES.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

BETH C. DRAIN, CA CSR NO. 7152

1 CHAIRMAN THOMAS: OKAY. THANK YOU. I
2 THINK WE'RE GOING TO TAKE A FIVE-MINUTE BREAK HERE
3 JUST TO GIVE BETH A CHANCE TO RECOVER. AND WE HAVE
4 A FEW MORE ACTION ITEMS COMING, INCLUDING ITEM 10,
5 WHICH WE ARE REALLY LOOKING FORWARD TO FOR MARIA.
6 SO WE WILL RESUME BACK IN ABOUT FIVE MINUTES. THANK
7 YOU.

8 (A RECESS WAS TAKEN.)

9 CHAIRMAN THOMAS: OKAY. IF WE COULD ALL
10 REGROUP PLEASE. ALL RIGHT. WE HAVE A COUPLE OF
11 FAIRLY MINISTERIAL ACTION ITEMS. FIRST UP, SO ITEM
12 8, CONSIDERATION OF AMENDMENTS TO GWG BYLAWS. GIL.

13 DR. SAMBRANO: THANK YOU, MR. CHAIRMAN, SO
14 WE HAVE SOME PROPOSED AMENDMENTS FOR THE GRANTS
15 WORKING GROUP BYLAWS. AND THE BYLAWS OUTLINE THE
16 OVERALL RESPONSIBILITIES, FUNCTIONS, AND PROCESSES
17 OF THE GRANTS WORKING GROUP. AND PERIODICALLY WE
18 PROVIDE UPDATES OR PROPOSED UPDATES TO PROVIDE
19 CLARITY AND ADDRESS CHANGES IN OUR PROCESS AND/OR
20 RULES. AND THE LAST TIME WE DID THIS WAS IN
21 FEBRUARY OF 2021.

22 THE PRIMARY CHANGES FOR THIS ROUND ARE AS
23 FOLLOWS. THE PRIMARY CHANGE IS THE ADDITION OF
24 EVALUATION AND SCORING OF APPLICATION COMPONENTS
25 ADDRESSING DIVERSITY, EQUITY, AND INCLUSION BY

BETH C. DRAIN, CA CSR NO. 7152

1 PATIENT ADVOCATE MEMBERS OF THE GRANTS WORKING
2 GROUP. WE WANTED TO ENSURE THAT WITHIN THE GRANTS
3 WORKING GROUP BYLAWS WE INCLUDE THIS ELEMENT AND
4 OUTLINE THE FACT THAT OUR PATIENT ADVOCATE MEMBERS
5 CAN, IN FACT, SCORE APPLICATIONS BASED ON THIS
6 ELEMENT.

7 SOME ADDITIONAL CHANGES, CLARIFICATION OF
8 LANGUAGE RELATED TO THE ROLE OF THE CIRM SCIENTIFIC
9 TEAM IN REVIEW TO ALIGN WITH OUR CURRENT PROCESS AND
10 POLICIES. A CLARIFICATION OF THE DEFINITION OF
11 VITAL RESEARCH OPPORTUNITY, WHICH IS SIMPLY MATCHING
12 IT TO THE LANGUAGE THAT EXISTS IN PROP 14, AND SOME
13 MINOR EDITS TO LANGUAGE FOR GRAMMAR OR
14 CLARIFICATION.

15 SO THESE AMENDMENTS THAT WE ARE PROPOSING
16 WE SEEK APPROVAL FROM THE BOARD TO DO SO. MR.
17 CHAIRMAN.

18 CHAIRMAN THOMAS: THANKS, GIL. IS THERE A
19 MOTION TO APPROVE?

20 DR. BLUMENTHAL: SO MOVED.

21 CHAIRMAN THOMAS: SECOND?

22 MS. DURON: SECOND.

23 CHAIRMAN THOMAS: THANK YOU. ANY
24 QUESTIONS OR COMMENTS FROM MEMBERS OF THE BOARD?
25 ANY PUBLIC COMMENT?

BETH C. DRAIN, CA CSR NO. 7152

1 MS. BONNEVILLE: I DO NOT SEE ANY HANDS
2 RAISED.

3 CHAIRMAN THOMAS: HEARING NONE, MARIA,
4 WILL YOU PLEASE CALL THE ROLL.

5 MS. BONNEVILLE: HAIFAA ABDULHAQ.

6 DR. ABDULHAQ: YES.

7 MS. BONNEVILLE: MOHAMMED ABOUSALEM.

8 DR. ABOUSALEM: YES.

9 MS. BONNEVILLE: KIM BARRETT.

10 DR. BARRETT: AYE.

11 MS. BONNEVILLE: DAN BERNAL.

12 MR. BERNAL: AYE.

13 MS. BONNEVILLE: GEORGE BLUMENTHAL.

14 DR. BLUMENTHAL: YES.

15 MS. BONNEVILLE: MICHAEL BOTCHAN. LINDA
16 BOXER.

17 DR. BOXER: YES.

18 MS. BONNEVILLE: JUDY CHOU.

19 DR. CHOU: AYE.

20 MS. BONNEVILLE: LEONDRA CLARK-HARVEY.
21 DEBORAH DEAS.

22 DR. DEAS: YES.

23 MS. BONNEVILLE: ANNE-MARIE DULIEGE.
24 YSABEL DURON.

25 MS. DURON: YES.

BETH C. DRAIN, CA CSR NO. 7152

1 MS. BONNEVILLE: MARK FISCHER-COLBRIE.
2 FRED FISHER. ELENA FLOWERS.
3 DR. FLOWERS: YES.
4 MS. BONNEVILLE: JUDY GASSON.
5 DR. GASSON: YES.
6 MS. BONNEVILLE: LARRY GOLDSTEIN.
7 DR. GOLDSTEIN: YES.
8 MS. BONNEVILLE: STEPHEN JUELSGAARD.
9 MR. JUELSGAARD: YES.
10 MS. BONNEVILLE: RICH LAJARA.
11 MR. LAJARA: YES.
12 MS. BONNEVILLE: PAT LEVITT.
13 DR. LEVITT: YES.
14 MS. BONNEVILLE: LINDA MALKAS.
15 DR. MALKAS: YES.
16 MS. BONNEVILLE: SHLOMO MELMED. CHRISTINE
17 MIASKOWSKI.
18 DR. MIASKOWSKI: YES.
19 MS. BONNEVILLE: LAUREN MILLER-ROGEN.
20 MS. MILLER-ROGEN: YES.
21 MS. BONNEVILLE: ADRIANA PADILLA.
22 DR. PADILLA: YES.
23 MS. BONNEVILLE: JOE PANETTA. AL ROWLETT.
24 MARVIN SOUTHARD. MICHAEL STAMOS.
25 DR. STAMOS: YES. THIS TIME I GOT TO MY

BETH C. DRAIN, CA CSR NO. 7152

1 MUTE BUTTON IN TIME. THANK YOU.

2 MS. BONNEVILLE: JONATHAN THOMAS.

3 CHAIRMAN THOMAS: YES AND YES.

4 MS. BONNEVILLE: ART TORRES. KAROL
5 WATSON.

6 DR. WATSON: YES.

7 MS. BONNEVILLE: SO I'M GOING TO GO BACK
8 AND ASK FOR A FEW AND SEE IF THEY JOINED.

9 MICHAEL BOTCHAN. HOW ABOUT ANNE-MARIE?

10 DR. DULIEGE: YES. I DID JOIN.

11 MS. BONNEVILLE: MARK FISCHER-COLBRIE.
12 CHRISTINE MIASKOWSKI.

13 DR. MIASKOWSKI: YES.

14 MS. BONNEVILLE: THANK YOU. AND HOW ABOUT
15 ART? DID WE GET ART BACK? THERE'S NO ART.

16 DR. YAMAMOTO: MARIA, YOU DIDN'T CALL ME.

17 MS. BONNEVILLE: WHO? KEITH. SO SORRY.
18 KEITH YAMAMOTO.

19 DR. YAMAMOTO: YES.

20 MS. BONNEVILLE: THE MOTION CARRIES.
21 WE ARE MISSING A COUPLE OF BOARD MEMBERS. HOPEFULLY
22 THEY CAN REJOIN.

23 CHAIRMAN THOMAS: THANK YOU.

24 ITEM 9, CONSIDERATION OF MINUTES FROM THE
25 SEPTEMBER 20 ARS MEETING AND SEPTEMBER 29 ICOC

BETH C. DRAIN, CA CSR NO. 7152

1 MEETING. WE HAVE A MOTION TO APPROVE? I'LL MOVE TO
2 APPROVE. IS THERE A SECOND?

3 DR. DULIEGE: SECOND.

4 CHAIRMAN THOMAS: ANY QUESTIONS OR
5 COMMENTS ON THIS ITEM FROM MEMBERS OF THE BOARD?
6 ANY PUBLIC COMMENT? MARIA, WILL YOU PLEASE CALL THE
7 ROLL.

8 MS. BONNEVILLE: YES. HAIFAA ABDULHAQ.

9 DR. ABDULHAQ: YES.

10 MS. BONNEVILLE: MOHAMMED ABOUSALEM.

11 DR. ABOUSALEM: YES.

12 MS. BONNEVILLE: KIM BARRETT.

13 DR. BARRETT: AYE.

14 MS. BONNEVILLE: DAN BERNAL.

15 MR. BERNAL: AYE.

16 MS. BONNEVILLE: GEORGE BLUMENTHAL.

17 DR. BLUMENTHAL: YES.

18 MS. BONNEVILLE: MICHAEL BOTCHAN. LINDA
19 BOXER.

20 DR. BOXER: YES.

21 MS. BONNEVILLE: JUDY CHOU.

22 DR. CHOU: YES.

23 MS. BONNEVILLE: LEONDRA CLARK-HARVEY.
24 DEBORAH DEAS.

25 DR. DEAS: YES.

BETH C. DRAIN, CA CSR NO. 7152

1 MS. BONNEVILLE: ANNE-MARIE DULIEGE.
2 DR. DULIEGE: YES.
3 MS. BONNEVILLE: YSABEL DURON.
4 MS. DURON: YES.
5 MS. BONNEVILLE: MARK FISCHER-COLBRIE.
6 ELENA FLOWERS.
7 DR. FLOWERS: YES.
8 MS. BONNEVILLE: JUDY GASSON.
9 DR. GASSON: YES.
10 MS. BONNEVILLE: LARRY GOLDSTEIN.
11 DR. GOLDSTEIN: YES.
12 MS. BONNEVILLE: STEPHEN JUELSGAARD.
13 MR. JUELSGAARD: YES.
14 MS. BONNEVILLE: RICH LAJARA.
15 MR. LAJARA: YES.
16 MS. BONNEVILLE: PAT LEVITT.
17 DR. LEVITT: YES.
18 MS. BONNEVILLE: LINDA MALKAS.
19 DR. MALKAS: YES.
20 MS. BONNEVILLE: SHLOMO MELMED. CHRISTINE
21 MIASKOWSKI.
22 DR. MIASKOWSKI: YES.
23 MS. BONNEVILLE: LAUREN MILLER-ROGEN.
24 MS. MILLER-ROGEN: YES.
25 MS. BONNEVILLE: ADRIANA PADILLA.

BETH C. DRAIN, CA CSR NO. 7152

1 DR. PADILLA: YES.

2 MS. BONNEVILLE: JOE PANETTA. AL ROWLETT.

3 MARVIN SOUTHARD. MICHAEL STAMOS.

4 DR. STAMOS: YES.

5 MS. BONNEVILLE: JONATHAN THOMAS.

6 CHAIRMAN THOMAS: YES.

7 MS. BONNEVILLE: ART TORRES. KAROL

8 WATSON.

9 DR. WATSON: YES.

10 MS. BONNEVILLE: KEITH YAMAMOTO.

11 DR. YAMAMOTO: YES.

12 MS. BONNEVILLE: THE MOTION CARRIES.

13 CHAIRMAN THOMAS: OKAY. THANK YOU. ALL

14 RIGHT.

15 MR. TORRES: I LOST THE INTERNET, SO I

16 MISSED THAT ROLL CALL. COULD YOU RECORD ME AS AN

17 AYE?

18 MS. BONNEVILLE: YES. NO PROBLEM. THANK

19 YOU, ART.

20 CHAIRMAN THOMAS: OKAY. ITEM NO. 10. I

21 AM SO DELIGHTED AND PROUD TO BE ABLE TO INTRODUCE TO

22 YOU OUR NOMINEE FOR NEXT VICE CHAIR OF CIRM, WHO, AS

23 YOU KNOW, RAN THE TABLE AND RECEIVED THE NOMINATIONS

24 OF FOUR CONSTITUTIONAL OFFICERS, OR I SHOULD SAY ALL

25 FOUR CONSTITUTIONAL OFFICERS, OUR OWN MARIA

BETH C. DRAIN, CA CSR NO. 7152

1 BONNEVILLE.

2 AND THE PROCESS WE'RE GOING TO GO THROUGH
3 HERE TO CONSIDER HER NOMINATION IS MARIA, HAVING
4 BEEN VETTED AND DISCUSSED ALREADY BY THE GOVERNANCE
5 SUBCOMMITTEE, WHICH WE'LL GO INTO A BIT LATER, IS
6 GOING TO READ IN OPEN SESSION HER LETTER TO THE
7 BOARD EXPRESSING HER INTEREST AND REASONS FOR
8 WANTING TO BE VICE CHAIR. AND AFTER THAT, WE WILL
9 GO INTO CLOSED SESSION FOR Q AND A WITH MARIA IN
10 CLOSED SESSION WITH THE WHOLE BOARD, AND THEN I WILL
11 GIVE FURTHER DIRECTION OF WHAT WE'RE GOING TO DO
12 ONCE WE GET IN THERE. BUT THE FIRST THING THAT
13 WE'RE GOING TO DO IS, WITHOUT FURTHER ADO, TO HEAR
14 FROM MARIA HERSELF. SO, MARIA, PLEASE TAKE IT AWAY.

15 MS. BONNEVILLE: THANK YOU. DEAR BOARD
16 MEMBERS, I AM VERY HONORED AND EXCITED TO BE
17 NOMINATED TO THE VICE CHAIR POSITION OF THE ICOC.
18 HAVING ARRIVED AT CIRM 11 YEARS AGO AT A TIME WHEN
19 MY FATHER WAS NEWLY DIAGNOSED WITH PARKINSON'S, I
20 WAS ENTHRALLED WITH THE PROMISE OF REGENERATIVE
21 MEDICINE AND THE POSSIBILITIES OF ADVANCES THAT
22 WOULD EASE THE BURDEN FOR NOT JUST HIM, BUT ALSO FOR
23 THE HUNDREDS OF THOUSANDS WHO LIVE WITH
24 NEURODEGENERATIVE DISEASES. TO THIS DAY I AM STILL
25 AWED BY AND EXCITED AT THE POSSIBILITY OF MAKING A

BETH C. DRAIN, CA CSR NO. 7152

1 DIFFERENCE FOR SO MANY WHO SUFFER FROM INCURABLE
2 DISEASES.

3 AS SOMEONE WHO CAME TO LOVE AND APPRECIATE
4 SCIENCE LATE IN LIFE, I STILL SIT IN AMAZEMENT AT
5 THE ACCOMPLISHMENT IN THE FIELD AS WELL AS THE ROLE
6 CIRM HAS PLAYED IN MAKING THIS HAPPEN. I BELIEVE MY
7 EXPERIENCE AT CIRM POSITIONS ME WELL FOR THE VICE
8 CHAIR ROLE. CIRM IS A UNIQUE AGENCY WITH A LARGE
9 BOARD AND A LONG HISTORY. IN MY VARIOUS ROLES, I
10 HAVE WORKED WITH BOTH THE CHAIR AND VICE CHAIR IN
11 SETTING AGENDAS, PRIORITIZING WORK, DRIVING POLICY,
12 AND ADVISING ACCORDINGLY.

13 IN ADDITION, I WORKED HARD TO BUILD
14 TRUSTED RELATIONSHIPS WITH ALL OF YOU SO THAT I
15 COULD LEARN AND UNDERSTAND WHAT AREAS WERE OF THE
16 MOST INTEREST AND WHERE I COULD HELP SHED LIGHT ON
17 THOSE PROGRAMS OR INITIATIVES.

18 FURTHER, I HAVE WORKED CLOSELY WITH MARIA
19 MILLAN FOR THE LAST DECADE, AND WE HAVE A GREAT
20 WORKING RELATIONSHIP. I BELIEVE I PROVIDE A LEVEL
21 OF CONTINUITY AND EXPERTISE THAT BENEFITS THE BOARD
22 AND HELPS IN TIMES OF TRANSITION.

23 ONE AREA OF SUBSTANTIVE EXPERTISE AND
24 PASSION THAT I HAVE DEVELOPED THROUGH MY TIME AT
25 CIRM HAS BEEN IN PUBLIC OUTREACH AND COMMUNICATION.

BETH C. DRAIN, CA CSR NO. 7152

1 WITH THE PASSAGE OF PROPOSITION 14 AND ITS INCREASED
2 IMPORTANCE ON THESE AREAS AND THEIR EXPANSION INTO
3 AFFORDABILITY AND ACCESSIBILITY, MY EXPERIENCE
4 UNIQUELY POSITIONS ME TO UNDERTAKE THE VICE CHAIR'S
5 NEW RESPONSIBILITY OF CHAIRING THE ACCESSIBILITY AND
6 AFFORDABILITY WORKING GROUP AND GUIDING THIS PART OF
7 CIRM'S MISSION.

8 NOTABLY, AFTER PROP 14'S PASSAGE, I WORKED
9 CLOSELY WITH THE CHAIR AND VICE CHAIR TO IDENTIFY,
10 RECRUIT, AND INTERVIEW ALMOST ALL THE CURRENT
11 MEMBERS ON THAT WORKING GROUP. THE AAWG'S WORK HAS
12 ONLY RECENTLY STARTED AND WILL GREATLY EXPAND OVER
13 THE NEXT FEW YEARS. WHILE ITS WORK HAS MOST
14 RECENTLY BEEN FOCUSED ON PATIENT SUPPORT SERVICES
15 AND ACCESSING THE \$15.6 MILLION IN THE PATIENT
16 ASSISTANCE FUND, IT WILL SOON NEED TO ADDRESS THE
17 COMMUNITY CARE CENTERS OF EXCELLENCE. THIS PROGRAM
18 IS DRIVEN BY COMMUNITY, WORKING GROUP, AND BOARD
19 INPUT.

20 ADDITIONALLY, AS THE TEAM GROWS, THE
21 PARTNERSHIP BETWEEN THE BOARD, THE ACCESSIBILITY AND
22 AFFORDABILITY WORKING GROUP, AND CIRM'S MEDICAL
23 AFFAIRS TEAM WILL BE CRITICAL TO SET PRIORITIES AND
24 BRING A ROAD MAP TO THE BOARD FOR FINAL APPROVAL.
25 THIS PLAN SHOULD INCLUDE YEARLY GOALS AND ESTIMATED

BETH C. DRAIN, CA CSR NO. 7152

1 BUDGET BOTH FOR ADMINISTRATIVE FUNDS AND FOR
2 RESEARCH-RELATED PROGRAMS.

3 THERE ARE PLENTY OF POLICY AREAS TO COVER
4 AS WELL, SOME OF WHICH WILL REQUIRE AAWG INPUT, SOME
5 WILL REQUIRE STANDARDS WORKING GROUP INPUT, AND SOME
6 WILL REQUIRE FINAL ENDORSEMENT BY THE BOARD. THESE
7 AREAS, STANDARDS FOR REIMBURSEMENT, APPROPRIATE USE
8 OF CIRM'S PATIENT ASSISTANCE FUND, HOW TO COMBAT
9 STEM CELL TOURISM, PRICING, AND OTHERS ALSO NEED
10 FOCUS AND GUIDANCE. I SPENT OVER A DECADE WORKING
11 IN SACRAMENTO BOTH ON CAMPAIGNS AND ON STAFF AND
12 MAINTAIN CLOSE RELATIONSHIPS WITH FORMER COLLEAGUES
13 WHO NOW WORK IN VARIOUS FUNCTIONS IN STATE
14 GOVERNMENT. IT IS IMPORTANT TO CONTINUE OUR CURRENT
15 VICE CHAIR'S STEADFAST WORK KEEPING SACRAMENTO UP TO
16 SPEED ON CIRM'S PROGRESS.

17 HAVING WORKED CLOSELY WITH THE BOARD, I
18 HAVE OTHER SUGGESTIONS TO OPTIMIZE THE BOARD'S
19 EFFECTIVENESS AND INFLUENCE. THEY INCLUDE SETTING A
20 BOARD CALENDAR FOR THE YEAR THAT LAYS OUT
21 ORGANIZATIONWIDE INITIATIVES WITH TIME FRAMES SO
22 THAT THE BOARD CAN RELY ON A MORE CONSISTENT
23 SCHEDULE. A BOARD RETREAT WHEN THE NEW CHAIR
24 STARTS. ALL MEMBERS COULD BENEFIT FROM A FOCUSED
25 DAY DISCUSSING CIRM'S PRIORITIES, THE YEARS AHEAD,

BETH C. DRAIN, CA CSR NO. 7152

1 AND ANY NEW SUBJECT MATTERS OR POLICY AREAS TO BE
2 CONSIDERED THROUGHOUT THAT YEAR. PUBLIC OUTREACH
3 WORK AS DIRECTED BY THE TEAM, CONTINUED WORK ON
4 DIVERSITY, EQUITY, AND INCLUSION POLICIES AND
5 PROGRAMS, AND WORKING GROUP AND SUBCOMMITTEE
6 MEMBERSHIP.

7 THANK YOU ALL FOR CONSIDERING MY
8 NOMINATION AND ALLOWING ME TO CONTINUE TO WORK TO
9 FULFILL CIRM'S MISSION TO THE PEOPLE OF CALIFORNIA.

10 CHAIRMAN THOMAS: THANK YOU, MARIA. I'M
11 GOING TO HOLD ALL COMMENTS, QUESTIONS TILL WE GET
12 INTO CLOSED SESSION HERE. AND TOWARDS THAT END,
13 KAREN GETMAN WILL BE READING US THE APPROPRIATE
14 SUBSECTION LANGUAGE TO TAKE US INTO CLOSED SESSION.
15 KAREN.

16 MS. GETMAN: WE ARE GOING INTO CLOSED
17 SESSION PURSUANT TO GOVERNMENT CODE SECTION 11126,
18 SUBDIVISION A AND HEALTH AND SAFETY CODE SECTION
19 125290.30(F)(3)(D) FOR A DISCUSSION OF PERSONNEL, IN
20 PARTICULAR, THE RECOMMENDATION CONCERNING THE
21 NOMINEE FOR VICE CHAIR, INCLUDING PERCENT EFFORT,
22 COMPENSATION, AND START DATE, AND THE RECOMMENDATION
23 REGARDING PERCENT EFFORT, COMPENSATION, AND START
24 DATE FOR THE CHAIR.

25 CHAIRMAN THOMAS: THANK YOU. AND SO,

BETH C. DRAIN, CA CSR NO. 7152

1 DOUG, WILL YOU -- EVERYBODY CAN JUST JOIN CLOSED
2 SESSION. WE'LL SEE YOU ON THE OTHER SIDE.

3 (THE BOARD THEN WENT INTO CLOSED
4 SESSION, NOT REPORTED, NOR HEREIN TRANSCRIBED.)

5 CHAIRMAN THOMAS: OKAY. SO WE ARE BACK
6 NOW. WE HAVE TWO MORE ACTION ITEMS THAT DIRECTLY
7 STEM FROM THE DISCUSSION WE JUST HAD IN CLOSED
8 SESSION.

9 ITEM NO. 12, CONSIDERATION OF VICE CHAIR
10 CANDIDATE, INCLUDING PERCENT EFFORT AND COMPENSATION
11 AND START DATE. AND BEFORE WE LOOK TO A MOTION, I'M
12 GOING TO ASK THE CHAIR OF THE GOVERNANCE
13 SUBCOMMITTEE, DR. GASSON, IF SHE WOULD REPORT OUT
14 THE RECOMMENDATIONS OF THE GOVERNANCE SUBCOMMITTEE
15 AND THE RECOMMENDATIONS THAT WERE JUST DISCUSSED BY
16 THE FULL BOARD IN CLOSED SESSION. JUDY.

17 DR. GASSON: THANK YOU VERY MUCH,
18 CHAIRMAN THOMAS. AS A REMINDER, THE GOVERNANCE
19 SUBCOMMITTEE, WITH CONSULTANTS AND KEVIN, SPENT
20 ABOUT A YEAR HARMONIZING THE POSITIONS AT CIRM INTO
21 TEN LEVELS AND THEN CONDUCTING A VERY EXTENSIVE
22 MARKET SURVEY TO TRY TO DETERMINE THE APPROPRIATE
23 SALARY RANGES FOR EACH OF THOSE LEVELS.

24 SO THE RECOMMENDATIONS THAT WE'RE GOING TO
25 MAKE NOW REFLECT THE MIDPOINT OR THE 50TH PERCENTILE

BETH C. DRAIN, CA CSR NO. 7152

1 OF THOSE RANGES FROM THE MARKET SURVEY.

2 SO THE FIRST RECOMMENDATION OF THE
3 GOVERNANCE SUBCOMMITTEE IS TO ENTHUSIASTICALLY
4 RECOMMEND MARIA BONNEVILLE TO THE POSITION OF ICOC
5 VICE CHAIR, THAT THE POSITION IS A ONE HUNDRED
6 PERCENT EFFORT, AND THAT THE SALARY WOULD BE AT THE
7 MIDPOINT FOR LEVEL 9, WHICH IS \$336,500.

8 CHAIRMAN THOMAS: THANK YOU. DO WE HEAR A
9 MOTION TO THAT EFFECT?

10 DR. DULIEGE: MOVE.

11 MR. TORRES: SECOND.

12 CHAIRMAN THOMAS: SECONDED, I THINK THAT
13 WAS ART.

14 MR. TORRES: YES.

15 CHAIRMAN THOMAS: IS THERE FURTHER
16 DISCUSSION BY MEMBERS OF THE BOARD?

17 MS. DURON: SAY THAT I DON'T THINK WE
18 COULD DO BETTER THAN TAKING ON MARIA BONNEVILLE
19 GONZALEZ TO BECOME OUR VICE CHAIR. SHE IS WELL
20 EDUCATED IN TERMS OF CIRM. SHE'S GOT A LONG RUNNING
21 TRACK RECORD WITH CIRM. AND SHE IS BOTH, NOT ONLY
22 INWARDLY POSITIONED TO WORK WELL, BUT SHE IS VERY
23 EMPATHETIC AND CARING AND WILL BE A STEWARD FOR THE
24 COMMUNITY AND FOR THE TAXPAYERS TO MAKE SURE THAT
25 THE WORK WE ARE DOING SERVES THEM WELL. THANK YOU,

BETH C. DRAIN, CA CSR NO. 7152

1 MR. CHAIR.

2 CHAIRMAN THOMAS: THANK YOU. OTHER
3 COMMENTS? I'LL SAY FOR MEMBERS OF THE PUBLIC THAT
4 THERE WAS EXTREME ENTHUSIASM FOR MARIA IN A CASCADE
5 OF GLOWING COMMENTS IN THE CLOSED SESSION THAT WE
6 WON'T REPEAT HERE, BUT I JUST WANT EVERYBODY TO KNOW
7 THAT THAT WAS THE CASE. AND I WILL REPEAT ONE THING
8 I SAID, WHICH IS IN MY ELEVEN AND A HALF YEARS AS
9 CHAIR OF CIRM, THERE IS NOTHING I'M NOT MORE
10 ENTHUSIASTIC ABOUT VOTING ON THAN THIS ITEM ELECTING
11 MARIA TO BE OUR NEW VICE CHAIR.

12 SO ARE THERE ANY COMMENTS FROM MEMBERS OF
13 THE PUBLIC?

14 MS. DEQUINA-VILLABLANCA: I DON'T SEE ANY,
15 J.T. OH, HOLD ON. MARIA M.

16 CHAIRMAN THOMAS: WE HAVE MARIA M.

17 DR. MILLAN: FIRST OF ALL, CONGRATULATE
18 MARIA BONNEVILLE AND ALSO THANK THE BOARD. I AGREE
19 WITH YSABEL, NO ONE BETTER. AND WE'RE SO EXCITED AS
20 A TEAM TO WORK WITH MARIA IN HER NEW ROLE.

21 CHAIRMAN THOMAS: THANK YOU, MARIA. ARE
22 THERE COMMENTS FROM MEMBERS OF THE PUBLIC?

23 MS. DEQUINA-VILLABLANCA: I SEE NONE,
24 J.T.

25 CHAIRMAN THOMAS: OKAY. MARIANNE, PLEASE

BETH C. DRAIN, CA CSR NO. 7152

1 CALL THE ROLL .
2 MS. DEQUINA-VILLABLANCA: HAIFAA ABDULHAQ.
3 DR. ABDULHAQ: YES.
4 MS. DEQUINA-VILLABLANCA: MOHAMMED
5 ABOUSALEM.
6 DR. ABOUSALEM: YES.
7 MS. DEQUINA-VILLABLANCA: KIM BARRETT.
8 DR. BARRETT: AYE.
9 MS. DEQUINA-VILLABLANCA: DAN BERNAL .
10 MR. BERNAL: ENTHUSIASTICALLY AYE.
11 MS. DEQUINA-VILLABLANCA: GEORGE
12 BLUMENTHAL .
13 DR. BLUMENTHAL: ALSO ENTHUSIASTICALLY
14 YES.
15 MS. DEQUINA-VILLABLANCA: MICHAEL BOTCHAN.
16 LINDA BOXER.
17 DR. BOXER: YES.
18 MS. DEQUINA-VILLABLANCA: JUDY CHOU.
19 DR. CHOU: YES.
20 MS. DEQUINA-VILLABLANCA: DEBORAH DEAS .
21 DR. DEAS: YES.
22 MS. DEQUINA-VILLABLANCA: ANNE-MARIE
23 DULIEGE .
24 DR. DULIEGE: YES.
25 MS. DEQUINA-VILLABLANCA: YSABEL DURON.

BETH C. DRAIN, CA CSR NO. 7152

1 MS. DURON: YES.
2 MS. DEQUINA-VILLABLANCA: MARK
3 FISCHER-COLBRIE.
4 DR. FISCHER-COLBRIE: YES.
5 MS. DEQUINA-VILLABLANCA: ELENA FLOWERS.
6 DR. FLOWERS: YES.
7 MS. DEQUINA-VILLABLANCA: JUDY GASSON.
8 DR. GASSON: YES.
9 MS. DEQUINA-VILLABLANCA: LARRY GOLDSTEIN.
10 DR. GOLDSTEIN: YES.
11 MS. DEQUINA-VILLABLANCA: STEPHEN
12 JUELSGAARD.
13 MR. JUELSGAARD: YES.
14 MS. DEQUINA-VILLABLANCA: RICH LAJARA.
15 MR. LAJARA: YES.
16 MS. DEQUINA-VILLABLANCA: PAT LEVITT.
17 DR. LEVITT: YES.
18 MS. DEQUINA-VILLABLANCA: LINDA MALKAS.
19 DR. MALKAS: YES.
20 MS. DEQUINA-VILLABLANCA: SHLOMO MELMED.
21 DR. MELMED: YES.
22 MS. DEQUINA-VILLABLANCA: CHRISTINE
23 MIASKOWSKI.
24 DR. MIASKOWSKI: ENTHUSIASTIC YES.
25 MS. DEQUINA-VILLABLANCA: LAUREN

BETH C. DRAIN, CA CSR NO. 7152

1 MILLER-ROGEN.

2 MS. MILLER-ROGEN: YES.

3 MS. DEQUINA-VILLABLANCA: ADRIANA PADILLA.

4 DR. PADILLA: YES.

5 MS. DEQUINA-VILLABLANCA: AL ROWLETT.

6 MARVIN SOUTHARD. MICHAEL STAMOS.

7 DR. STAMOS: ANOTHER ENTHUSIASTIC YES.

8 MS. DEQUINA-VILLABLANCA: JONATHAN THOMAS.

9 CHAIRMAN THOMAS: YES, ALL CAPS.

10 MS. DEQUINA-VILLABLANCA: ART TORRES.

11 MR. TORRES: VERY ENTHUSIASTIC AYE.

12 MS. DEQUINA-VILLABLANCA: KAROL WATSON.

13 DR. WATSON: ONE HUNDRED PERCENT YES.

14 MS. DEQUINA-VILLABLANCA: KEITH YAMAMOTO.

15 DR. YAMAMOTO: ABSOLUTELY, YES.

16 MS. DEQUINA-VILLABLANCA: THE MOTION

17 CARRIES. CONGRATULATIONS.

18 CHAIRMAN THOMAS: ALL RIGHT, MARIA.

19 MS. BONNEVILLE: THANK YOU, EVERYONE,

20 REALLY FOR HAVING FAITH AND TRUST IN ME. SO I

21 REALLY APPRECIATE IT. I'M SUPER EXCITED. SO THANK

22 YOU.

23 CHAIRMAN THOMAS: THANK YOU. OKAY. ITEM

24 13, CONSIDERATION OF CHAIR, PERCENT EFFORT AND

25 COMPENSATION AND START DATE. AGAIN, TURN THIS OVER

BETH C. DRAIN, CA CSR NO. 7152

1 TO JUDY TO GIVE RECOMMENDATIONS ON THIS ITEM.

2 DR. GASSON: OKAY. SO THE RECOMMENDATION
3 OF THE GOVERNANCE SUBCOMMITTEE IS THAT THE NEXT
4 CHAIR OF THE ICOC MUST ALSO COMMIT TO A ONE HUNDRED
5 PERCENT TIME, FULL-TIME EFFORT, WITH AN ANNUAL
6 SALARY SET AT THE MEDIAN OF THE APPROVED RANGE FOR
7 LEVEL 10, WHICH IS \$569,000.

8 CHAIRMAN THOMAS: DO WE HEAR A MOTION TO
9 THAT EFFECT?

10 MR. TORRES: SO MOVED.

11 DR. BARRETT: SECOND.

12 CHAIRMAN THOMAS: MOVED BY ART. WAS THAT
13 DEBORAH THE SECOND?

14 DR. GASSON: IT WAS KIM.

15 CHAIRMAN THOMAS: KIM. THANK YOU. OKAY.
16 COMMENTS BY MEMBERS OF THE BOARD. ANY PUBLIC
17 COMMENT?

18 MS. DEQUINA-VILLABLANCA: I DON'T SEE
19 ANY.

20 CHAIRMAN THOMAS: THANK YOU. HEARING
21 NONE, MARIANNE, WILL YOU PLEASE CALL THE ROLL.

22 MS. DEQUINA-VILLABLANCA: HAIFAA ABDULHAQ.

23 DR. ABDULHAQ: YES.

24 MS. DEQUINA-VILLABLANCA: MOHAMMED
25 ABOUSALEM.

BETH C. DRAIN, CA CSR NO. 7152

1 DR. ABOUSALEM: YES.
2 MS. DEQUINA-VILLABLANCA: KIM BARRETT.
3 DR. BARRETT: AYE.
4 MS. DEQUINA-VILLABLANCA: DAN BERNAL.
5 MR. BERNAL: AYE.
6 MS. DEQUINA-VILLABLANCA: GEORGE
7 BLUMENTHAL.
8 DR. BLUMENTHAL: YES.
9 MS. DEQUINA-VILLABLANCA: LINDA BOXER.
10 DR. BOXER: YES.
11 MS. DEQUINA-VILLABLANCA: JUDY CHOU.
12 DR. CHOU: AYE.
13 MS. DEQUINA-VILLABLANCA: DEBORAH DEAS.
14 DR. DEAS: YES.
15 MS. DEQUINA-VILLABLANCA: ANNE-MARIE
16 DULIEGE.
17 DR. DULIEGE: YES.
18 MS. DEQUINA-VILLABLANCA: YSABEL DURON.
19 MS. DURON: YES.
20 MS. DEQUINA-VILLABLANCA: MARK
21 FISCHER-COLBRIE.
22 DR. FISCHER-COLBRIE: YES.
23 MS. DEQUINA-VILLABLANCA: ELENA FLOWERS.
24 DR. FLOWERS: YES.
25 MS. DEQUINA-VILLABLANCA: JUDY GASSON.

BETH C. DRAIN, CA CSR NO. 7152

1 DR. GASSON: YES.
2 MS. DEQUINA-VILLABLANCA: LARRY GOLDSTEIN.
3 DR. GOLDSTEIN: YES.
4 MS. DEQUINA-VILLABLANCA: STEPHEN
5 JUELSGAARD.
6 MR. JUELSGAARD: YES.
7 MS. DEQUINA-VILLABLANCA: RICH LAJARA.
8 MR. LAJARA: YES.
9 MS. DEQUINA-VILLABLANCA: PAT LEVITT.
10 DR. LEVITT: YES.
11 MS. DEQUINA-VILLABLANCA: LINDA MALKAS.
12 DR. MALKAS: YES.
13 MS. DEQUINA-VILLABLANCA: SHLOMO MELMED.
14 DR. MELMED: YES.
15 MS. DEQUINA-VILLABLANCA: CHRISTINE
16 MIASKOWSKI.
17 DR. MIASKOWSKI: YES.
18 MS. DEQUINA-VILLABLANCA: LAUREN
19 MILLER-ROGEN.
20 MS. MILLER-ROGEN: YES.
21 MS. DEQUINA-VILLABLANCA: ADRIANA PADILLA.
22 DR. PADILLA: YES.
23 MS. DEQUINA-VILLABLANCA: JONATHAN THOMAS.
24 CHAIRMAN THOMAS: YES.
25 MS. DEQUINA-VILLABLANCA: ART TORRES.

BETH C. DRAIN, CA CSR NO. 7152

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

MR. TORRES: AYE.

MS. DEQUINA-VILLABLANCA: KAROL WATSON.

DR. WATSON: YES.

DR. STAMOS: DID YOU SKIP ME?

MS. DEQUINA-VILLABLANCA: KEITH YAMAMOTO.
MICHAEL STAMOS. SORRY. I DIDN'T REALIZE YOU WERE
BACK. MICHAEL STAMOS.

DR. STAMOS: YES.

MS. DEQUINA-VILLABLANCA: KEITH YAMAMOTO.

DR. YAMAMOTO: YES.

MS. DEQUINA-VILLABLANCA: THE MOTION
CARRIES.

CHAIRMAN THOMAS: OKAY. JUST TO REMIND
EVERYBODY, THE BOARD CHAIR ELECTION IS GOING TO BE
AT THE NEXT FULL BOARD MEETING DECEMBER 15TH. AND
THIS IS ONE WE WANT TO HAVE AS MANY PEOPLE AS WE
POSSIBLY CAN ATTEND. THIS IS OBVIOUSLY, AS WAS
TODAY, A VERY IMPORTANT VOTE DAY. SO PLEASE MAKE
SURE YOU'VE GOT THAT ONE CIRCLED ON YOUR CALENDAR.

ALL RIGHT. WE ARE HEADING AROUND THE
CLUBHOUSE TURN, HEADING HERE TOWARDS THE FINAL
STRETCH. THROUGH OUR ACTION ITEMS. NOW, IN
DISCUSSION ITEMS, ITEM 14 --

DR. GASSON: ASK YOU AND ART TORRES TO
RECUSE YOURSELVES FROM THE NEXT ITEM.

BETH C. DRAIN, CA CSR NO. 7152

1 CHAIRMAN THOMAS: FORGOT ABOUT THAT. YES.

2 MS. GASSON: YOU DON'T HAVE TO LEAVE, BUT
3 PLEASE DON'T PARTICIPATE IN THE DISCUSSION.

4 AS J.T. JUST MENTIONED, THE ELECTION OF
5 NEW BOARD CHAIR BEING DECEMBER 15TH, BOTH OF THE
6 CANDIDATES, AS YOU ARE AWARE, ARE OUTSIDE OF THE
7 CURRENT ORGANIZATION. SO THE GOVERNANCE
8 SUBCOMMITTEE IS RECOMMENDING THAT THE NEXT CHAIR AND
9 VICE CHAIR OF THE ICOC ASSUME THOSE POSITIONS AT THE
10 FIRST FULL BOARD MEETING IN JANUARY, WHICH IS
11 CURRENTLY SCHEDULED TO BE JANUARY 26TH. AND THE
12 CHAIR SENT OUT AN INVITATION EARLIER TODAY HOPING
13 THAT WE WOULD BE ABLE TO MEET IN PERSON FOR THAT
14 MEETING ON JANUARY 26TH.

15 SO I WOULD ENTERTAIN A MOTION FOR THIS
16 PROPOSAL FROM THE GOVERNANCE SUBCOMMITTEE.

17 DR. LEVITT: SO MOVED.

18 DR. STAMOS: SECOND.

19 MS. GASSON: MARIANNE, WOULD YOU CALL THE
20 ROLL PLEASE.

21 MS. DEQUINA-VILLABLANCA: HAIFAA ABDULHAQ.

22 DR. ABDULHAQ: YES.

23 MS. DEQUINA-VILLABLANCA: MOHAMMED
24 ABOUSALEM.

25 DR. ABOUSALEM: YES.

BETH C. DRAIN, CA CSR NO. 7152

1 MS. DEQUINA-VILLABLANCA: KIM BARRETT.
2 DR. BARRETT: AYE.
3 MS. DEQUINA-VILLABLANCA: DAN BERNAL.
4 MR. BERNAL: AYE.
5 MS. DEQUINA-VILLABLANCA: GEORGE
6 BLUMENTHAL.
7 DR. BLUMENTHAL: YES.
8 MS. DEQUINA-VILLABLANCA: MICHAEL BOTCHAN.
9 LINDA BOXER.
10 DR. BOXER: YES.
11 MS. DEQUINA-VILLABLANCA: JUDY CHOU.
12 DR. CHOU: AYE.
13 MS. DEQUINA-VILLABLANCA: DEBORAH DEAS.
14 DR. DEAS: YES.
15 MS. DEQUINA-VILLABLANCA: ANNE-MARIE
16 DULIEGE.
17 DR. DULIEGE: YES.
18 MS. DEQUINA-VILLABLANCA: YSABEL DURON.
19 MS. DURON: YES.
20 MS. DEQUINA-VILLABLANCA: MARK
21 FISCHER-COLBRIE.
22 DR. FISCHER-COLBRIE: YES.
23 MS. DEQUINA-VILLABLANCA: ELENA FLOWERS.
24 DR. FLOWERS: YES.
25 MS. DEQUINA-VILLABLANCA: JUDY GASSON.

BETH C. DRAIN, CA CSR NO. 7152

1 DR. GASSON: YES.
2 MS. DEQUINA-VILLABLANCA: LARRY GOLDSTEIN.
3 DR. GOLDSTEIN: YES.
4 MS. DEQUINA-VILLABLANCA: STEPHEN
5 JUELSGAARD.
6 MR. JUELSGAARD: YES.
7 MS. DEQUINA-VILLABLANCA: RICH LAJARA.
8 MR. LAJARA: YES.
9 MS. DEQUINA-VILLABLANCA: PAT LEVITT.
10 DR. LEVITT: YES.
11 MS. DEQUINA-VILLABLANCA: LINDA MALKAS.
12 DR. MALKAS: YES.
13 MS. DEQUINA-VILLABLANCA: SHLOMO MELMED.
14 DR. MELMED: YES.
15 MS. DEQUINA-VILLABLANCA: CHRISTINE
16 MIASKOWSKI.
17 DR. MIASKOWSKI: YES.
18 MS. DEQUINA-VILLABLANCA: LAUREN
19 MILLER-ROGEN.
20 MS. MILLER-ROGEN: YES.
21 MS. DEQUINA-VILLABLANCA: ADRIANA PADILLA.
22 DR. PADILLA: YES.
23 MS. DEQUINA-VILLABLANCA: MICHAEL STAMOS.
24 DR. STAMOS: YES.
25 MS. DEQUINA-VILLABLANCA: KAROL WATSON.

BETH C. DRAIN, CA CSR NO. 7152

1 DR. WATSON: YES.

2 MS. DEQUINA-VILLABLANCA: KEITH YAMAMOTO.

3 DR. YAMAMOTO: YES.

4 MS. DEQUINA-VILLABLANCA: THE MOTION
5 CARRIES.

6 CHAIRMAN THOMAS: OKAY. THANK YOU. JUDY,
7 AGAIN, THANK YOU AND ALL MEMBERS OF THE GOVERNANCE
8 SUBCOMMITTEE FOR YOUR EXTREME AMOUNT OF WORK OVER
9 THE PAST YEAR. ALMOST THROUGH ONCE WE GET TO
10 DECEMBER, BUT WE CANNOT THANK YOU ALL ENOUGH. THIS
11 HAS BEEN EXPERTLY SHEPHERDED FROM START TO FINISH.
12 AND WE ARE SO HAPPY THAT WE ARE GETTING TO WHERE WE
13 ARE. SO THANK YOU VERY MUCH.

14 DR. GASSON: THANK YOU, J.T. I SEE THAT
15 YSABEL HAS HER HAND UP.

16 MS. DURON: THANK YOU, JUDY. THANK YOU,
17 MR. CHAIR. I DON'T KNOW IF MY COMMENT IS OUT OF
18 ORDER. I DON'T KNOW IF I COULD EVEN SAY THIS
19 COMMENT, BUT MY CONSCIENCE REQUIRES ME TO DO SO.

20 I KNOW THAT WHEN WE DO THESE GUIDELINES
21 BASED ON SALARIES, THAT WE LOOK AT INDUSTRY, WE LOOK
22 AT THESE POSITIONS, WE LOOK AT THE PEOPLE WHO ARE
23 HIGHLY QUALIFIED TO BE IN THESE POSITIONS. I JUST
24 THINK ABOUT SOME OF THE PEOPLE OF CALIFORNIA, OUR
25 VERY MOST VULNERABLE POPULATIONS WHO ARE STRUGGLING

BETH C. DRAIN, CA CSR NO. 7152

1 TO SURVIVE ON LIMITED AMOUNTS OF DOLLARS. AND PART
2 OF ME AS A SOCIAL JUSTICE LAWYER FINDS THE AMOUNT OF
3 MONEY FOR A PUBLIC SERVANT REALLY DIFFICULT TO IN
4 SOME WAYS EMBRACE AND UNDERSTAND.

5 I APPRECIATE THE QUALIFICATION, THE
6 QUALITY, AND THE HARD WORK THAT PEOPLE PUT IN TO GET
7 TO THESE PLACES WHERE THEY'RE, IN FACT, REWARDED FOR
8 THEIR HARD WORK. IT'S JUST A PART OF ME, GIVEN THE
9 CIRCUMSTANCE OF OUR ECONOMY AND THE STRUGGLES OF
10 SOME OF OUR PEOPLES, THAT THIS IS -- THIS WAS HARD
11 FOR ME TO VOTE ON. BUT I'M HOPING THAT THE NEW
12 CHAIR WILL RECOGNIZE THE RESPONSIBILITIES TO THE
13 PEOPLE OF CALIFORNIA WITH A GREAT DEAL OF HEART AND
14 COMMITMENT.

15 BUT, JUDY, I JUST NEEDED TO SAY THIS. I
16 KNOW HOW HARD YOU ALL HAVE DONE THIS WORK, BUT IT'S
17 TROUBLING TO ME SOME OF THE SALARIES THAT EVERYBODY
18 GETS WHEN WE START TALKING ABOUT HALF A MILLION
19 DOLLARS OR MORE. AND I HOPE THAT THEY TAKE SOME OF
20 THAT MONEY OUT OF THEIR POCKET AND PUT IT BACK INTO
21 COMMUNITY WORK TO HELP COMMUNITY-BASED ORGANIZATIONS
22 DO THEIR WORK BETTER TO HELP THESE FOLKS WHO ARE
23 MOST VULNERABLE IN OUR POPULATIONS. THANK YOU AND
24 FORGIVE ME IF I'M SPEAKING OUT OF TURN, BUT I JUST
25 HAD TO SAY IT.

BETH C. DRAIN, CA CSR NO. 7152

1 DR. GASSON: NOT AT ALL. I THINK YOU
2 STARTED OUT YOUR COMMENT BY STATING THE SORT OF
3 GUIDELINES THAT WE HAVE AGREED UPON, WHICH IS THAT
4 WE WANT TO BE ABLE TO RECRUIT AND RETAIN THE HIGHEST
5 QUALITY TALENT FROM ALL THE DIFFERENT SECTORS,
6 INCLUDING INDUSTRY. AND SO WE LOOKED AT EACH OF
7 THOSE SALARY RANGES VERY CAREFULLY AND CAME UP WITH
8 A RANGE THAT I THINK REPRESENTS PRIMARILY THE
9 ACADEMIC INSTITUTIONS, BUT THERE IS A COMPONENT IN
10 THERE THAT LOOKS AT INDUSTRY.

11 J.T., DO YOU WANT TO ADD TO THAT?

12 CHAIRMAN THOMAS: NO. I THINK THAT'S
13 RIGHT. I THINK THIS IS CONSISTENT WITH WHAT CIRM
14 HAS DONE IN PAST SALARY SURVEYS FOR THE SPECIFIC
15 PURPOSE JUDY IS MENTIONING, WHICH IS ABOUT
16 ATTRACTING AND RETAINING WHAT WE BELIEVE WILL BE THE
17 BEST PEOPLE WE CAN HAVE FOR THOSE ROLES. BUT THANK
18 YOU. NONETHELESS, YSABEL, THANK YOU VERY MUCH FOR
19 THAT PERSPECTIVE.

20 OKAY. I THINK THAT NOW DOES FINALLY --
21 SORRY I WAS JUMPING THE GUN EARLIER -- CONCLUDE THE
22 ACTION ITEMS. WE'RE INTO DISCUSSION ITEMS, THE
23 FIRST ONE OF WHICH IS 14, GENERAL COMMENTS ON THE
24 ARS PROCESS. SO I SENT A MEMO OUT TO YOU FAIRLY
25 RECENTLY WHICH BASICALLY SAID, BECAUSE CERTAIN

BETH C. DRAIN, CA CSR NO. 7152

1 PEOPLE ARE CONFLICTED AT DIFFERENT TIMES FROM VOTING
2 FOR THIS OR THAT IN THE ARS PROCESS, THERE MAY BE
3 COMMENTS FROM CONFLICTED PARTIES ABOUT THAT PROCESS
4 THAT SOMEBODY MIGHT WISH TO MAKE THAT THEY AREN'T
5 ABLE TO BECAUSE THEY'RE CONFLICTED DURING THE
6 APPLICATION REVIEW SUBCOMMITTEE MEETINGS.

7 SO AT THIS POINT IS THERE ANY COMMENT FROM
8 ANY MEMBER OF THE BOARD ON THE ARS PROCESS ITSELF?
9 OKAY. HEARING AND SEEING NONE, THAT WAS QUICK.

10 WE WILL NOW MOVE ON. DO WE KNOW IF CRAIG
11 IS ON THE CALL YET FOR THE NEXT ITEM?

12 MS. BONNEVILLE: HE IS INDEED.

13 CHAIRMAN THOMAS: GREAT. SO ITEM 15,
14 FINANCIAL AUDIT FOR FISCAL 2021. TURN THIS OVER TO
15 POUNEH, SUMI, AND CRAIG HARNER FROM MGO TO GIVE US
16 THAT REPORT.

17 MS. THOMPSON: THANK YOU, CHAIRMAN THOMAS.
18 GOOD AFTERNOON, MEMBERS OF THE COMMITTEE. I AM SUMI
19 THOMPSON. I'M THE FINANCE OFFICER HERE AT CIRM.
20 AND I'M HERE TO INTRODUCE THE NEXT DISCUSSION ITEM,
21 WHICH IS THE FINANCIAL AUDIT RESULTS FOR FISCAL YEAR
22 20/21. AS CHAIRMAN THOMAS ANNOUNCED, THAT IT'S
23 CRAIG HARNER. HE'S THE DIRECTOR AT MGO, AND HE'S
24 HERE TO PRESENT THE RESULTS OF THAT AUDIT. WELCOME,
25 CRAIG.

BETH C. DRAIN, CA CSR NO. 7152

1 MR. HARNER: THANK YOU, SUMI.

2 I THINK, MARIANNE, ARE YOU GOING TO PUT UP
3 THE SLIDES THAT I HAD SENT?

4 MS. DEQUINA-VILLABLANCA: I WILL GET
5 THOSE UP RIGHT NOW.

6 MR. HARNER: ALL RIGHT. THANK YOU,
7 MARIANNE.

8 THANK YOU, MEMBERS OF THE ICOC, FOR
9 ALLOWING US TO OR GIVING US THE OPPORTUNITY TO
10 PRESENT THE RESULTS OF OUR WORK. IF WE GO TO THE
11 NEXT SLIDE, I HAVE KIND OF AN AGENDA THAT WE'LL GO
12 OVER THIS AFTERNOON. I'LL TALK ABOUT THE SCOPE OF
13 SERVICES AND THE DELIVERABLES THAT WE ISSUE AS A
14 RESULT OF OUR AUDIT, THE RESPONSIBILITIES OF
15 OURSELVES AT MGO AS YOUR INDEPENDENT AUDITORS. I'LL
16 GO OVER THE AUDIT RESULTS. AND THE LAST SECTION IS
17 CALLED THE REQUIRED COMMUNICATIONS, AND THIS IS KIND
18 OF A SUMMARY OF DIFFERENT THINGS THAT ARE STANDARD
19 SETTERS REQUIRING US TO COMMUNICATE TO THE
20 GOVERNANCE COMMITTEE AND THOSE THAT OVERSEE THE
21 ORGANIZATION'S AUDIT FUNCTIONS.

22 SO IF YOU ADVANCE TWO SLIDES, WE'LL GO
23 OVER THE SCOPE OF SERVICES AND OUR DELIVERABLES. WE
24 ARE ENGAGED BY CIRM TO AUDIT THE FINANCIAL
25 STATEMENTS AS OF JUNE 30, 2021. AND THIS INCLUDES

BETH C. DRAIN, CA CSR NO. 7152

1 WHAT'S CALLED THE STATEMENTS OF THE GOVERNMENTAL
2 ACTIVITIES AND THEN THE STEM CELL FUND.

3 AND AS A BY-PRODUCT OF OUR AUDIT, WE ISSUE
4 THREE REPORTS. THE FIRST TWO ARE INCLUDED IN THE
5 FINANCIAL STATEMENT PACKET. THE FIRST TWO REPORTS
6 ARE INDEPENDENT AUDITOR'S REPORT AND OUR INDEPENDENT
7 AUDITOR'S REPORT ON INTERNAL CONTROLS OVER FINANCIAL
8 REPORTING AND ON COMPLIANCE AND OTHER MATTERS. THIS
9 IS AN ADDITIONAL REPORT REQUIRED BY GOVERNMENT
10 AUDITING STANDARDS, AND IT'S EITHER THE VERY FIRST
11 AND LAST SECTIONS OF THAT FINANCIAL STATEMENT
12 REPORT. AND THEN A SEPARATE REPORT THAT WE ISSUE IS
13 OUR REPORT TO THE ICOC, AND THIS CONSISTS OF OUR
14 REQUIRED COMMUNICATIONS, WHICH, AGAIN, ARE JUST SOME
15 ITEMS OF IMPORTANCE THAT WE ARE REQUIRED TO
16 SUMMARIZE AND COMMUNICATE.

17 GO TO THE NEXT TWO SLIDES. SO AS THE
18 INDEPENDENT AUDITORS FOR CIRM, OUR RESPONSIBILITY IS
19 TO PLAN AND PERFORM AN AUDIT TO OBTAIN WHAT IS KNOWN
20 AS REASONABLE ASSURANCE TO MAKE SURE THAT THE
21 FINANCIAL STATEMENTS ARE FREE OF MATERIAL
22 MISSTATEMENT. REASONABLE ASSURANCE ISN'T ABSOLUTE.
23 IT'S NOT A HUNDRED PERCENT ASSURANCE; HOWEVER, IT'S
24 STILL A VERY HIGH LEVEL OF ASSURANCE TO MAKE SURE
25 THAT, AGAIN, THOSE FINANCIAL STATEMENTS ARE FREE OF

BETH C. DRAIN, CA CSR NO. 7152

1 MATERIAL MISSTATEMENTS WHETHER DUE TO FRAUD OR
2 ERRORS. AND OUR MAIN RESPONSIBILITY IS EXPRESSING
3 AN OPINION AS TO THE FAIR PRESENTATION OF THOSE
4 FINANCIAL STATEMENTS IN ALL MATERIAL RESPECTS,
5 CONFORMING WITH THE ACCOUNTING PRINCIPLES GENERALLY
6 ACCEPTED IN THE UNITED STATES. THEY'RE KNOWN AS
7 USGAP.

8 WE ALSO APPLY CERTAIN LIMITED PROCEDURES
9 TO THE MANAGEMENT, ESPECIALLY AN ANALYSIS, WHICH IS
10 THE VERY FIRST PART OF THE REPORT AFTER OUR
11 INDEPENDENT AUDITOR'S REPORT, BUT PRECEDING THE
12 FINANCIAL STATEMENTS. AND WHAT THIS SECTION IS IS
13 REQUIRED SUPPLEMENTARY INFORMATION. WE DON'T GIVE
14 AN OPINION ON IT. WE DON'T PROVIDE ANY ASSURANCE
15 OVER IT, BUT WE READ THROUGH IT. WE MAKE SURE
16 THERE'S NO MATERIAL INCONSISTENCIES WITH THE
17 FINANCIAL STATEMENTS. AND WITH THE MANAGEMENT
18 DISCUSSION AND ANALYSIS, MD&A, IT'S PROVIDING A
19 NARRATIVE OF WHAT HAPPENED DURING THE YEAR. IT
20 DESCRIBES SIGNIFICANT CHANGES IN THE ACCOUNTS AND
21 THE FINANCIAL STATEMENTS. SO WE ALWAYS ENCOURAGE
22 EVERYONE TO READ THIS IN CONJUNCTION WHILE LOOKING
23 AT THE FINANCIAL STATEMENTS.

24 AND THEN THE LAST RESPONSIBILITY IS
25 EXPRESSING WHAT'S CALLED AN IN-RELATION-TO OPINION

BETH C. DRAIN, CA CSR NO. 7152

1 ON SUPPLEMENTARY INFORMATION THAT IS INCLUDED IN THE
2 FINANCIAL STATEMENTS. NOW, THESE AREN'T REQUIRED,
3 BUT THEY'VE BEEN -- THESE AREN'T REQUIRED BY ANY
4 STANDARD SETTERS, BUT IT IS INCLUDED BECAUSE THERE'S
5 SOME IMPORTANCE TO THE ENTITY. AND THESE SCHEDULES
6 ARE THE DOLBY GRANT SCHEDULE OF REVENUES,
7 EXPENDITURES, AND AVAILABLE RESOURCES. AND THEN FOR
8 THE FIRST TIME MANAGEMENT PRESENTED A WHAT WE CALL A
9 COMBINED BALANCE SHEET FOR THE STEM CELL FUND AND A
10 COMBINED STATEMENT OF REVENUE, EXPENDITURES, AND
11 CHANGES IN THE FUND BALANCE.

12 THE PURPOSE OF THESE WERE TO -- WITH THE
13 PASSAGE OF PROP 14 AND HAVING A NEW FUNDING POOL OR
14 BUCKET, IF YOU WILL, IT WAS TO PRESENT COLUMNS FOR
15 EACH OF THE DIFFERENT PROPOSITIONS SO YOU CAN TRACK
16 THE REVENUES, EXPENDITURES, AND THE ACTIVITIES OF
17 THOSE OVER TIME AND KIND OF SEE THE DIFFERENCES
18 THERE. AND THEN THERE'S A TOTAL COLUMN IN THESE
19 SCHEDULES, IN THESE COMBINED SCHEDULES, THAT WILL
20 AGREE INTO THE FINANCIAL STATEMENTS THAT WE ISSUE.

21 AND SO WE ISSUE WHAT WE CALL AN
22 IN-RELATION-TO OPINION ON THESE SCHEDULES. THAT
23 MEANS THAT IN RELATION TO THE FINANCIAL STATEMENTS
24 THEMSELVES, THESE SCHEDULES ARE FAIRLY STATED.

25 IF WE GO TWO MORE SLIDES, WE'LL GET INTO

BETH C. DRAIN, CA CSR NO. 7152

1 THE AUDIT RESULTS. SO WE, AGAIN, AS I MENTIONED,
2 THE FINANCIAL STATEMENTS ARE PREPARED BY MANAGEMENT
3 IN ACCORDANCE WITH USGAP. WE SUBJECTED THEM TO THE
4 AUDITING STANDARDS THAT ARE GENERALLY ACCEPTED IN
5 THE UNITED STATES AND ALSO GOVERNMENT AUDITING
6 STANDARDS.

7 WE ISSUED OUR REPORT ON THE FISCAL YEAR
8 20/21 FINANCIAL STATEMENTS ON OCTOBER 29TH, 2021,
9 AND WE ISSUED AN UNMODIFIED OPINION, WHICH IS THE
10 HIGHEST LEVEL OF ASSURANCE THAT AN INDEPENDENT
11 AUDITOR CAN GIVE AN ORGANIZATION REGARDING THEIR
12 FINANCIAL STATEMENTS PRESENTATION. SO ANOTHER
13 UNMODIFIED OPINION. SO THAT'S A TESTAMENT TO
14 EVERYONE WHO WORKS AT CIRM IN THE FINANCE DEPARTMENT
15 AND ALSO AT THE STATE DEPARTMENT OF GENERAL SERVICES
16 JUST WHAT THE FINANCIAL REPORTING IS ON THE
17 ACCOUNTING FOR THE TRANSACTIONS.

18 ALL RIGHT. AND THEN WE GO TO THE LAST
19 SECTION, REQUIRED COMMUNICATIONS. AGAIN, THIS IS
20 JUST A SUMMARY. IT'S CALLED THE "SIGNIFICANT AUDIT
21 FINDINGS." FINDINGS HERE DOESN'T MEAN THERE'S ANY
22 ISSUES OR ERRORS OR ANYTHING. IT'S JUST THE
23 LANGUAGE THAT THE ASCPA USES. SO IT'S KIND OF A
24 SUMMARY OF HOW THE AUDIT WENT, AND I'LL JUST GO
25 THROUGH SOME OF THE KEY ITEMS.

BETH C. DRAIN, CA CSR NO. 7152

1 WE WENT OVER ALREADY OUR RESPONSIBILITY
2 FOR THE FINANCIAL STATEMENTS. OUR PLANNED SCOPE AND
3 TIMING OF THE AUDIT IS ALWAYS 55 DAYS. WE HAVE TO
4 ISSUE OUR REPORT 55 DAYS AFTER THE CLOSE OF THE
5 BOOKS. SO THAT'S USUALLY AROUND SOMETIME MID TO
6 LATE OCTOBER. OUR SCOPE OF THE AUDIT, AGAIN, WAS
7 AUDITING THE FINANCIAL STATEMENTS OF THE
8 GOVERNMENTAL ACTIVITY AND THE STEM CELL FUND. WE
9 ALSO AT MGO, WE COMPLIED WITH ALL OF OUR ETHICAL
10 REQUIREMENTS REGARDING INDEPENDENCE. SO WE GO
11 THROUGH A PRETTY REGULAR INDEPENDENCE REVIEW OF ALL
12 OUR CLIENTS EVERY YEAR TO MAKE SURE THAT WE ARE, IN
13 FACT, IN APPEARANCE INDEPENDENT FROM CIRM.

14 NOW WE KIND OF GET INTO SOME QUALITATIVE
15 ASPECTS OF ACCOUNTING PRACTICES. ONE HAS TO DO WITH
16 ACCOUNTING POLICIES AND ACCOUNTING ESTIMATES. THERE
17 WERE NO CHANGES TO THE ACCOUNTING POLICIES DURING
18 THE YEAR ENDED JUNE 30, 2021, AND THERE WEREN'T ANY
19 POLICIES THAT CIRM USES THAT DON'T HAVE A CONSENSUS
20 OR DON'T HAVE A BASIS IN GAP. THERE'S NO REALLY
21 SENSITIVE ACCOUNTING ESTIMATES THAT CIRM USES IN
22 DETERMINING AMOUNTS IN THEIR FINANCIAL STATEMENTS.
23 WE DIDN'T HAVE THEY SIGNIFICANT DIFFICULTIES
24 ENCOUNTERED DURING THE AUDIT. THERE WEREN'T ANY
25 UNCORRECTED MISSTATEMENTS OR CORRECTED MISSTATEMENTS

BETH C. DRAIN, CA CSR NO. 7152

1 FOR THAT MATTER. WE HAD NO DISAGREEMENT WITH
2 MANAGEMENT. MANAGEMENT WAS ABLE TO PROVIDE US WITH
3 A SIGNED REPRESENTATION LETTER AT THE END OF OUR
4 AUDIT, WHICH IS THE LAST PIECE OF AUDIT EVIDENCE
5 THAT WE REQUIRE. AND THEN WE REALLY DIDN'T HAVE ANY
6 OTHER FINDINGS OR ISSUES DURING THE YEAR ENDING JUNE
7 30, 2021. IT WAS ANOTHER PRETTY STEADY EVEN YEAR.

8 SO WITH THAT, THAT KIND OF WRAPS UP MY
9 PRESENTATION OVER THE JUNE 30, 2021, AUDIT, AND I
10 WOULD BE HAPPY TO ANSWER ANY QUESTIONS IF THERE ARE
11 ANY.

12 CHAIRMAN THOMAS: SO THANK YOU VERY MUCH.
13 AND THANK YOU, FINANCE TEAM, FOR ANOTHER YEAR OF
14 IMPECCABLE AUDIT. REALLY APPRECIATE ALL THAT YOU DO
15 TO MAKE SURE THAT THAT HAPPENS.

16 ARE THERE ANY QUESTIONS HERE BASED ON THIS
17 REPORT? OKAY. THERE YOU GO. SUCH A COMPREHENSIVE
18 REPORT. EVERYBODY LOVES THE CONCLUSIONS. SO THANK
19 YOU.

20 SO THIS IS NOT AN ACTION ITEM. THIS IS
21 JUST A DISCUSSION ITEM. SO THERE'S NO MOTION
22 NECESSARY HERE, BUT WE JUST WANTED TO THANK ALL OF
23 YOU AGAIN. THANKS, CRAIG, FOR THE PRESENTATION AND
24 TO ALL THE MEMBERS OF TEAM. SO IF THERE ARE NO
25 FURTHER COMMENTS, WE WILL THANK CRAIG AND SAY WE

BETH C. DRAIN, CA CSR NO. 7152

1 MOVE ON TO THE NEXT AGENDA ITEM. OKAY. THANK YOU.

2 ALL RIGHT. THE LAST ITEM ON THE AGENDA
3 TODAY IS PUBLIC COMMENT. DO WE HAVE PUBLIC COMMENT,
4 MARIANNE, THAT YOU SEE ON YOUR SCREEN? LOOKS LIKE I
5 SEE A HAND OUT THERE. I'M NOT SURE WHICH PHONE
6 NUMBER THAT GOES TO. SO COULD YOU PLEASE CALL ON
7 THAT PERSON AND HAVE THEM IDENTIFY THEMSELVES?

8 MS. DEQUINA-VILLABLANCA: YES. SO PHONE
9 NUMBER 310-469-1180, YOU HAVE THREE MINUTES FOR
10 PUBLIC COMMENT.

11 DR. FLINT: THANK YOU VERY MUCH. MY NAME
12 IS DR. JONATHAN FLINT. I'M A PSYCHIATRIST IN
13 NEUROSCIENCES WORKING AT UCLA. AND I'M CALLING IN
14 REALLY TO EMPHASIZE TO THE BOARD THE CRUSHING BURDEN
15 THAT MENTAL HEALTH AND NEUROPSYCHIATRIC ILLNESS
16 IMPOSES THROUGHOUT CALIFORNIA, DISEASES THAT HAVE A
17 DISPROPORTIONATE EFFECT ON OUR DISADVANTAGED
18 COMMUNITIES. GENERALLY PSYCHIATRIC DISEASES ARE NOW
19 RECOGNIZED AS A LEADING CAUSE OF DISABILITY, NOT
20 JUST IN CALIFORNIA, BUT GLOBALLY.

21 AS A COMMISSION I'M TREATING PATIENTS AND
22 FINDING THIS VERY FRUSTRATING BECAUSE WE HAVE SO FEW
23 EFFECTIVE TREATMENTS. THOSE THAT WE DO HAVE
24 CURRENTLY ONLY TREAT SYMPTOMS. WE HAVE NO WAY OF
25 ADDRESSING THE CORE PROBLEMS, THE CAUSES OF MENTAL

BETH C. DRAIN, CA CSR NO. 7152

1 ILLNESS, UNTIL NOW. I CAN'T EMPHASIZE ENOUGH HOW
2 MUCH CALIFORNIA WITH ITS DIVERSE COMMUNITIES, ITS
3 WELL LEADING STRENGTHS IN NEUROSCIENCE AND
4 HEALTHCARE IS UNIQUELY POSITIONED TO CARRY OUT
5 WHAT'S NECESSARY, THE ADVANTAGE WE'VE ACHIEVED IN
6 GENETICS, IPS CELLS, BRAIN ORGANIDS INTO POWERFUL
7 MECHANISTIC AND SCREENING TOOLS SO THAT WE CAN FOR
8 THE FIRST TIME REALLY FIND THE CAUSES OF MENTAL
9 DISORDERS AND DEVELOP NEW RESPECTED TREATMENTS.
10 THESE ADVANTAGES SHOULD AND CAN BE MADE HERE IN
11 CALIFORNIA.

12 I'M ARGUING THAT WE NEED A COMPREHENSIVE
13 PLAN TO MAKE SURE THAT THE MONEY, THE 1.5 BILLION,
14 ASSIGNED TO THIS WORK HAS MAXIMAL IMPACTS HERE IN
15 CALIFORNIA. AND TO THAT END, THAT PLAN SHOULD
16 INVOLVE ACADEMIC MEDICAL CENTERS WHERE STRENGTHS IN
17 RESEARCH AND CLINICAL TRIALS ARE BASED AND
18 INCORPORATE THE COMMUNITY GROUPS THAT CONSIST OF AND
19 REPRESENT OUR PATIENTS WHO ARE SUFFERING FROM
20 PSYCHIATRIC DISABILITY.

21 THANK YOU FOR YOUR ATTENTION, AND I'D LIKE
22 TO HELP CIRM IN ANY WAY IN ITS IMPORTANT WORK.

23 CHAIRMAN THOMAS: THANK YOU AND THANK YOU
24 FOR THOSE VERY IMPORTANT COMMENTS. AS YOU NOTE AND
25 AS WE'VE NOTED THROUGHOUT THIS MEETING, WE DO HAVE

BETH C. DRAIN, CA CSR NO. 7152

1 THE BILLION AND A HALF THAT IS EARMARKED FOR
2 DISEASES OF THE BRAIN IN PROP 14. MENTAL HEALTH
3 OBVIOUSLY IS A VERY MAJOR COMPONENT OF THAT,
4 PARTICULARLY WITH THE BREAKTHROUGHS IN IDENTIFYING
5 GENES FOR THE FIRST TIME THAT ACTUALLY ARE LINKED TO
6 MENTAL ILLNESS IN ONE FASHION OR ANOTHER.

7 AND WE'VE HAD SEVERAL DISCUSSIONS ON THIS
8 TOPIC, AND I WOULD ASK DR. MILLAN THAT, AS THE PLAN
9 FOR HOW TO DEAL WITH THE 1.5 BILLION COMES INTO
10 PLAY, THAT THESE COMMENTS AND THE NEED TO ADDRESS
11 MENTAL ILLNESS SPECIFICALLY BE INTEGRATED INTO THAT
12 PLAN. AND THAT DR. MILLAN AND THE TEAM COME BACK TO
13 THE BOARD WITH THOUGHTS ON HOW TO MAKE THAT HAPPEN
14 AS THIS IS SOMETHING THAT WE DO NEED TO VIEW AS A
15 MAJOR PRIORITY. IN GENERAL, WE HAVE A
16 DISPROPORTIONATE NUMBER OF PATIENT ADVOCATES ON THE
17 BOARD DEVOTED TO MENTAL HEALTH. AND SO I THINK THAT
18 THIS IS A VERY TIMELY COMMENT, AND THANK YOU VERY
19 MUCH FOR THAT.

20 DO WE HAVE OTHER MEMBERS OF THE PUBLIC,
21 ANY OTHER PUBLIC COMMENT?

22 MS. DEQUINA-VILLABLANCA: THERE IS NONE.

23 CHAIRMAN THOMAS: OKAY. HEARING NONE,
24 THAT CONCLUDES A VERY SUBSTANTIVE MEETING. THANK
25 YOU ALL MEMBERS OF THE BOARD FOR YOUR ATTENDANCE.

BETH C. DRAIN, CA CSR NO. 7152

1 AGAIN, PLEASE CIRCLE DECEMBER 15TH. THAT'S A VERY
2 IMPORTANT DATE AS WELL AS WE WILL BE VOTING ON THE
3 NEW CHAIR AT THAT TIME. AND WITH THAT, I WISH
4 EVERYBODY A HAPPY HALLOWEEN, AND WE WILL SEE YOU AT
5 VARIOUS SUBCOMMITTEES IN NOVEMBER AND BACK AGAIN EN
6 BANC IN MID-DECEMBER. WE STAND ADJOURNED.

7 (THE MEETING WAS THEN CONCLUDED AT 1:26 P.M.)
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE VIRTUAL PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE AND THE APPLICATION REVIEW SUBCOMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD ON OCTOBER 27, 2022, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CA CSR 7152
133 HENNA COURT
SANDPOINT, IDAHO
(208) 920-3543